



US010889800B2

(12) **United States Patent**
Noggle et al.

(10) **Patent No.: US 10,889,800 B2**
(45) **Date of Patent: Jan. 12, 2021**

(54) **METHOD AND COMPOSITION FOR GENERATING BASAL FOREBRAIN CHOLINERGIC NEURONS (BFCNS)**

(71) Applicants: **New York Stem Cell Foundation, Inc.**, New York, NY (US); **ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI**, New York, NY (US)

(72) Inventors: **Scott Noggle**, New York, NY (US); **Maitane Ortiz-Virumbrales**, New York, NY (US); **Sam Gandy**, New York, NY (US); **Ilya Kruglikov**, New York, NY (US); **Michelle Ehrlich**, New York, NY (US)

(73) Assignees: **New York Stem Cell Foundation, Inc.**, New York, NY (US); **Icahn School of Medicine at Mount Sinai**, New York, NY (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **15/990,208**

(22) Filed: **May 25, 2018**

(65) **Prior Publication Data**

US 2019/0002826 A1 Jan. 3, 2019

Related U.S. Application Data

(60) Provisional application No. 62/511,271, filed on May 25, 2017, provisional application No. 62/571,741, filed on Oct. 12, 2017, provisional application No. 62/574,639, filed on Oct. 19, 2017, provisional application No. 62/586,571, filed on Nov. 15, 2017.

(51) **Int. Cl.**

A61K 35/30 (2015.01)
C12N 5/0793 (2010.01)
C12N 15/11 (2006.01)
C12N 9/22 (2006.01)
G01N 33/50 (2006.01)
C12N 5/074 (2010.01)

(52) **U.S. Cl.**

CPC **C12N 5/0619** (2013.01); **A61K 35/30** (2013.01); **C12N 5/0696** (2013.01); **C12N 9/22** (2013.01); **C12N 15/11** (2013.01); **G01N 33/5058** (2013.01); **C12N 2310/20** (2017.05); **C12N 2501/15** (2013.01); **C12N 2501/41** (2013.01); **C12N 2501/999** (2013.01); **C12N 2506/02** (2013.01); **C12N 2506/45** (2013.01); **C12N 2510/00** (2013.01); **C12N 2800/80** (2013.01); **G01N 2800/2814** (2013.01)

(58) **Field of Classification Search**

CPC **C12N 5/0619**; **C12N 5/0696**; **C12N 15/11**; **C12N 9/22**; **C12N 2506/02**; **C12N 2501/15**; **C12N 2501/41**; **C12N 2510/00**; **C12N 2506/45**; **C12N 2501/999**; **C12N 2800/80**; **C12N 2310/20**; **A61K 35/30**; **G01N 33/5058**; **G01N 2800/2814**

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

7,022,893 B1 4/2006 Takeda et al.
2012/0207744 A1 8/2012 Mendlein et al.

FOREIGN PATENT DOCUMENTS

WO WO 2006/029197 A1 3/2006
WO WO 2014/176606 A1 10/2014

OTHER PUBLICATIONS

Ochalek et al., Hindawi Publishing Corporation, Stem Cells International, vol. 2016, Article ID 5838934. (Year: 2016).*

Ortiz-Vimbrales et al., Acta Neuropathologica Communications, 5:77, 2017 (Year: 2017).*

Rajala et al., Human Reproduction vol. 22, No. 5 pp. 1231-1238, (Year: 2007).*

International Search Report dated Aug. 23, 2018, regarding PCT/US2018/034725.

Nakajima et al.: "Dissociated cell culture of cholinergic neurons from nucleus basalis of Meynert and other basal forebrain nuclei"; Proc Natl Acad Sci USA, Sep. 1985, vol. 82, pp. 6325-6329.

Ortiz-Virumbrales et al.: "CRISPR/Cas9-Correctable mutation-related molecular and physiological phenotypes in iPSC-derived Alzheimer's PSEN2 N141I neurons"; Acta Neuropathol Commun, Oct. 27, 2017, vol. 5, No. 1:77, pp. 1-20.

Pires et al.: "Generation of a gene-corrected isogenic control cell line from an Alzheimer's disease patient iPSC line carrying a A79V mutation in PSEN1"; Stem Cell Res, Aug. 7, 2016, vol. 17, No. 2, pp. 285-288.

* cited by examiner

Primary Examiner — Kimberly Ballard

Assistant Examiner — Stacey N MacFarlane

(74) Attorney, Agent, or Firm — DLA Piper LLP (US)

(57) **ABSTRACT**

The invention relates to methods and compositions for developing basal forebrain cholinergic neurons (BFCNs) from stem cells, and in particular, BFCNs having repaired electrophysiological defects relating to one or more mutations in PSEN2, and to the use of such BFCNs in cell-based therapies to treat Alzheimer's disease.

24 Claims, 11 Drawing Sheets

Specification includes a Sequence Listing.




FIG. 1A-1E




FIG. 2A-2F





FIG. 3A-3B



Sequence Name	Bases	Sequence
g1N1411 guide RNA F	25	5'-CTCCGGTGGCTCATCATGATCAGCCGTCATCG-3'
g1N1411 guide RNA R	25	3'-GAGGCACSACTACTGGGAGTAGTACTAGTCCGCASTAGCACCARTACTG-5'
Donor sgODRNA N1411	127	5'-GAGGCACSACTACTGGGAGTAGTACTAGTCCGCASTAGCACCARTACTGCTGCTGATCATCATGATCAGCCGTCATCG-3'






FIG. 4A-4D





FIG. 5A-5B




FIG. 6A-6F




FIG. 7A-7B




FIG. 8A-8C




FIG. 9A-9D




FIG. 10A-10B




FIG. 11B




FIG. 11A

1

METHOD AND COMPOSITION FOR GENERATING BASAL FOREBRAIN CHOLINERGIC NEURONS (BFCNS)

CROSS REFERENCE TO RELATED APPLICATION(S)

This application claims the benefit of priority under 35 U.S.C. § 119(e) of U.S. Provisional Patent Application Ser. No. 62/511,271, filed May 25, 2017, U.S. Provisional Patent Application Ser. No. 62/571,741, filed Oct. 12, 2017, U.S. Provisional Patent Application Ser. No. 62/574,639, filed Oct. 19, 2017, and U.S. Provisional Patent Application Ser. No. 62/586,571, filed Nov. 15, 2017, the entire contents of each of which is incorporated herein by reference in their entireties.

STATEMENT OF GOVERNMENT SUPPORT

This invention was made with government support under Grant Nos. AG005138, AG046170, and AG042965 awarded by the National Institutes of Health. The government has certain rights in the invention.

INCORPORATION OF SEQUENCE LISTING

The material in the accompanying sequence listing is hereby incorporated by reference into this application. The accompanying sequence listing text file, name NYSC1390_4_Sequence_Listing.txt, was created on May 24, 2018, and is 53 kb. The file can be accessed using Microsoft Word on a computer that uses Windows OS.

BACKGROUND OF THE INVENTION

Field of the Invention

The present invention relates generally to the field of medicine, and more specifically to methods and compositions for developing basal forebrain cholinergic neurons (BFCNs) from stem cells, and in particular, BFCNs comprising repaired electrophysiological defects relating to one or more mutations in the presenilin 2 gene (PSEN2), and the use of such BFCNs in cell-based therapies to treat Alzheimer's disease.

Background Information

Alzheimer's disease (AD) is a progressive disease resulting in senile dementia. Broadly speaking the disease falls into two categories: late onset, which occurs in old age (65+ years) and early onset, which develops well before the senile period, i.e., between 35 and 60 years. In both types of disease, the pathology is the same but the abnormalities tend to be more severe and widespread in cases beginning at an earlier age. The disease is characterized by at least two types of lesions in the brain, senile plaques and neurofibrillary tangles. Senile plaques are areas of disorganized neuropil up to 150 μm across with extracellular amyloid deposits at the center visible by microscopic analysis of sections of brain tissue. Neurofibrillary tangles are intracellular deposits of microtubule associated tau protein consisting of two filaments twisted about each other in pairs.

The principal constituent of the plaques is a peptide termed A β or β -amyloid peptide. A β peptide is an internal fragment of 39-43 amino acids of a precursor protein termed amyloid precursor protein (APP). Several mutations within

2

the APP protein have been correlated with the presence of Alzheimer's disease. Such mutations are thought to cause Alzheimer's disease by increased or altered processing of APP to A β , particularly processing of APP to increased amounts of the long form of A β (i.e., A β 1-42 and A β 1-43). Mutations in other genes, such as the presenilin genes, PSEN1 and PSEN2, are thought indirectly to affect processing of APP to generate increased amounts of long form A β . These observations suggest that A β , and particularly its long form, is a causative element in Alzheimer's disease.

There are 5 million people currently affected by Alzheimer's disease in the US and, according to the Alzheimer's Association, this number will increase to 16 million by the year 2050. Unfortunately, we only have direct evidence for genetic causation that accounts for 3-5% of these patients. This percentage encompasses the autosomal dominant early onset familial Alzheimer's disease (EOFAD) variants caused by inherited fully penetrant autosomal dominant mutations in the APP, or PSEN1, PSEN2 that constitute the γ -secretase apparatus [87], and changes in their function increases the production of A β 42 oligomers and/or deposition of amyloid plaques.

After decades studying murine models of AD that do not fully recapitulate the pathophysiology of this disease in the human brain [5, 57, 58], a complementary new concept of AD modeling in vitro has emerged upon the breakthrough by [81] allowing adult human tissue reprogramming into iPSC using defined factors, and their subsequent in vitro differentiation into specific brain cell types.

BFCNs are one of the most vulnerable neuronal populations whose deterioration explains, in part, the cognitive decline in AD patients. Apart from the evidence for BFCN failure and atrophy, other studies have revealed that human embryonic stem cell-derived BFCNs transplanted into AD mouse models can be associated with improvement in the learning behavior of the implanted mouse [94]. These findings highlight the relevance of iPSC- and ESC-derived BFCNs as not only early clinical indicators but also as a potential strategy for subtype-specific cell-based therapy for AD [39]. In order to move this cell-based therapeutic strategy forward, there has been an urgent need for a refined differentiation protocol to generate human ESC- and/or iPSC-derived BFCNs.

SUMMARY OF THE INVENTION

The present invention provides a highly reproducible protocol to efficiently derive BFCNs from pluripotent stem cells (PSCs), including embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs).

Accordingly, in one embodiment, the invention provides a method of generating BFCNs. The method includes culturing PSCs in a basal media comprising an inhibitor of transforming growth factor beta (TGF- β) signaling and an activator of sonic hedgehog (Shh) signaling to induce neuroectodermal differentiation. In some aspects, the basal media is a modified mTeSR1 formulation that lacks factors that support pluripotency including basic fibroblast growth factor (bFGF), TGF- β , lithium chloride (Li-Cl), GABA and pipercolic acid. In some aspects, culturing is performed in the presence of dual SMAD inhibitors, such as SB431542 and LDN193189 along with one or more agonists of smoothened protein, such as smoothened agonist (SAG) and purmorphamine. After about 9, 10, 11 or 12 days of culturing, CD271+ cells are selected and in a neuronal basal medium, such as BrainphysTM to generate neuronal embryoid bodies (NEBs). The neuronal basal medium is

optionally supplemented with one or more of B27 supplement, an inhibitor of rho-associated protein kinase (ROCK), nerve growth factor (NGF) and brain derived neurotrophic factor (BDNF). After about 7, 8, 9 or 10 days of culturing the CD271+ cells, the formed NEBs are harvested, dissociated, and plated as monolayer cultures and further cultured in a neuronal basal medium optionally supplemented with B27 supplement, NGF and BDNF. To ensure differentiation into BFCNs, the cultured cells are analyzed for positive expression of Tuj1, MAP2, BF1, Nkx2.1 and p75.

In another embodiment, the method utilizes iPSCs which may be treated with a gene editing system to repair one or more mutations, such as a mutation of presenilin 1 (PSEN1) or presenilin 2 (PSEN2). In one aspect, the mutation is PSEN2^{N141I}, repair of which restores neuronal excitability in BFCNs.

Accordingly, in another embodiment, the invention provides a method of treating a disease or disorder in a subject. The method includes administering to a subject a BFCN generated using the culturing method described herein. In certain aspects, the disease or disorder is an amyloidogenic disease, such as systemic amyloidosis, Alzheimer's disease, mature onset diabetes, Parkinson's disease, Huntington's disease, fronto-temporal dementia, and prion-related transmissible spongiform encephalopathies. In embodiments, a BFCN having a mutation that impairs neuronal excitability, such as PSEN2^{N141I}, may be obtained from a subject and used to generate an iPSC, which in turn may be treated with a gene editing system to repair the mutation. The gene edited iPSC is then cultured as described herein to produce BFCNs having restored neuronal excitability which are administered to the subject to treat the disease or disorder. In certain aspects, the disease or disorder is AD.

In a related embodiment, the invention provides a method of restoring neuronal excitability in BFCNs in a subject. The method includes: a) isolating a BFCN from the subject, wherein the BFCN has a mutation in PSEN2 resulting in impaired neuronal excitability of the BFCN; b) generating an iPSC using the BFCN of (a); c) repairing the PSEN2 mutation in the iPSC; d) culturing the iPSC of (c) using the differentiation protocol described herein to generate a BFCN having the repaired mutation; and e) administering the iPSC of (d) to the subject, thereby restoring neuronal excitability in BFCNs in the subject.

Also provided is a method of identifying a compound for treatment or prevention of a disease or disorder associated with diminished neuronal excitability in BFCNs. The method includes: a) contacting a BFCN or neuronal embryoid body (NEB) generated using the differentiation protocol described herein with a candidate compound, wherein the BFCN comprises a mutation in PSEN2 resulting in impaired neuronal excitability of the BFCN; and b) detecting neuronal excitability of the BFCN after contact with the candidate compound. An increase in neuronal excitability of the BFCN after contact with the candidate compound identifies the compound as a compound potentially capable of restoring neuronal excitability in BFCNs.

The invention further provides a BFCN generated using the differentiation protocol as described herein. The BFCN may include a gene edited repair of PSEN2, as well as a detectable marker recombinantly introduced into the BFCN genome.

The invention also provides a kit for generating a BFCN. The kit includes a culture media having an inhibitor of TGF- β signaling and an activator of Shh signaling. In embodiments, the culture media is a modified mTeSR1 formulation that lacks factors that support pluripotency

including bFGF, TGF- β , lithium chloride (Li—Cl), GABA and pipercolic acid. In embodiments, the culture media includes dual SMAD inhibitors, such as SB431542 and LDN193189, along with one or more agonists of smoothed protein, such as smoothed agonist (SAG) and purmorphamine. The kit may also include a neuronal basal medium, such as BrainphysTM optionally supplemented with one or more of B27 supplement, an inhibitor of ROCK, NGF and BDNF. In embodiments, the kit includes reagents for detection of CD271+ cells as well as cells which positively express Tuj1, MAP2, BF1, Nkx2.1 and p75.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1A-1E. Overview schematic of basal cholinergic differentiation protocol. (A) Cells are plated and allowed to reach 100% confluency (Day 0), before the initiation of dual SMAD inhibition and the subsequent introduction of ventralizing agents (Day 2). At day 10 the monolayer is dissociated, sorted for p75+ cells, and kept as NEBs until day 19. Then the culture is dissociated again into a monolayer (See Methods for more details). (B) Left panel shows sustained EGFP expression driven by Nkx2.1 induction in NKx2.1-EGFP hESCs upon SHH plus purmorphamine or SAG plus purmorphamine treatment, maintained at Day 14, after removal of treatment at Day 8. Right panel shows Nkx2.1, Lhx8 and BF1 relative gene expression to GAPDH measured by qPCR, in NKx2.1-EGFP cell line in the presence of the indicated ventralizing agents, or unpatterned (UNP) at Day 12. n=3, in technical triplicates. (C) Confocal microscope images of Nestin, Sox2 and DRAQ5 immunostaining in fControl and control lines at Day 11, showing typical neural rosettes (left panel), or Tuj1, Nkx2.1 right and DRAQ5 in the right panel. Images representative of 3 independent experiments. (D) Fluorescence microscope images of immunostained NEB cryosections or dissociated NEBs into a monolayer with the BFCN markers Nkx2.1/Tuj1/p75/BF1/MAP2/ChAT. (E) Dissociated NEBs into a monolayer immunostained at Day 50 with MAP2, ChAT and Hoescht. Fluorescence microscope images the effect of NGF addition to SAG plus purmorphamine treatment alone. Images are representative of at least 3 independent experiments.

FIGS. 2A-2F. Basal cholinergic markers in PSEN2^{N141I} neuroprecursors. (A) Table showing the cell lines used. Four iPSC lines reprogrammed from fibroblasts were used; two controls (949 and 050643, labelled as fControl and Control, respectively) that do not carry the PSEN2^{N141I} mutation nor the $\epsilon 4$ allele; and two AD patients (948 and 950, labelled as AD1 and AD2, respectively) who carry the mutation and the $\epsilon 4$ allele. Three of the four iPSC lines were family related (fControl, AD1, and AD2). (B) Representative Sanger sequencing chromatograms showing a fragment of exon 5 of PSEN2. Arrow marks site of the missense point mutation Chr1:227,073,304 A>T. (C) Immunocytochemistry and RT-PCR for early neuronal and basal forebrain markers. n=3, 3 independent experiments with technical triplicates. (D) RTPCR fold changes for TUJ1 and BF1. n=3, 3 independent experiments with technical triplicates. (E) Representative histograms for P75 staining. n>6. (F) A β 40 and A β 42 ELISA quantifications. n=3, 3 independent experiments with technical triplicates. ***, p<0.001. *, p<0.05.

FIGS. 3A-3B. Neuronal and basal cholinergic markers by immunocytochemistry. (A) Immunostaining for TrkA on DIV 21. (B) Immunostainings for ChAT and vAChT at

5

different magnifications at DIV65; and Tuj1 and MAP2. Images are representative of at least 3 independent experiments.

FIGS. 4A-4D. CRISPR/Cas9-mediated correction of PSEN2^{N141I} iPSC lines. (A) Schematic showing guide RNAs used in the targeting of CRISPR/Cas9, as well as donor ssODNs utilized to introduce wild-type genotype. Sequence identifiers from top to bottom: SEQ ID NOs: 26-31. (B) Left 2 panels show GFP positive HEK293T cells indicating Cas9 system with guide RNA expression, NT refers to non-transfected; right 2 panels show sample of GFP positive iPSCs after lipofection with pCas9-gN141I-GFP vector. (C) Sanger sequencing results from iPSC lines, showing corrections in the N141I mutation. (D) AP 42/40 ratio detected by ELISA in 72 h conditioned media from mutant, control or Cispr-Cas9 corrected BFCNs (DIV 34). n=4, 4 independent experiments with technical triplicates. *, p<0.05; **, p<0.01 Student T-test.

FIGS. 5A-5B. BFCNs carrying various PSEN mutations are not consistently more susceptible to A β 42 oligomer toxicity. (A) Sample images of BFCNs from the indicated genotypes treated with propidium iodide to visualize cell death in response to 72-h exposure to A β 42 oligomers (5 μ M). (B) % LDH Release recorded from media collected after 72-h exposure. n=3, 3 independent experiments with technical triplicates. *, p<0.05; **, p<0.01 as detected by 2-Way ANOVA Bonferroni post hoc tests.

FIGS. 6A-6F. NLRP2 inflammasome mRNA levels are over-expressed in some PSEN2^{N141I} cells, but it is not driven by mutation. RT-PCR expression of (A) NLRP2, (B) NLRP3, and (C) ASB9 in cholinergic neuroprecursors. (D) Western blot showing NLRP2, PSEN2 and 13-Actin. RT-PCR expression of NLRP2 in Neuroprecursors (E) and BFCNs (F). n=3, 3 independent experiments with technical triplicates, for all panels. ***, p<0.001.

FIGS. 7A-7B. Electrophysiological and morphological features of BFCN. (A) Top row—compound sodium and potassium currents produced by a voltage protocol shown in bottom row. Current trace produced by a voltage step to -20 mV shown in red. Inset shows first 25 ms of a current produced by a voltage step to -20 mV (scale bars 200 pA, 5 ms). (B) Differential interference contrast image of a patched BFCN recorded in (A). Ninety-four neurons (22 wild-type control, 21 familial control, 18 AD1, 28 AD2 and 5 iAD1_control). Scale bar is 30 μ m.

FIGS. 8A-8C. Electrophysiological deficits in BFCNs from AD lines. (A) Co-localization of biocytin-labelled neurons with cholinergic markers ChAT and VAcHT. Arrows indicate positions of recorded neurons somas, scale bar is 50 μ m. (B) Representative firing patterns of BFCNs produced by a 1 sec negative and positive square current injection are depicted. A grand total of 94 individual neurons were studied electrophysiologically: 22 wild-type control neurons, 21 familial control neurons, 18 AD1 neurons, 28 AD2 neurons, and 5 iAD1_(CRISPR-corrected) neurons. The experiments on the 94 neurons required days to weeks. On each experimental day, representatives from each genotype were included, with at least three samples from each genotype studied each day. (C) Summary data on maximum number of action potentials that neurons are capable of sustaining (left) and height of a single action potential at rheobase (right) across all conditions. Individual data points are shown as circles, group means are shown as bars. **, p<0.01 Tukey HSD test.

FIGS. 9A-9D. Intrinsic electrophysiological properties of BFCNs. Summary data on all recorded BFCNs from five groups. Ninety-four neurons (22 wild-type control, 21 famil-

6

ial control, 18 AD1, 28 AD2 and 5 iAD1_control). Histograms show individual values from each neuron (circle) and group means (bars) for membrane resistance (A), capacitance (B), resting potential (C) and rheobase current (D). Statistical significance was tested with ANOVA and Tukey's post hoc comparisons.

FIGS. 10A-10B. Quality control of iPSC lines. (A) Immunofluorescence shows expression of pluripotency markers SSEA4, Nanog, Tra160 and in 7889(S)B iPSC line. (B) Three germ layers (endoderm, mesoderm, and ectoderm) from teratomas generated by 7889(S)B iPSC line.

FIGS. 11A-11B. Amyloid β levels in mature BFCNs. (A) Levels of A β 40 on BFCNs (DIV 34). *, P<0.01 vs. other lines in study according to One-Way ANOVA Bonferroni Post-hoc test. (B) Levels of A β 42 on BFCNs (DIV 34). n=3, 3 independent experiments with technical triplicates. *, P<0.01 based on Student's T-test.

DETAILED DESCRIPTION OF THE INVENTION

The present invention is based on the discovery of a robust, fast, and reproducible differentiation protocol to generate BFCNs from PSCs using a chemically defined medium.

The following is a detailed description of the invention provided to aid those skilled in the art in practicing the present invention. Those of ordinary skill in the art may make modifications and variations in the embodiments described herein without departing from the spirit or scope of the present invention. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The terminology used in the description of the invention herein is for describing particular embodiments only and is not intended to be limiting of the invention. All publications, patent applications, patents, figures and other references mentioned herein are expressly incorporated by reference in their entirety.

Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present invention, the preferred methods and materials are now described. All publications mentioned herein are incorporated herein by reference to disclose and described the methods and/or materials in connection with which the publications are cited.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The following references, the entire disclosures of which are incorporated herein by reference, provide one of skill with a general definition of many of the terms (unless defined otherwise herein) used in this invention: Singleton et al., Dictionary of Microbiology and Molecular Biology (2nd ed. 1994); The Cambridge Dictionary of Science and Technology (Walker ed., 1988); The Glossary of Genetics, 5th Ed., R. Rieger et al. (eds.), Springer Verlag (1991); and Hale & Marham, the Harper Collins Dictionary of Biology (1991). Generally, the procedures of molecular biology methods described or inherent herein and the like are common methods used in the art. Such standard techniques can be found in reference manuals such as for example Sambrook et al., (2000, Molecular Cloning—A Laboratory Manual, Third Edition, Cold Spring Harbor Laboratories); and Ausubel et al., (1994, Current Protocols in Molecular Biology, John Wiley & Sons, New-York).

The terminology used in the description is for describing particular embodiments only and is not intended to be limiting of the invention. Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise (such as in the case of a group containing a number of carbon atoms in which case each carbon atom number falling within the range is provided), between the upper and lower limit of that range and any other stated or intervening value in that stated range is encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges is also encompassed within the invention, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either both of those included limits are also included in the invention.

The following terms are used to describe the present invention. In instances where a term is not specifically defined herein, that term is given an art-recognized meaning by those of ordinary skill applying that term in context to its use in describing the present invention.

The articles "a" and "an" as used herein and in the appended claims are used herein to refer to one or to more than one (i.e., to at least one) of the grammatical object of the article unless the context clearly indicates otherwise. By way of example, "an element" means one element or more than one element.

The phrase "and/or," as used herein in the specification and in the claims, should be understood to mean "either or both" of the elements so conjoined, i.e., elements that are conjunctively present in some cases and disjunctively present in other cases. Multiple elements listed with "and/or" should be construed in the same fashion, i.e., "one or more" of the elements so conjoined. Other elements may optionally be present other than the elements specifically identified by the "and/or" clause, whether related or unrelated to those elements specifically identified. Thus, as a non-limiting example, a reference to "A and/or B", when used in conjunction with open-ended language such as "comprising" can refer, in one embodiment, to A only (optionally including elements other than B); in another embodiment, to B only (optionally including elements other than A); in yet another embodiment, to both A and B (optionally including other elements).

As used herein in the specification and in the claims, "or" should be understood to have the same meaning as "and/or" as defined above. For example, when separating items in a list, "or" or "and/or" shall be interpreted as being inclusive, i.e., the inclusion of at least one, but also including more than one, of a number or list of elements, and, optionally, additional unlisted items. Only terms clearly indicated to the contrary, such as "only one of" or "exactly one of," or, when used in the claims, "consisting of," will refer to the inclusion of exactly one element of a number or list of elements. In general, the term "or" as used herein shall only be interpreted as indicating exclusive alternatives (i.e., "one or the other but not both") when preceded by terms of exclusivity, such as "either," "one of," "only one of," or "exactly one of."

As used herein in the specification and in the claims, the phrase "at least one," in reference to a list of one or more elements, should be understood to mean at least one element selected from anyone or more of the elements in the list of elements, but not necessarily including at least one of each and every element specifically listed within the list of elements and not excluding any combinations of elements in the list of elements. This definition also allows that elements

may optionally be present other than the elements specifically identified within the list of elements to which the phrase "at least one" refers, whether related or unrelated to those elements specifically identified. Thus, as a nonlimiting example, "at least one of A and B" (or, equivalently, "at least one of A or B," or, equivalently "at least one of A and/or B") can refer, in one embodiment, to at least one, optionally including more than one, A, with no B present (and optionally including elements other than B); in another embodiment, to at least one, optionally including more than one, B, with no A present (and optionally including elements other than A); in yet another embodiment, to at least one, optionally including more than one, A, and at least one, optionally including more than one, B (and optionally including other elements).

It should also be understood that, in certain methods described herein that include more than one step or act, the order of the steps or acts of the method is not necessarily limited to the order in which the steps or acts of the method are recited unless the context indicates otherwise.

The term "PSEN2 gene" refers herein to a gene that encodes a PSEN2 polypeptide. The PSEN2 gene is represented by NCBI Reference Sequence: NC_000001.11 (SEQ ID NO: 1) as well as known orthologs. The term "PSEN2 polypeptide" refers herein to a polypeptide that is represented by NCBI Reference Sequence: NP_000438.2 (SEQ ID NO: 2) as well as known orthologs.

The term "amyloidogenic disease" includes any disease associated with (or caused by) the formation or deposition of insoluble amyloid fibrils. Exemplary amyloidogenic diseases include, but are not limited to systemic amyloidosis, Alzheimer's disease, mature onset diabetes, Parkinson's disease, Huntington's disease, fronto-temporal dementia, and the prion-related transmissible spongiform encephalopathies (kuru and Creutzfeldt-Jacob disease in humans and scrapie and BSE in sheep and cattle, respectively). Different amyloidogenic diseases are defined or characterized by the nature of the polypeptide component of the fibrils deposited. For example, in subjects or patients having Alzheimer's disease, β -amyloid protein (e.g., wild-type, variant, or truncated β -amyloid protein) is the characterizing polypeptide component of the amyloid deposit. Accordingly, Alzheimer's disease is an example of a "disease characterized by deposits of $A\beta$ " or a "disease associated with deposits of $A\beta$ ", e.g., in the brain of a subject or patient. The terms " β -amyloid protein", " β -amyloid peptide", " β -amyloid", " $A\beta$ " and " $A\beta$ peptide" are used interchangeably herein.

The term "patient" or "subject" is used throughout the specification to describe an animal, preferably a human or a domesticated animal, to whom treatment, including prophylactic treatment, with the compositions according to the present disclosure is provided. For treatment of conditions or disease states which are specific for a specific animal such as a human patient, the term patient refers to that specific animal, including a domesticated animal such as a dog or cat or a farm animal such as a horse, cow, sheep, etc. In general, in the present disclosure, the term patient refers to a human patient unless otherwise stated or implied from the context of the use of the term.

The terms " β -amyloid protein", " β -amyloid peptide", " β -amyloid", " $A\beta$ " and " $A\beta$ peptide" are used interchangeably herein. $A\beta$ peptide (e.g., $A\beta$ 39, $A\beta$ 40, $A\beta$ 41, $A\beta$ 42 and $A\beta$ 43) is about 4-kDa internal fragment of 39-43 amino acids of APP. $A\beta$ 40, for example, consists of residues 672-711 of APP and $A\beta$ 42 consists of residues 672-713 of APP. $A\beta$ peptides include peptides resulting from secretase cleavage of APP and synthetic peptides having the same or

essentially the same sequence as the cleavage products. A β peptides can be derived from a variety of sources, for example, tissues, cell lines, or body fluids (e.g. sera or cerebrospinal fluid). For example, an A β can be derived from APP-expressing cells such as Chinese hamster ovary (CHO) cells stably transfected with APP_{717V}F, as described, for example, in Walsh et al., (2002), *Nature*, 416, pp 535-539. An A β preparation can be derived from tissue sources using methods previously described (see, e.g., Johnson-Wood et al., (1997), *Proc. Natl. Acad. Sci. USA* 94:1550). Alternatively, A β peptides can be synthesized using methods which are well known to those in the art. See, for example, Fields et al., *Synthetic Peptides: A User's Guide*, ed. Grant, W.H. Freeman & Co., New York, N.Y., 1992, p 77). Hence, peptides can be synthesized using the automated Merrifield techniques of solid phase synthesis with the .alpha.-amino group protected by either t-Boc or F-moc chemistry using side chain protected amino acids on, for example, an Applied Biosystems Peptide Synthesizer Model 430A or 431. Longer peptide antigens can be synthesized using well known recombinant DNA techniques. For example, a polynucleotide encoding the peptide or fusion peptide can be synthesized or molecularly cloned and inserted in a suitable expression vector for the transfection and heterologous expression by a suitable host cell. A β peptide also refers to related A β sequences that results from mutations in the A β region of the normal gene.

As used herein the phrase "substantially pure" refers to a population of cells wherein at least 95% of the cells have the recited phenotype. In all embodiments that refer to a "substantially pure" cell population, alternative embodiments in which the cell populations have a lower or higher level of purity are also contemplated. For example, in some embodiments, instead of a given cell population being "substantially pure" the cell population may be one in which at least 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% of the cells, or 100% of the cells, have the recited phenotype.

The terms "co-administration", "co-administered" and "co-administering" or "combination therapy" refer to both concurrent administration (administration of two or more agents at the same time) and time varied administration (administration of one or more agents at a time different from that of the administration of an additional agent or agents), as long as the agents are present in the area to be treated to some extent, preferably at effective amounts, at the same time.

The term "therapeutically effective amount" means the amount required to achieve a therapeutic effect. The therapeutic effect could be any therapeutic effect ranging from prevention, symptom amelioration, symptom treatment, to disease termination or cure, e.g., the treatment of Alzheimer's disease or an associated condition.

As used herein, the term "administering" is meant to refer to a means of providing the composition to the subject in a manner that results in the composition being inside the subject's body. Such an administration can be by any route including, without limitation, subcutaneous, intradermal, intravenous, intra-arterial, intraperitoneal, and intramuscular.

The term "effective" is used to describe an amount of a compound, composition or component which, when used within the context of its intended use, effects an intended result. The term effective subsumes all other effective amount or effective concentration terms, which are otherwise described or used in the present application.

As used herein, the term "comprising" is intended to mean that the compositions and methods include the recited elements, but do not exclude other elements. "Consisting essentially or", when used to define compositions and methods, shall mean excluding other elements of any essential significance to the combination. Thus, a composition consisting essentially of the elements as defined herein would not exclude trace contaminants from the isolation and purification method and pharmaceutically acceptable carriers, such as phosphate buffered saline, preservatives, and the like. "Consisting of" shall mean excluding more than trace elements of other ingredients and substantial method steps for administering the compositions of this invention. Embodiments defined by each of these transition terms are within the scope of this invention.

Ranges provided herein are understood to be shorthand for all of the values within the range. For example, a range of 1 to 50 is understood to include any number, combination of numbers, or sub-range from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, and 50.

As used herein, "kits" are understood to contain at least the non-standard laboratory reagents of the invention and one or more non-standard laboratory reagents for use in the methods of the invention.

The term "obtaining" is understood herein as manufacturing, purchasing, or otherwise coming into possession of.

As used herein, the term "treated," "treating" or "treatment" includes the diminishment or alleviation of at least one symptom associated or caused by the state, disorder or disease being treated. A subject that has been treated can exhibit a partial or total alleviation of symptoms (for example, Alzheimer's disease or associated condition), or symptoms can remain static following treatment according to the invention. The term "treatment" is intended to encompass prophylaxis, therapy and cure.

As used herein, the term "control" refers to a sample or standard used for comparison with an experimental sample. In some embodiments, the control is a sample obtained from a healthy patient. In other embodiments, the control is a historical control or standard reference value or range of values (such as a previously tested sample, subject, or group of samples or subjects).

Methods

BFCNs are believed to be one of the first cell types to be affected in all forms of AD, and their dysfunction is clinically correlated with impaired short-term memory formation and retrieval. As detailed in the Example of this disclosure, the inventors present an optimized in vitro protocol to generate human BFCNs from iPSCs, using cell lines from PSEN2 mutation carriers and controls. Cell lines harboring the PSEN2^{N141I} mutation displayed an increase in the A β 42/40 in iPSC-derived BFCNs. Neurons derived from PSEN2^{N141I} lines generated fewer maximum number of spikes in response to a square depolarizing current injection. The height of the first action potential at rheobase current injection was also significantly decreased in PSEN2^{N141I} BFCNs. CRISPR/Cas9 correction of the PSEN2 point mutation abolished the electrophysiological deficit, restoring both the maximal number of spikes and spike height to the levels recorded in controls. Increased A β 42/40 was also normalized following CRISPR/Cas-mediated correction of the PSEN2^{N141I} mutation. The genome editing data set forth herein confirms the robust consistency of mutation-related changes in A β 42/40 ratio while also showing a PSEN2-mutation-related alteration in electrophysiology.

Accordingly, in one embodiment, the invention provides a method of generating BFCNs. The method may first include preparing PSC colonies. PSCs are seeded (plated) at low density and grown in an adherent culture for about 1-2 days. "Low density" means about 8,000 to about 11,000 cells/cm². Cells are preferably seeded at about 9,500 to about 10,500 cells/cm², more preferably at about 10,000 cells/cm². After about 1-2 days (or greater, i.e., 3, 4, 5, 6, 7, 8, 9, 10 or more), the PSCs form colonies, which are preferably about 75 μm to about 300 μm in diameter, more preferably about 100 μm to about 250 μm in diameter.

The term "PSCs" has its usual meaning in the art, i.e., self-replicating cells that have the ability to develop into endoderm, ectoderm, and mesoderm cells. Preferably, PSCs are hPSCs. PSCs include ESCs and iPSCs, preferably hESCs and hiPSCs. PSCs can be seeded on a surface comprising a matrix, such as a gel or basement membrane matrix. A preferable matrix is the protein mixture secreted by Engelbreth-Holm-Swarm (EHS) mouse sarcoma cells, sold under trade names including MATRIGEL®, CULTREX®, and GELTREX®. Other suitable matrices include, without limitation, collagen, fibronectin, gelatin, laminin, poly-lysine, vitronectin, and combinations thereof.

In some embodiments, media suitable for use in maintaining pluripotent stem cells is used. In embodiments such a medium is mTeSR1 medium from Stem Cell Technologies. However, one of skill in the art will recognize that there are several other types of media that are equivalent to mTeSR1 medium in terms of their suitability for use in maintaining pluripotent stem cells, any of which could be used. Typically such media will contain one or more pluripotency factors to facilitate the maintenance of cells in a pluripotent state. The composition of mTeSR1 medium is known in the art and described in, for example, Ludwig et al., 2006 (Nat Methods. 2006 August; 3(8):637-46; "Feeder-Independent Culture of Human Embryonic Stem Cells"), the contents of which are hereby incorporated by reference.

The pluripotent stem cells used in the method of the invention can be any suitable type of pluripotent stem cells. Where iPSCs are used, such cells may have been "reprogrammed" to the pluripotent state from a non-pluripotent state using any suitable means known in the art, including, but not limited to, modified RNA-based methods, Sendai virus based methods, and the like. Furthermore, such cells may have been reprogrammed to the pluripotent state using any suitable cocktail of reprogramming factors known in the art.

In one embodiment, after PSCs are prepared and grown to confluence in, for example mTeSR1 media, the method includes culturing the PSCs in a basal media comprising an inhibitor of transforming growth factor beta (TGF-β) signaling and an activator of sonic hedgehog (Shh) signaling to induce neuroectodermal differentiation. The basal media utilized is a modified mTeSR1 medium, which is a variant of mTeSR1 medium (sometimes referred to herein as "mTeSR1 Custom" medium) that does not comprise lithium chloride, GABA, pipercolic acid, bFGF or TGFβ1. Inhibitors of TGFβ signaling include, for example, one or more of SB431542, GW788388, LDN193189, LY2109761, LY2157299, and LY364947. Activators of Shh signaling include agonists of Smoothed, such as Smoothed Agonist (SAG; 3-chloro-N-[(1r,4r)-4-(methylamino)cyclohexyl]-N-[3-(pyridin-4-yl)benzyl]benzo[b]thiophene-2-carboxamide) and purmorphamine.

After about 6, 7, 8, 9, 10, 11 or 12 days (or greater, i.e., 15, 16, 17, 18, 19, 20, 25, 30 or more) of culturing, CD271+ cells are selected and cultured in a neuronal basal medium,

such as Brainphys™ to generate neuronal embryoid bodies (NEBs). The neuronal basal medium is optionally supplemented with one or more of B27 supplement, an inhibitor of rho-associated protein kinase (ROCK), nerve growth factor (NGF) and brain derived neurotrophic factor (BDNF). Inhibitors of ROCK include, for example, GSK269962, GSK429286, H-1152, HA-1077, RKI-1447, thiazovivin, Y-27632, or derivatives thereof.

To select for CD271+ cells, overconfluent cells are lifted from the culture surface and purified by FACS and re-plated. This process allows for the formation of cell aggregates or spheres, also referred to herein as NEBs. For purposes of the present invention, the terms "NEB," "aggregate" and "sphere" are used interchangeably and refer to a multicellular three-dimensional structure, preferably, but not necessarily, of at least about 100 cells.

Lifting can be performed mechanically, with a cell scraper or other suitable implement, or chemically. Chemical lifting can be achieved using a proteolytic enzyme, for example, collagenase, trypsin, trypsin-like proteinase, recombinant enzymes, such as that sold under the trade name TRYPLE™, naturally derived enzymes, such as that sold under the trade name ACCUTASE™, and combinations thereof. Chemical lifting can also be done using a chelator, such as EDTA, or a compound such as urea. Mechanical lifting or detachment offers the advantage of minimal cell death, however it produces aggregates of variable size, thus suitable spheres need to be selected through a manual picking process. Good spheres are defined as those having a round-shape, golden/brown color, with darker core and with a diameter between about 300 μm and about 800 μm. Detaching the cells using chemical methods, such as enzymatic digestion predominantly produces spheres that are appropriate for further culture. Therefore manual picking of spheres is not required, and the detachment steps can be adapted for automation and used in high throughput studies. However, enzymatic digestion increases cell death, resulting in a lower number of spheres.

After about 5, 6, 7, 8, 9 or 10 days (or greater, i.e., 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30 or more) of culturing selected CD271+ cells, the formed NEBs are harvested, dissociated, and plated as monolayer cultures and further cultured in a neuronal basal medium, such as Brainphys™, optionally supplemented with B27 supplement, NGF and BDNF. The surface on which the cells are plated and cultured can comprise an extracellular matrix protein (e.g., collagen, fibronectin, laminin) and/or a positively charged poly-amino acid (e.g., poly-arginine, poly-lysine, poly-ornithine). Preferably the surface comprises laminin and/or poly-ornithine.

To ensure differentiation into BFCNs, the cultured cells are analyzed for positive expression of Tuj1, MAP2, BF1, Nkx2.1 and p75.

Many of the embodiments of the present invention involve certain factors to be used in (or excluded from) the compositions and methods described herein, for example as media supplements. These include, but are not limited to, bFGF, GABA, pipercolic acid, lithium chloride, TGF-β, NGF and BDNF. Each of these factors is well known in the art, including the full names of each of these factors in the cases where acronyms or other abbreviations are used. Furthermore, all of these factors are available to the public from multiple sources, including commercial sources. Exemplary amounts/concentrations for use of each of these factors in the methods and compositions of the present invention are provided in the Examples section of this patent disclosure. For all embodiments where specified amounts are referred

to, amounts that are “about” the specified amount are also intended. Furthermore, one of skill in the art will recognize that in some situations further deviations from the specified amounts can be used, and will be able to determine how much of each factor to use by performing routine testing, optimization, dose-response studies, and the like, for example to reduce or increase the specified amounts, as long as the amounts used still achieve the stated effect, e.g. the stated differentiation effect. For example, in some embodiments specified amounts of the specified agents may be reduced to 10%, or 20%, or 30%, or 40%, or 50%, or 60%, or 70%, or 80%, or 90% of the stated amounts. Similarly, in some embodiments the specified amounts of the specified agents may be increased by 10%, by 20%, by 30%, by 40%, by 50%, by 60%, by 70%, by 80%, by 90%, by 100%, by 150%, by 200%, by 300%, by 400%, or by 500% of the stated amounts. Similarly, where specified factors are referred to, one of skill in the art will recognize that analogs, variants, or derivatives of such factors can also be used as long as the analogs, variants, or derivatives have the same general function/activity as the specified factors.

As discussed herein, the inventors have discovered that mutation of PSEN2 results in impaired neuronal excitability in BFCNs. As discussed in the Example herein the inventors observed significant mutation-related, editing-reversible differences in excitability of BFCNs via repair of PSEN2^{N141I} mutation which restored neuronal excitability. Accordingly, the method of the invention may utilize iPSCs which may be treated with a gene editing system to repair one or more mutations, such as a mutation of presenilin 1 (PSEN1) or presenilin 2 (PSEN2). In one embodiment, the mutation is PSEN2^{N141I}, repair of which restores neuronal excitability in BFCNs.

As used herein the term “gene editing” or “genome editing” refers to a type of genetic engineering in which DNA is inserted, replaced, or removed from a target DNA, e.g., the genome of a cell, using one or more nucleases and/or nickases. The nucleases create specific double-strand breaks (DSBs) at desired locations in the genome, and harness the cell’s endogenous mechanisms to repair the induced break by homology-directed repair (HDR) (e.g., homologous recombination) or by nonhomologous end joining (NHEJ). The nickases create specific single-strand breaks at desired locations in the genome. In one non-limiting example, two nickases can be used to create two single-strand breaks on opposite strands of a target DNA, thereby generating a blunt or a sticky end. Any suitable nuclease can be introduced into a cell to induce genome editing of a target DNA sequence including, but not limited to, CRISPR-associated protein (Cas) nucleases, zinc finger nucleases (ZFNs), transcription activator-like effectors (TALENs), meganucleases, other endo- or exo-nucleases, variants thereof, fragments thereof, and combinations thereof. In particular embodiments, nuclease-mediated genome editing of a target DNA sequence (e.g., a safe harbor gene) by homology-directed repair (HDR) (e.g., homologous recombination) is used for generating a genetically modified human neural stem cell in accordance with the methods described herein.

The term “DNA nuclease” refers to an enzyme capable of cleaving the phosphodiester bonds between the nucleotide subunits of DNA, and may be an endonuclease or an exonuclease. According to the invention, the DNA nuclease may be an engineered (e.g., programmable or targetable) DNA nuclease which can be used to induce genome editing of a target DNA sequence such as a safe harbor gene. Any suitable DNA nuclease can be used including, but not

limited to, CRISPR-associated protein (Cas) nucleases, zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), meganucleases, other endo- or exo-nucleases, variants thereof, fragments thereof, and combinations thereof.

In various embodiments of the invention, a gene editing system utilizes a DNA nuclease to edit a gene and repair a mutation. In specific embodiments, a mutation is repaired using one or more of the following gene editing system: CRISPR/Cas system, Cre/Lox system, TALEN system and homologous recombination.

The differentiation protocol of the present invention may be utilized to treat a disease or disorder in a subject. The method includes administering to a subject a BFCN generated using the culturing method described herein. In various embodiments, the disease or disorder is an amyloidogenic disease, such as systemic amyloidosis, Alzheimer’s disease, mature onset diabetes, Parkinson’s disease, Huntington’s disease, fronto-temporal dementia, and prion-related transmissible spongiform encephalopathies. In embodiments, a BFCN having a mutation that impairs neuronal excitability, such as PSEN2^{N141I}, may be obtained from a subject and used to generate an iPSC, which in turn may be treated with a gene editing system to repair the mutation. The gene edited iPSC is then cultured as described herein to produce BFCNs having restored neuronal excitability which are administered to the subject to treat the disease or disorder.

In a related manner, neuronal excitability in BFCNs in a subject may be restored. This method includes: a) isolating a BFCN from the subject, wherein the BFCN has a genetic mutation resulting in impaired neuronal excitability of the BFCN; b) generating an iPSC using the BFCN of (a); c) repairing the mutation in the iPSC; d) culturing the iPSC of (c) using the differentiation protocol described herein to generate a BFCN having the repaired mutation; and e) administering the iPSC of (d) to the subject, thereby restoring neuronal excitability in BFCNs in the subject. In embodiments, the mutations is of PSEN1 or PSEN2, such as PSEN2^{N141I}.

The invention also encompasses BFCNs generated using the differentiation protocol as described herein. The BFCN may include a gene edited repair of PSEN2, as well as a detectable marker recombinantly introduced into the BFCN genome. In some embodiments, BFCNs are differentiated from PSCs, and in such embodiments, the PSCs can be iPSCs. The iPSCs can be derived from a somatic cell of a subject. In one aspect, the subject has an amyloidogenic disease or disorder.

Alongside its potential for autologous cell transplantation, iPSC technology is emerging as a tool for developing new drugs and gaining insight into disease pathogenesis. Han, S. S. W. et al., *Neuron*. 70:626-644 (2011). The methods and cells of the invention can aid the development of high-throughput in vitro screens for compounds that promote restoration of neuronal excitability. To that end, the disclosure provides a method of identifying a compound that can be used for treatment or prevention of a disease or disorder associated with diminished neuronal excitability in BFCNs. The method includes: a) contacting a BFCN or neuronal embryoid body (NEB) generated using the differentiation protocol described herein with a candidate compound, wherein the BFCN comprises a mutation in PSEN2 resulting in impaired neuronal excitability of the BFCN; and b) detecting neuronal excitability of the BFCN after contact with the candidate compound. A beneficial effect on neuronal excitability is evident in partial or complete restoration of neuronal excitability, thereby being indicative of a can-

didate therapeutic agent for treating a disease or disorder associated with diminished neuronal excitability in BFCNs, such as an amyloidogenic disease or disorder. Preferably, the method is conducted in a high-throughput format.

The invention also provides a model system for a neurological disease, preferably a disease or disorder associated with diminished neuronal excitability in BFCNs, such as an amyloidogenic disease or disorder. In one aspect, the model system comprises a BFCN differentiated from an iPSC derived from a subject having a disease or disorder associated with diminished neuronal excitability in BFCNs, such as an amyloidogenic disease or disorder. The model system can further comprise a non-human mammal into which the myelin-producing cell has been transplanted. In one embodiment, the non-human mammal is a mouse or a rat. Model systems provided by the invention can be used to study diseases or disorders, including understanding underlying mechanisms and defining therapeutic targets.

In some embodiments the present invention provides tissue culture media, tissue culture media supplements, and various kits useful in performing the various methods described herein.

In one embodiment, the invention provides a kit for generating a BFCN via the differentiation protocol of the invention. The kit includes a culture media having an inhibitor of TGF- β signaling and an activator of Shh signaling. In embodiments, the culture media is a modified mTeSR1 formulation that lacks factors that support pluripotency including bFGF, TGF- β , lithium chloride (Li-Cl), GABA and pipercolic acid. In embodiments, the culture media includes dual SMAD inhibitors, such as SB431542 and LDN193189, along with one or more agonists of smoothened protein, such as smoothened agonist (SAG) and purmorphamine.

The kit may also include an additional neuronal basal medium, such as BrainphysTM optionally supplemented with one or more of B27 supplement, an inhibitor of ROCK, NGF and BDNF.

The kit may also include reagents for detection and isolation of CD271+ cells via FACS as well as detection of expression of Tuj1, MAP2, BF1, Nkx2.1 and p75.

The kit may optionally comprise instructions for use, one or more containers, one or more antibodies, or any combination thereof. A label typically accompanies the kit, and includes any writing or recorded material, which may be electronic or computer readable form (e.g., disk, optical disc, memory chip, or tape) providing instructions or other information for use of the kit contents.

The following example is provided to further illustrate the advantages and features of the present invention, but it is not intended to limit the scope of the invention. While this example is typical of those that might be used, other procedures, methodologies, or techniques known to those skilled in the art may alternatively be used.

Example I

CRISPR/Cas9-Correctable Mutation-Related Molecular and Physiological Phenotypes in iPSC-Derived Alzheimer's PSEN2^{N141I} Mutation

Basal forebrain cholinergic neurons (BFCNs) are believed to be one of the first cell types to be affected in all forms of AD, and their dysfunction is clinically correlated with impaired short-term memory formation and retrieval. We present an optimized in vitro protocol to generate human BFCNs from iPSCs, using cell lines from presenilin 2

(PSEN2) mutation carriers and controls. As expected, cell lines harboring the PSEN2^{N141I} mutation displayed an increase in the A β 42/40 in iPSC-derived BFCNs. Neurons derived from PSEN2^{N141I} lines generated fewer maximum number of spikes in response to a square depolarizing current injection. The height of the first action potential at rheobase current injection was also significantly decreased in PSEN2^{N141I} BFCNs. CRISPR/Cas9 correction of the PSEN2 point mutation abolished the electrophysiological deficit, restoring both the maximal number of spikes and spike height to the levels recorded in controls. Increased A β 42/40 was also normalized following CRISPR/Cas-mediated correction of the PSEN2^{N141I} mutation. The genome editing data confirms the robust consistency of mutation-related changes in A β 42/40 ratio while also showing a PSEN2-mutation-related alteration in electrophysiology.

The "amyloid hypothesis" is one of the most popular formulations for the pathogenesis of Alzheimer's disease (AD). Recent examples of clinicopathological and/or clinicoradiological dissociation have led to the consideration of alternative models in order to explain, respectively, why neuropathological AD is not always associated with dementia [24], and why about one-third of patients with clinical AD have negative amyloid brain scans [40]. It has been proposed that clinical AD can be caused by one of several "feed-forward" scenarios linking amyloidosis, tauopathy, neuroinflammation, and neurodegeneration [22]. Mutations in the gene encoding presenilin 2 (PSEN2) are associated with autosomal dominant early onset familial Alzheimer's disease (EOFAD). The linkage of a locus on human chromosome 1q31-42 linked to EOFAD led to the identification of the PSEN2^{N141I} point mutation in the Volga German kindreds in 1995 [43]. This mutation causes elevation in the A β 42-43/40 ratio, thereby promoting assembly of A β oligomers and fibrils [83].

In considering the progression of AD, human basal forebrain cholinergic neurons (BFCNs) are one of the first cell types whose dysfunction underlies the early loss of short-term memory recall in all forms of AD. The "cholinergic hypothesis of AD" was formulated in the mid-1970s [6, 20, 61], and the discoveries of reduced acetylcholine release from neurons of the nucleus basalis of Meynert confirmed the presence of a presynaptic cholinergic deficit in the basal forebrain of AD patients [1, 71]. Based on those observations, acetylcholinesterase inhibitors were developed and continue as the most widely used symptomatic treatments for AD [21, 28, 33, 82]. Eventually, post-mortem brain biochemical and volumetric studies at different stages of the disease identified several other regions of the brain that were also affected early in the course of AD [63]. These studies have traditionally focused on the hippocampus and cortex, but more recently, attention has begun shifting back to the basal forebrain and adding other areas, such as the striatum [27, 62]. The latest analyses suggest that cholinergic basal forebrain volume measurement may be a better predictor of the transition from MCI to AD than the previous standard, hippocampal volume [10].

We previously reported the generation of iPSC-derived neurons from banked fibroblasts from subjects harboring PSEN1^{A246E} and PSEN1^{M146L} mutations [77]. In characterizing the gene expression profiles from these iPSC-derived neurons, we observed an unexpected association of elevated expression of the inflammasome gene NLRP2 in undifferentiated PSEN1 mutant iPSCs and their and neuronally differentiated progeny [77]. This led us to examine NLRP2 expression in our PSEN2 mutant lines and employ CRISPR/Cas9 [15] to investigate if activation of the inflammasome

was tightly linked to the pathogenic mutation in PSEN2. While we did not find altered expression of NLRP2 in gene-corrected PSEN2 lines, we observed significant mutation-related, editing-reversible differences in excitability of BFCNs.

Materials and Methods

Generation and Maintenance of iPSC Lines

7889(s)B, 050643 (Control), 948 (AD1), 949(fControl), and 950 (AD2) iPSC lines were obtained via the NYSCF Repository following the guidelines from [60]. The derivation and characterization of Nkx2.1-GFP ESC line was previously published [30]. ES and iPSC cell lines were expanded and maintained in serum-free mTeSR1™ media (Stem Cell Technologies). Cells were lifted using Strem-Pro™ Accutase (ThermoFisher) and media was supplemented with 10 μM ROCK inhibitor (Y27632, Stemgent) during cell passaging.

For all studies in this paper, cell lines underwent at least 3 independent differentiations from the iPSC stage to the mature neuron stage. Data were routinely compared across these independently derived genotype-identical neurons (or in some cases neuronal precursors), and if comparable results were obtained across independently genotype-identical derived cells, they were considered to be qualified representatives of their genotype and so were passed along for genotype-specific experimentation.

Aβ42 Oligomer Preparation

Aβ42 oligomers were prepared as previously reported [23, 78]. Briefly, we dissolved 1 mg of Aβ42 (American Peptide Company) in 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP) (Sigma). This preparation was aliquoted and dried using a SpeedVac™ centrifuge. The pellet was then resuspended in DMSO to obtain a 5 mM solution which was sonicated in a water bath for 10 min. From here aliquots were stored at -20 C and used within 2 weeks by diluting with 100 μl of PBS and leaving for 12 h at 4° C. in order for oligomerization to proceed. This final solution was diluted 1:16 in cell media for studies, allowing cells to be exposed to 5 μM of Aβ42 oligomers. Control wells were diluted with 1:16 PBS. Cells were exposed to oligomers or PBS without media change for a period of 3 days.

Cell Death Assays

Cells were assayed in a 96-well plate format. Oligomer or vehicle solutions were added to media and allowed to incubate for a period of 3 days. Media was then collected and assayed using a lactate dehydrogenase toxicity assay (Thermo Fisher Scientific). 50 μl of media and an equal amount of reaction mix buffer were incubated for a period of 30 min. An additional set of wells per experiment were treated with 2% Triton™ X-100 for a 5-min period in order to lyse all cells, and media from these wells was also collected and incubated as described. After incubation absorbance was recorded at 490 nm and 680 nm, signal and background absorbance, respectively. Signal values were subtracted from background, and values were adapted to the total LDH content as determined by Triton X-100 treated wells. Propidium iodide (Thermo Fisher Scientific) was added to cell media for a 1 μM final concentration and allowed to incubate for 5 min. Cells were then washed twice with media and imaged. Images were captured using CELIGO™ image cytometer and accompanying software (Nexcelom Bioscience). Each biological variable was assessed in technical triplicates within each designated “Experiment”, and each designated “Experiment” was performed in at least three complete “start to finish” iterations.

Differentiation of Basal Forebrain Cholinergic Neurons from iPSC and ES Cells

Human ES or iPSC were plated as single cells after chemical dissociation using Accutase™ (Sigma-Aldrich) into Cul-Trex™ (Trevigen) coated plates, at a density of 4-8×10⁵ cells per well in 6-well plates or petri dishes and adapting cell numbers. Cells were initially maintained in mTeSR1™ media (Stem Cell Technologies) until reaching full confluency. On “day 0” of differentiation, media was replaced by Custom mTeSR1™ media (Stem Cell Technologies) lacking factors promoting pluripotency i.e., bFGF, TGF-β, Li—Cl, GABA and pipercolic acid. The addition of dual SMAD inhibitors (SB431542 10 μM plus LDN193189 250 nM, Selleckchem) at day 0 drives cells towards neuroectoderm specification. At day 2 of differentiation, media was replaced by Custom mTeSR1 containing dual SMAD inhibitors plus two ventralizing agents: SAG at 500 nM (R&D) and Purmorphamine at 2 μM (Stemgent™). Cells were fed every 2 days with this media until day 9, when media was progressively switched to Brainphys™ media (Stemcell Technologies) supplemented with B27 (Life Technologies) [3]. Neural progenitors were harvested at day 11 using Accutase, p75+(CD271) NPCs were purified by FACS and plated at a density of 80,000 cells per well into non-adherent 96 well V-bottom plates in Brainphys™+B27 supplemented with 10 μM ROCK inhibitor (Y27632, Stemgent), Nerve Growth Factor, NGF, (Alamone labs, 50 ng/mL) and Brain Derived Neurotrophic Factor, BDNF, (R&D, 50 ng/mL). Cells were allowed to aggregate and form Neuronal Embryoid Bodies (NEBs) and were fed every other day until day 19. At day 19 NEBs were dissociated using Accutase (Sigma-Aldrich) and were plated as monolayer cultures on plates coated with branched polyethylenimine (0.1%, Sigma-Aldrich) and laminin (10 mg/mL, Life Technology) in Brainphys™ media+B27 supplement with BDNF and NGF. The media was changed every 2 days until analysis. As an alternative, 3D NEBs were dissected manually into 3-4 pieces for expansion and further grown, or were cryopreserved. Initial versions of the protocol used Neurobasal™ as a base media instead of Brainphys™.

Genomic DNA Isolation and Sequencing

Genomic DNA was isolated from PSEN2 mutant or control iPSC lines using High Pure™ PCR Template Preparation Kit (Roche) following manufacturer instructions. Genomic samples were treated with RNase (QIAGEN) prior to amplification. A fragment from exon 5 of PSEN2 containing PSEN2^{N141I} mutation was amplified using the following primers: Forward 5'-CATCAGCCC TTTGCTTCT-3' (SEQ ID NO: 3), Reverse: 5'-CTCACCTTGTAGCAGCGGTA-3' (SEQ ID NO: 4), generating a 173 bp fragment, regardless of the genotype. For detection of ApoE allelic variants, a fragment of 244 bp was amplified prior to sequencing using the primers: Forward: 5'-ACAGAATTCCGCCCGCCTGGTACAC-3' (SEQ ID NO: 5), Reverse: 5'-TAAGCTTGGCACGGCTGTC-CAAGGA-3' (SEQ ID NO: 6). Both PCR were performed with the following settings: 10 min 94 C, 40 cycles (30 s 94 C, 20 s 62 C, 10 s 72 C) 7 min 72 C. PCR products were run in a 2% agarose gel to check the size of the amplified fragment. After amplification, samples were cleaned using EXOSAP-It™ (Thermo Fisher Scientific) and then sequenced using the following primers: PSEN2 (Forward: 5'-TCAGCATCTACACGCCATTC-3' (SEQ ID NO: 7), Reverse: 5'-AGCACCACCAAGAAGATGGT-3') (SEQ ID NO: 8), from [53]; ApoE (Forward: 5'-ATTCGCC-CCGGCCTGGTACTGCCA-3' (SEQ ID NO: 9), Reverse: 5'-CTGTCCAAGGAGCTGCAGGCGGCAG-3' (SEQ ID NO: 10)), from [36].

CRISPR/Cas9 Gene Correction

iAD1 Control and iAD2 Control lines were originated from 948 (AD1) and 950 (AD2) iPSC lines by CRISPR/Cas9-mediated correction of the PSEN2^{N141I/WT} heterozygous point mutation to PSEN2^{WT/WT}. g1N141I single guide RNA (sgRNA) was cloned into pSpCas9(BB)-2A-GFP (PX458) vector, generating pSpCas9-g1N141I-GFP vector to direct gene editing to the sequence in exon 5 of PSEN2 where the Volga mutation is located. Single stranded oligonucleotides (ssODN) are efficient templates for the CRISPR/Cas9 correction [13, 66]. ssODN#A-N141I (sequence detail below) was used as donor sequence for gene correction. We designed asymmetric ssODN sequences with a long homology arm of 91 bp, and a short homology arm of 36 bp since asymmetrical ssODNs showed a higher efficiency of homology-directed repair using CRISPR/Cas9 [68].

TABLE 1

Sequence Name	Bases	Sequence	SEQ ID NO
g1N141I guide RNA F	25	/5Phos/CACCGCATCATGATCAGCGTCATCG	11
g1N141I guide RNA R	25	/5Phos/AAACCGATGACGCTGATCATGATGC	12
Donor ssODN#A N141I	127	GAGAGAAGCGTGGCTGGAGGGCAGGGC CAGGGCCTCACCTGTAGCAGCGTACT TGTAGAGCACCAACAAGAAGATGGTCA TAACCACGATGACGCTGATCATGATGA GGGT <u>G</u> TCAGCACGGAGT	13

Underline = base of the ssODN that corrects the point mutation.

The donor sequence and pSpCas9-g1N141I-GFP vector were transduced in the AD1 and AD2 iPSC lines, plated at 50-70% confluency, using Amaxa Human Stem Cell Nucleofector™ kit (Lonza VPH-5002) and re-plated for recovery. GFP⁺ cells were sorted in a BD FACSAria IIu Cell Sorter™ and were seeded at 30-50 cells per well in 96-well format to detect and pick single clones. Positive clones were expanded, qDNA was extracted and analyzed for successful HDR was determined using a custom designed TaqMan™ genotyping assay with a probe specific for the SNP (dbSNP ID: r563750215) located in Chr1:227,073,304 A>T. Selected clones were analyzed by Sanger sequencing to confirm correction of Chr1:227,073,304 location and discard possible insertions or deletions in the surrounding areas.

Fluorescence-Activated Cell Sorting (FACS)

Neural progenitors at day 12 of differentiation were dissociated with Accutase (Sigma-Aldrich) for 5 min at 37 C and inactivated in Neurobasal media. Cells were spun at 1000 rpm for 4 min and the pellets were resuspended in FACS buffer (DPBS, 0.5% BSA Fraction V-Solution, 100 U/mL Penicillin-Streptomycin, 0.5% EDTA and 20 mM Glucose) with PE Mouse anti-human CD271 antibody (clone C40-1457, BD) at 1:100, also known as p75 or NGFR, and incubated for 20 min at room temperature (RT) in the dark. After the incubation time, cells were washed with FACS buffer and the pellet was resuspended in 2 mL of FACS buffer with 10 μM ROCK inhibitor (Y27632, Stemgent), p75 positive cells were purified in a BD FACSAria Hu Cell Sorter™ and data was analyzed using FlowJo™ software.

Real-Time Quantitative Polymerase Chain Reaction (RT-qPCR)

Human iPSC from PSEN2 mutants or control patients were grown in a monolayer and lysed directly in the cell culture wells with RLT buffer. Total RNA purification was performed with the RNeasy™ Micro kit (Qiagen), and was carried out according to the manufacturer's instructions. cDNA was synthesized using SuperScript™ III Reverse Transcriptase (RT) (Invitrogen, Carlsbad, Calif.). Semi-quantitative real-time PCR was performed on StepOne-Plus™ Real-Time PCR System (Applied Biosystems, Foster City, Calif.) using the primers listed in Table 2 below. We normalized expression levels to GAPDH. The PCR cycling parameters were: 50° C. for 2 min, 95° C. for 10 min, followed by 40 cycles of 95° C. for 15 s and 60° C. for 1 min. Each biological variable was assessed in technical triplicates within each designated "Experiment", and each designated "Experiment" was performed in at least three complete "start to finish" iterations. Expression levels were normalized to the control line, and results were expressed as AVG±SEM.

TABLE 2

Gene	Forward Primer 5'-3'	SEQ ID NO	Reverse Primer 5'-3'	SEQ ID NO
BDNF	TAACGGCGGCAGAC AAAAAGA	14	GAAGTATTGCTTCAG TTGGCCT	15
BF1	AGAAGAACGGCAA GTACGAGA	16	TGTTGAGGGACAGAT TGTGGC	17
Nkx2.1	TAACGGCGGCAGAC AAAAAGA	18	GAAGTATTGCTTCAG TTGGCCT	19
NLRP2, ASB9	From [77]	20	From [77]	21
NLRP3	ACGAATCTCCGACC ACCACT	22	CCATGGCCACAACAA CTGAC	23
Tuj1	GAAGTGTCCAGGA CATGATAA	24	CTCTGAGTAGCTGG GATTGAG	25

Aβ Assays

Cells were conditioned for 3 days after day 8 of dual SMAD inhibition to measure secretion of A3 by neural progenitors in vitro. A3 levels were quantified using human/rat 3 amyloid 40 ELISA Kit and 3 amyloid 42 ELISA Kit high sensitive (Wako). Each biological variable was assessed using technical triplicates within each designated "Experiment", and each designated "Experiment" was performed in at least three complete "start to finish" iterations.

Immunostaining/ICC

Cells were fixed with PFA 4% directly on the wells of 12, 48 or 96 well plates for 20 min, washed 3 times with DPBS 1x(ThermoFisher). For the staining, cells were incubated in blocking solution (DPBS 1x with 0.1% Triton™ X-100 plus 5% Donkey serum) for two hours at room temperature. The corresponding primary antibodies were diluted at suitable concentration in blocking solution, and incubated overnight at 4 C. The primary antibodies used are represented in the table below. Cells were washed three times with DPBST (DPBS 1x+0.1% Triton™ X-100) and suitable secondary antibody was added in blocking solution for 1 h at room temperature. Then cells were washed three times with DPBST and incubated with DRAQ5 or Hoescht 33,342 (1 μg/mL, diluted in DPBS 1x) for 10 min at room temperature for nuclear counterstain. Cells were visualized using an

inverted fluorescence microscope (Olympus™ IX71 microscope) or a confocal microscope (Zeiss™ LSMS Pascal microscope) under 10×, 20× or 63× magnification.

Western Blots

Human iPSC from PSEN2 mutants or control patients were grown in a monolayer and lysed directly in the cell culture wells with RIPA buffer (Thermo Scientific) with protease and phosphatase inhibitors. The protein concentration was measured using the BCA protein assay kit (Thermo Scientific). After protein estimation, 20 µg of cell lysate were separated by SDS-PAGE electrophoresis on a 4-12% Bis-Tris gel (Bolt™ protein gels) and transferred onto nitrocellulose membranes by electrophoresis blotting. The membranes were blocked with blocking buffer 1×TBST (tris-buffered saline +0.1% Tween) plus 5% nonfat dry milk for 1 h in agitation at room temperature and washed three times with TBST. After washing, membranes were incubated at 4° C. overnight in agitation, with the primary antibodies against NLRP2 (1:1000), PSEN2 (1:200) or 3-actin (1:1000). After rinsing, the membranes were incubated with horseradish peroxidase (HRP)-conjugated suitable secondary antibodies for 1 h at room temperature. Finally, protein bands were visualized with a chemiluminescent reagent according to the manufacturer's instructions. 3-actin was used as loading control.

Electrophysiology

Whole cell patch-clamp recordings were obtained from single neurons between differentiation days 38 and 55. Cells were seeded at low density onto plastic coverslips which were placed in a perfusion based enclosed recording chamber. Neurons were localized using differential interference contrast optics under an Olympus BX61WI microscope fitted with a Hamamatsu Orca™ R² CCD camera. Recordings were carried out at room temperature using Multi-Clamp™ 700 B amplifier (Molecular Devices, Sunnyvale, Calif., USA). Signals were sampled at 10 kHz and filtered at 6 kHz using a Digidata™ 1440 A analog to digital converter (Molecular Devices). Amplifier control and data acquisition was done using pClamp™ 10.0 software (Molecular Devices).

During recordings neurons were perfused with oxygenated Brainphys™ media (StemCell Technologies Inc). Medium resistance recording pipettes (4-6 MΩ) were filled with an intracellular solution consisting of (in mM) 130 K-gluconate, 10 KCl, 2 Mg-ATP, 0.2 Na-GTP, 0.6 CaCl₂, 2 MgCl₂, 0.6 EGTA, and 5 HEPES titrated to pH 7.1 and osmolarity of 310 mOsm. In some experiments, the intracellular solution also contained 4 mg/mL biocytin (Sigma-Aldrich) for post-hoc identification of individual neurons, which were visualized with streptavidin-conjugated Alexa 488 (Life Sciences) as described elsewhere [42]. After initial break-in, access resistance (Rs) was constantly monitored and recordings were discarded if Rs exceeded 20 MΩ or changed more than 30%. The voltage protocol for compound Na⁺ and K⁺ currents characterization was as follows: cells were held at -80 mV potential followed by 500 ms steps from -100 mV to 30 mV with 10 mV increment at a frequency of 0.1 Hz. Following transition to current-clamp mode, resting membrane potential was recorded and cells were hyperpolarized by a negative DC current injection to -70 mV to ensure consistency of excitability measurements. Action potentials were evoked with square 1 s current steps from -10 pA to 40 pA with 1 pA steps.

Electrophysiological recordings were analyzed using ClampFit™ software (Molecular Devices, Sunnyvale, Calif., USA) and statistical significance of the results was measured using ANOVA test with Tukey's post-hoc com-

parison of means. Salts and other reagents were purchased from Sigma-Aldrich (St. Louis, Mo., USA).

Statistical Analysis

qPCR gene expression experiments and Aβ_{42/40} ELISAs were analyzed for statistical significance using Student t-test. LDH Release assays were analyzed by 2-Way ANOVA Bonferroni post hoc tests. ANOVA test with Tukey's post hoc comparisons were used for analysis of electrophysiology results. The experiments needed to study each of the 94 neurons recorded for electrophysiology analyses required days to weeks. On each experimental day, representatives from each genotype were included, with at least three samples from each genotype studied on each day. *, p<0.05; **, p<0.01; ***, p<0.001.

Results

Optimization of Protocol for BFCN Differentiation

The scheme of BFCN differentiation is described in FIG. 1A. iPSCs from control subjects or AD patients were plated iii feeder-free conditions and allowed to reach 100% confluency prior to differentiation using mTeSR1 basal media. Both branches of TGF-β signaling were inhibited (dual SMAD inhibition) to induce neuroectodermal fate on "day 0" [12]. Differentiations (day 2-10) were performed using a modified mTeSR1 formulation, lacking factors that support pluripotency (bFGF, TGF-β, Li—Cl, GABA and pipercolic acid). To specify these cells to basal forebrain cholinergic neurons, ventralization for medial ganglionic eminences (MGE) induction is required [19, 85, 91]. As such cells were treated with the Sonic Hedgehog (Shh) analog (SAG) at 500 nM and Purmorphamine at 2 µM from days 2 to 8. SAG is a suitable substitute to activate Shh signaling, as demonstrated during differentiation of ChAT⁺ motor neurons and glutamatergic interneurons [91], with lower cost than recombinant Shh and some advantages in neuronal survival properties over Shh itself [7, 35]. We used the Nkx2.1-GFP embryonic stem cell (ESC) reporter line as a tool to adjust the combination, dosage and timing of ventralizing agents more beneficial for specification of BFCNs from induced Nkx2.1 basal forebrain precursors.

However, given the potential of Nkx2.1 intermediate neural precursors to generate multiple neuronal subtypes, such as TH⁺ and GABA⁺ hypothalamic neurons, we analyzed the expression of the downstream cholinergic specification factor Lhx8 over expression of the GABAergic interneuron specific transcription factor Lhx6 [26] under different specification conditions (FIG. 1b). These data agree with those from [50] supporting the existence of a synergistic effect of SAG and purmorphamine on Nkx2.1 induction although an effect that is less than the effect of Shh plus purmorphamine (FIG. 1B). Nkx2.1-driven GFP levels were maintained after Day 14, even after withdrawal of SAG+ purmorphamine at day 8 (FIG. 1B). We observed higher Lhx8 induction upon SAG plus purmorphamine treatment than SAG alone, or even Shh plus purmorphamine (FIG. 1B). Interestingly, intermediate Nkx2.1 levels driven by SAG plus purmorphamine correlate with higher induction of Lhx8 and BF1 gene expression (FIG. 1B). Our choice of starting SHH pathway-driven ventralization at day 2 was based on reports demonstrating other MGE-derived populations being generated by earlier (e.g., hypothalamic neurons) or later (e.g., GABAergic interneurons.) ventralization in the context of dual smad inhibition protocols.

Following the patterning stage, we gradually switched from Custom mTESR1™ media to Brainphys™ media with B27 supplement to support neuronal survival and growth [3]. At day 11, we observed neural rosettes positive for Nestin and Sox2 markers (FIG. 1C); also, we observed

Tuj1+ neurites as early as day 11 (FIG. 1C). To obtain cholinergic populations of a higher purity, we developed a P75+ FACS strategy to isolate progenitors specific for cholinergic neurons due to the fact that BFCNs are the only CNS neuron type to express robust levels of P75 under non-pathogenic conditions in the adult brain). Support for this strategy includes a previously published protocol using FACS to isolate high expressing P75+ cells from the embryonic murine septum [65]. This population correlated with best expression of cholinergic-related markers.

At day 11/12, we lifted the cells using chemical dissociation (Accutase) and purified day 11-12 p75+(CD271) neural progenitors and generated 3D neuronal embryoid bodies (NEBs) by spinning down neural progenitors in V-bottom 96 well plates. On day 19 NEBs were dissociated and re-plated as a monolayer on plates coated with branched polyethylenimine (Aldrich catalog number 408727) and laminin. Monolayer cultures were maintained with the addition of growth factors BDNF, NGF and DAPT until day 26, when cultures no longer had DAPT added. Immunostaining of both cryosections of NEB structures and fixed monolayers, resulting from chemical dissociation of NEBs from several control iPSC and H9 hESC lines, demonstrated expression of BFCN lineage markers Tuj1, MAP2, BF1, Nkx2.1 and p75, at final stages of the differentiation protocol (FIG. 1D). NGF addition to neuronal cultures showed an advantageous effect on maturation, neurite outgrowth and presence of ChAT (FIG. 1E).

Generation and QC of PSEN2^{N141I} iPSC Lines

PSEN2^{N141I} mutant iPSC and control lines were generated from fresh skin biopsies. Established fibroblast lines were grown from skin punches donated by a kindred of 2 carriers for presenilin 2 Volga familial AD mutation (PSEN2^{N141I}) and one non-affected member. Additionally, we included a non-family related control. Fibroblasts were reprogrammed using modified RNA method to introduce the Yamanaka factors (Oct4, KLF4, SOX2 and c-Myc), and the iPSC lines obtained were subject to several quality control processes to ensure robust cell-renewal and pluripotency, including alkaline-phosphatase (AP) enzymatic activity, gene expression analysis and immunostaining for pluripotency markers, as well as karyotyping for detection of chromosome abnormalities, following the automated iPSC reprogramming and QC methods developed by [60]. A summary of the genotypes, sex and age of the subjects included in the study is shown in FIG. 2a. The two PSEN2^{N141I} iPSC lines were also heterozygous for APOE ε4 (ε3/ε4), whereas the control iPSC lines were homozygous ε3/ε3. The characterization of the iPSC lines, expression of pluripotency markers and quality control results are shown in FIG. 10. Briefly, all iPSC clones selected demonstrated pluripotency by embryoid body formation and differentiation into the three germ layers (FIG. 10A), incorporated herein by reference). Finally, the lines were fingerprinted (Cell Line Genetics) to ensure they matched the parental fibroblast lines (data not shown). All the parental fibroblast lines and the iPSC lines were subject to Sanger sequencing to determine PSEN2 and APOE genotypes. A 173 bp fragment from the exon 5 of PSEN2, surrounding the area where the PSEN2^{N141I} point mutation is located (Chr1:227,073, 304 A>T), was amplified by PCR and sequenced using the primers published in [53]; similarly a fragment of 244 bp from APOE locus that contains two SNPs which determine the three allelic variants was amplified by PCR from genomic DNA, and subsequently sequenced to distinguish between ε2/ε3/ε4 variants, using the primers from [36]. Sample chromatograms showing the presence of

PSEN2N141I point mutation are shown in FIG. 2B, and all genotypes are summarized in FIG. 2A.

Characterization of PSEN2^{N141I} Neural Progenitors

To study the effect of the PSEN2^{N141I} mutation in early stages of the differentiation of cholinergic neurons, we analyzed the neural progenitors (NPCs) obtained at DIV 11-16 along the BFCN differentiation protocol. The analysis of this intermediate immature population allows us to detect possible early alterations in the generation of BFCNs that would otherwise not be detected in terminally differentiated cholinergic neurons. Such defects could potentially play roles in mature neurons and contribute to the pathophysiology of AD. We analyzed the expression of early neuronal markers in PSEN2^{N141I} mutant and control NPCs by gene expression and immunofluorescence methods. Although, we found a lower RNA expression of Tuj1 (βIII-Tubulin), a general neuronal marker, in mutant NPCs at day 11 of differentiation, we did not detect quantifiable differences by immunocytochemistry circa days 16-21, (FIGS. 2C and D). NPC monolayer cultures at day 11 were also immunostained for typical NPC markers: Sox2, and Pax6; with Pax6 levels dropping as expected along with Nkx2.1 induction (not shown). We observed comparable expression of Sox2 and Nestin in PSEN2^{N141I} cultures at day 11 (FIG. 2C, top panel). At day 21, mutant NPCs expressed comparable levels of Nkx2.1 (MGE marker), but reduced levels of BF1 (forebrain marker) by qPCR; however, BF1 protein expression did not seem affected by immunostaining at this differentiation stage (FIG. 2C bottom panel, and D). We did not observe differences in the surface expression of NGFR (p75/CD271) in DIV11-12 PSEN2^{N141I} cells, in terms of percentage of positive cells or fluorescence mean peak value (FIG. 2E).

As previously published by [59, 73], the expression of mutant PSEN2^{N141I} causes an increase in the Aβ42/40 ratio in the brains of transgenic mice; additionally, this enhanced Aβ42 production was observed in neural cell lines upon induced overexpression of mutant PSEN2^{N141I} protein [83] and in iPSC derived from PSEN2^{N141I} mutant patients [93]. Consistently, we observed a 2-fold increase in the Aβ42/40 ratio, a 50% increase in the amount of secreted Aβ40 and 2.5-fold increase in Aβ42 species in the conditioned media from PSEN2N141I neural progenitors at DIV 11 (**p<0.001) (FIG. 2e). The levels of secreted Aβ40 and 42 observed in our study and the levels found in [93], using a different neuronal differentiation method applied to FAD1/PS2 iPSC lines derived from fibroblasts from the Coriell repository are very similar in both absolute number and in fold-increase.

Characterization of Mature BFCNs from PSEN2^{N141I} iPSC Lines and Controls

With the aim of determining the impact of PSEN2^{N141I} mutation on the differentiation, gene expression, function, and communication of BFCNs, we characterized cells at later time points for appropriate expression markers; our goal was to explore whether PSEN2^{N141I} iPSC were able to complete BFCN maturation process and if so, if any abnormalities along later stages of BFCN differentiation may account for the pathophysiology of EOFAD (FIG. 3). In addition to p75, which preferentially binds pro-NGF, we analyzed the expression of TrkA, the primary mature NGF receptor, was also expressed in PSEN2^{N141I} BFCNs and control (FIG. 3a). This suggested that PSEN2^{N141I} BFCNs are susceptible to receiving and benefiting from NGF pro-survival and differentiation signals as expected and further confirms their proper identity. We observed comparable expression of additional cholinergic neuron specific markers

choline acetyltransferase (ChAT) and vesicular acetylcholine transporter (vAChT) in PSEN2^{N141I} BFCNs and controls (FIG. 3b). Other general neuronal markers such as Tuj1, and the mature marker microtubule-associated protein 2 (MAP2) showed no apparent differences by immunofluorescence (FIG. 3b).

CRISPR/Cas9-Mediated Correction of PSEN2^{N141I} Mutation and Effect on A β 42/40 Ratio

To determine if the molecular alterations in the processing and cleavage of APP and/or the exacerbated activation of NLRP2 inflammasome, as previously observed in PSEN1 mutants [77], can be attributed to PSEN2^{N141I} mutation only, we modified the PSEN2 locus in our iPSC lines employing CRISPR/Cas9 technology. We did this by correcting the PSEN2^{N141I} point mutation in the two PSEN2 mutant iPSC lines (AD1, AD2). For this purpose, a specific guide RNA (g1N141I) was designed using an online tool (tools.genome-engineering.org) to direct Cas9 to the region of PSEN2 exon 5 surrounding PSEN2^{N141I} mutation (23 bp upstream of Chr1:227,073,304 A>T). g1N141I was cloned into pSpCas9 (BB)-2A-GFP (PX458) vector. Expression was assessed by GFP fluorescence upon transfection of pSpCas9-g1N141I-GFP in HEK293T (FIG. 4a).

In order to correct the mutation, we designed an asymmetric ssODN HDR (homology directed repair) template, ssODN#A-N141I, with a long homology arm of 91 bp, and a short homology arm of 36 bp since asymmetrical donor sequences with a shorter arm oriented to the area closer to the PAM side demonstrated a superior efficiency of homology-directed repair using CRISPR/Cas9 system [13]. We then proceeded to transduce pSpCas9-g1N141I-GFP and ssODN #A-N141I into the iPSC lines using AmaxaTM nucleofection (FIG. 4a). Forty-eight hours post-nucleofection cells were dissociated and the GFP⁺ population was purified by FACS and replated at low density feeder free for isolation of single gene-corrected clones (FIG. 4b). Subsequently, clones were grown and gDNA extracted post expansion. The screening of positive clones that demonstrated successful HDR was determined by qPCR using a custom designed TaqManTM genotyping assay with a probe specific for the SNP (dbSNP ID: rs63750215) located in Chr1:227,073,304 A>T. We were able to distinguish by this method between homozygous PSEN2^{N141I} heterozygous PSEN2^{N141I} and PSEN2^{WT} single clones derived from the original iPSC lines, and pre-selected clones were subjected to Sanger sequencing to confirm Chr1:227,073,304 location and detect possible insertions, deletions or mismatches introduced by CRISPR/Cas9 modification in the surrounding area and corroborate successful HDR (FIG. 4c).

Successfully corrected clones were expanded and subjected to the BFCN differentiation protocol in parallel to the other 4 lines used in the study. We collected media from BFCNs (DIV 34) and re-tested for amyloid beta production. In support of our previous finding in NPCs at DIV11-12 (FIG. 20, we observed that mature BFCNs also display significant increases in A β 42/40 ratio (FIG. 4d) and overall A3 production (FIG. 11). Importantly, these results also showed a normalization of A β 42/40 ratio to control levels in corrected lines (iAD1 Control and iAD2 Control, are corrected clones of AD1 and AD2, respectively) (FIG. 4d). These results also strengthen previous findings linking the PSEN2^{N141I} mutation to abnormal APP processing and reinforcing that presenilins contains the catalytic site of γ -secretase [90].

Assessment of Sensitivity to A β 42 Oligomer Toxicity in iPSC-Derived PSEN2^{N141I} Neurons

Previous reports have shown that iPSC lines carrying FAD mutations may display an enhanced susceptibility to noxious stimuli, such as high concentrations of A β 42 oligomers [2]. We therefore tested whether our BFCNs from PSEN2^{N141I} mutants would display enhanced toxicity to A β 42 oligomers in the media (FIG. 5). We assessed neurotoxicity by measuring the percentage of lactate dehydrogenase (LDH) released by dead cells, thus providing an indirect measurement for toxicity. Using this methodology by 2-way ANOVA we detected a significant effect in toxicity driven by 5 μ M A β 42 oligomer addition to the culture media, after 72-h exposure (***, p<0.01). Post hoc Bonferroni analysis revealed significant differences between the AD2 line and its corrected isogenic control (iAD2 Control). However, this apparent enhanced sensitivity to A β 42 oligomer toxicity was not observed in the AD1 line and its corresponding control. These results indicate that differences in susceptibility to A β 42 are not exclusively linked to mutant PSEN2 genotype, and that likely additional genetic factors different between AD1 and AD2 subjects affect susceptibility to this stress, further emphasizing the importance of multiple isogenic models.

Assessment of NLRP2 mRNA in iPSC-Derived PSEN2^{N141I} Neurons

We previously reported that NLRP2 mRNA was elevated in PSEN1 mutant iPSC and NPCs, [77] which was also the case for PSEN1 mutant cortical neurons (unpublished observation). Therefore, we wanted to analyze the status of the components of the inflammasome in the context of PSEN2^{N141I} mutation. When we assayed by qPCR the mRNA levels of NLRP2 in NPCs at DIV12, we observed an increase over 100-fold in AD1 and AD2 lines, as compared to control lines (FIG. 6a). This correlated with a notable increase in NLRP2 protein, as observed by SDS-PAGE in whole cell lysates from day 11 PSEN2 mutants (FIG. 6d). Noticeably, however we did not detect bands for NLRP2 by immunoblot in the AD2 line lysates. Further, we were unable to corroborate some other transcriptional events previously seen in PSEN1 mutant iPSC neural precursors, such as the elevated ASB9 that encodes an E3 ligase that directs mitochondrial creatine kinase for degradation. Instead, we observed a trend toward decreased levels in PSEN2 mutation carriers by 20-30%.

Assessment of Excitability of iPSC-Derived PSEN2^{N141I} BFCNs

Using BFCN differentiation protocol, we were able to generate electrophysiologically active cholinergic neurons in a dish from two PSEN2^{N141I} mutant AD patients, wild-type and familial controls starting from differentiation day 35. We were initially unable to obtain mature action potential waveforms from BFCNs grown in neurobasal media at this stage, but switching to BrainphysTM media significantly improved electrophysiological properties of cultured neurons [3]. These findings are in line with electrophysiological characterization of other iPSC generated neurons used to compare both media [3]. The benefits of the protocol containing BrainphysTM media in two additional cell lines (including the H9 embryonic stem cell line) with comparable endpoint expression of ChAT and VAcHT as well as electrophysiological responses were repeated. In order to investigate the electrophysiological properties of BFCN, we recorded from a total of 94 neurons (22 wild-type control, 21 familial control, 18 AD1, 28 AD2 and 5 iAD1_control) using whole cell patch-clamp method. In all experimental groups, recorded neurons displayed voltage-activated cur-

rents through sodium and potassium ion channels, ability to generate action potentials and displayed classical neuronal morphologies (FIG. 7). In subset of experiments, recorded neurons were labeled with biocytin through a patch pipette, which allowed for post hoc cell identification and ICH 5 characterization. We found that all biocytin-labelled cells were also immuno-positive for ChAT and VACHT (n=12, FIG. 8a).

Significant differences between the groups in terms of neuronal membrane resistance and capacitance were not 10 observed, membrane resting potential and the minimum current required for generation of a single action potential (FIG. 9). However, it was observed that there were significant mutation-related, editing-reversible differences in excitability of BFCNs.

Neurons derived from AD1 and AD2 lines (as compared to WT and familial controls) were able to generate fewer maximum number of spikes in response to a square depolarizing current injection (ANOVA test with Tukey's post hoc comparisons, FIG. 8b, c). Height of the first action potential at rheobase current injection was also significantly 20 decreased in AD1 and AD2 BFCNs (FIG. 1c). Importantly, CRISPR/Cas9 correction of the PSEN2 point mutation in the AD1 mutant iPSC line abolished the observed electrophysiological deficit, restoring both the maximal number of spikes and spike height to the levels recorded in wild-type and familial controls (ANOVA test with Tukey's post hoc comparisons, FIG. 8).

Discussion

There are 5 million people currently affected by Alzheimer's 30 disease in the US and, according to the Alzheimer's Association, this number will increase to 16 million by the year 2050. Unfortunately, we only have direct evidence for genetic causation that accounts for 3-5% of these patients. This percentage encompasses the EOFAD variants, caused by inherited fully penetrant autosomal dominant mutations 35 in the amyloid protein precursor (APP), or PSEN1, PSEN2 that constitute the γ -secretase apparatus [87], and changes in their function increases the production of A β 42 oligomers and/or deposition of amyloid plaques.

After decades studying murine models of AD that do not fully recapitulate the pathophysiology of this disease in the human brain [5, 57, 58], a complementary new concept of AD modeling in vitro has emerged upon the breakthrough by [81] allowing adult human tissue reprogramming into iPSC 40 using defined factors, and their subsequent in vitro differentiation into specific brain cell types.

BFCNs are one of the most vulnerable neuronal populations whose deterioration explains, in part, the cognitive decline in AD patients. Apart from the evidence for BFCN 45 failure and atrophy, other studies have revealed that human embryonic stem cell-derived BFCNs transplanted into AD mouse models can be associated with improvement in the learning behavior of the implanted mouse [94]. These findings highlight the relevance of iPSC- and ESC-derived BFCNs as not only early clinical indicators but also as a potential strategy for subtype-specific cell-based therapy for AD [39]. In order to move this cell-based therapeutic strategy forward, there has been an urgent need for a refined differentiation protocol to generate human ESC- and/or 50 iPSC-derived BFCNs.

Our first goal was to develop an improved protocol for the generation of BFCNs and intermediate neural progenitors (NPCs), followed by the use of these methods when differentiating cell lines from both control subjects and those 65 harboring the PSEN2^{N141I} mutation. Using fibroblasts isolated from 3 sisters, 2 carrying the PSEN2 mutation and

displaying cognitive decline, with the third wild-type for the mutation, iPSCs were developed [60]. In order to approach the dissection of the fidelity of linkage of various phenotypes to the pathogenic mutation, we began by optimizing published BFCNs protocols [4, 17, 46, 50, 89] including the purification of an intermediate CD271⁺ (p75) forebrain progenitor population by Fluorescence Activated Cell Sorting (FACS) to generate 3D ventralized neural embryoid bodies (vNEBs), which can be later dissociated to look at neuronal populations in a monolayer.

After induction of BFCN differentiation in these cell lines, we have analyzed: (1) capacity to generate Tuj1⁺/BF1⁺/ChAT⁺ neurons in vitro; (2) expression of genes/proteins of interest related to neuronal differentiation or inflammation; 15 (3) generation of soluble and oligomeric A β 40 and 42; (4) electrophysiological (ePhys) properties; and (5) selective vulnerability of BFCNs to one or more innate or microenvironmental factors within or in close approximation to those cells.

Several studies in AD mouse models highlight electrophysiological defects associated to late stages of AD pathology. Synaptic function in the hippocampus was reduced in APP23 mouse models [70]. Similarly, cholinergic neurons from the prefrontal cortex of TgCRND8 mice are unable to sustain cholinergic excitation as compared to control mice [64]. Here we report deficient electrophysiological properties in PSEN2^{N141I} iPSC-derived BFCNs in vitro. Notably, correction of this point mutation re-established neuronal excitability to the level of the control iPSC-derived neurons.

We have optimized an in vitro BFCN differentiation protocol from human iPSC, focusing on generating a homogeneous population of electrophysiologically active ChAT⁺/VACHT⁺ neurons in a reproducible and fast way. The innovations introduced to the protocol granted a homogeneous expression of Nkx2.1, a transcriptional marker for MGE subregions, as soon as day 8 and very robust by day 11, compared to day 20 suggested in previously published protocols [38]; in defined serum-free media conditions and without forcing overexpression of factors implicated in cholinergic fate. We were able to record mature action potentials in neurons from day 38 in culture, accompanying co-expression of cholinergic specific markers, which is an earlier time point as compared to other existing protocols using ES or iPSC [4, 17, 46, 50, 89]. Therefore, our protocol 45 has potential application to high-throughput drug screening in homogeneous cholinergic cultures. In addition, the 3D structure of NEBs themselves if left undissociated organoid form would also allow mechanistic analysis in a more physiological setting.

After applying this optimized protocol to PSEN2^{N141I} mutant iPSC lines, we found an increase in A β 42/40 ratio in the conditioned media. We did not observe any evident defects in the neuronal differentiation process and expression of BFCN markers. Interestingly, we observed a decrease on BDNF gene expression in PSEN2^{N141I} NPCs, similar to results described in a report [18] wherein BDNF changes were observed in homozygous and heterozygous APP^{swE}/PSEN1^{M146V} mice. The two mutant lines are also carriers of one APOE ϵ 4 allele. The presence of this allelic variant, the most common and well characterized risk factor polymorphism for LOAD [16], may modulate the age of onset and severity of the phenotype [49]. Therefore, these iPSC lines combining both the EOFAD PSEN2 Volga mutation (or CRISPR/Cas9 corrected) and APOE E4 allele constitute a tremendously useful tool to study the pathophysiology of early onset AD in vitro, especially when apoE-secreting iPSC-derived astrocytes are also present.

Searching for adjacent mechanisms or events that may be a cause or a consequence of elevated β -amyloid production, researchers have found overactivated inflammation and electrophysiological defects associated with AD mutations. The concept of these defects being independent from β -amyloid deposition and their demonstration using CRISPR/Cas9 technology to correct EOFAD mutations would open the debate to the need of combined AD treatments not only targeting β -amyloid plaques (Gandy et al., in press), but also to overcome parallel inflammatory processes or excitotoxicity/defective neuronal firing.

NLRPs are components of the inflammasome, which induces the secretion of mature pro-inflammatory cytokine IL-13 in response to pathogens and toxic stimuli [11, 41]. NLRP2 appears dysregulated in astrocytes [45, 51], and NLRP3 in microglia [34] in the context of Alzheimer's disease as well as in other neurological diseases like Parkinson's disease [14, 32]; additionally, NLRP2/3 are altered in pathologies that show comorbidity with AD: obesity, type-2 diabetes. We previously reported an unexpected association of elevated expression of the inflammasome gene NLRP2 in iPSC-derived neurons from banked fibroblasts from subjects harboring PSEN1^{A246E} and PSEN1^{M146L} mutations [77]. This association reminded us of the association of the inflammatory skin disease acne inversa (AI) with mutations in presenilin 1, nicastrin, APH-1 and PEN-2, raising in our minds the question of whether some γ -secretase component mutations might be associated not only with proamyloidogenic actions but also with pro-inflammatory mechanisms.

Despite our observations PSEN2^{N141I} mutant cells had elevated NLRP2 compared to controls, we were not able to attribute this upregulation to the familial PSEN2 mutation, as gene correction did not significantly reduce NLRP2 levels. Our results suggest that, although inflammasome dysregulation may occur in the brains of EOFAD patients, there may be factors triggering this event apart from any effect of PSENs on inflammasome biology that are reflected in reprogrammed PSEN2 mutant cell lines. Some potential explanations for this PSEN2-independent NLRP2 upregulation include effects of the apoE4 allele present in both PSEN2 subjects (not preset in controls) or epigenetic effects on fibroblasts collected from the EOFAD subjects that are maintained through the reprogramming process.

Electrophysiological defects in neurons have been associated with PSEN1 and PSEN2 mutations. Some of these defects are attributed to altered function of voltage-gated K⁺ channels, potentially through the cleavage of channel components mediated by the PS/ γ -secretase apparatus [44, 72]. Presenilin mutations also disrupt calcium signaling by increasing the levels of calcium stored in the endoplasmic reticulum that result in increased stimulus-induced released into the cytosol, rather than altered influx of calcium. One of the mechanisms behind neuronal calcium dysregulation was described in cortical neurons from PSEN1^{M146V} mice, mediated by inositol triphosphate (IP3) [79]; and, more directly, the formation of dual function protein-ion channels by unprocessed PSEN1 and PSEN2 themselves, modulating the exit of calcium from the endoplasmic reticulum [29, 55, 80, 84]. Given the important role of presenilins on potassium and calcium flux and neuronal excitability, mutations in PSEN1 and PSEN2 may lead to reduced neuronal excitability and neurotoxicity. Mice carrying mutant forms of APP exhibited aberrant action potentials associated to a decrease in sodium currents with no alteration in potassium currents, only after plaque burden was considerable [9]. There is

evidence that APP overexpression causes hyperexcitability in mouse cortical neurons [75, 86, 92].

Mucke and Selkoe [52] have highlighted a toxic effect of A β 3 resulting in synaptic and network dysfunction. In fibroblasts and neural cell lines, A β 3-mediated accumulation of mitochondrial Ca²⁺ was elevated when mutant forms of PS1 were expressed [31]. Neuronal firing patterns in mouse hippocampal neurons were altered by exposure to A β 3 [67, 69]. A β 3 exposure was also associated with altered K⁺ channel conductance in pyramidal neurons [54]. PSEN1 mutations have been observed to associate with altered Ca²⁺ mitochondrial channels in the cerebellum, apparently causing reduced spike activity in Purkinje cells in the absence of amyloid plaque deposition [74]. A β 42 may accentuate the defects present in Ca²⁺ homeostasis by modulation of additional voltage-dependent ion channels [8, 25, 76, 88].

Apart from mouse data and immortalized neuronal cell lines, electrophysiological defects in iPSC-derived neurons upon exposure to A β 3 have been shown: hiPSC-derived cortical pyramidal neurons and GABAergic interneurons have deficient action potentials upon exposure to A β 3 [56], and neurons differentiated from hiPSC harboring PS1^{A426E} mutation also showed deficient firing patterns [47]. However, there are no previously published data on characterization of electrophysiological properties of PSEN2 mutant iPSC-derived BFCNs.

Hyper- or hypoexcitatory effects and differences in firing frequency vary with the gene mutation and are highly dependent on the neuronal subtype [37, 48]. All these events may contribute to the progressive neurodegeneration present in the pathogenesis of AD, and we specifically document events that may account for the neuronal defects associated to early stages of EOFAD human pathogenesis. Here we report defective electrophysiological properties in iPSC-derived BFCNs that are specifically associated with the PSEN2N141I familial mutation. Interestingly, although some of the previous studies attribute this impairment in neuronal activity to the build-up of plaques in the brain of AD mice, we found a substantial impairment in the induced action potentials in the absence of amyloid plaques, solely in the presence of a discrete excess of A β 42 oligomers in the culture media, consistent with other reports [18]. Correction of this point mutation re-established the firing patterns to those of the wildtype iPSC-derived neurons.

Modulators of potassium channels in neurons have proven efficacy in memory improvement in AD mouse models [44]. Modulation of Ca²⁺ channels and excitotoxicity may open a new wave of AD drugs. Understanding the mechanism through which PSEN2 mutations affect the electrophysiological activity in different subsets of neuronal populations and unraveling the connection between PSEN2, other genetic modulatory factors and inflammation will potentially lead to, not only alternative symptomatic treatments, but also to novel drugs decreasing the Ca²⁺-mediated vulnerability to ROS and potentially stopping the neuronal loss and progression of the disease, if administered at early stages.

It is clear that mutant presenilins alter neuronal excitability even before the formation of A β 3 plaques [18, 74]. One plausible hypothesis is that APP and presenilins may exert effects that modulate neuronal excitability through currently unrecognized mechanisms acting separate from their roles in the biogenesis of A β 3. Accumulation of A β 3 could synergize with the altered electrophysiological mechanisms in a pathway leading to AD. With the wealth of data supporting neuronal excitotoxicity as a key mechanism implicated in

AD, further studies focusing on clarifying the possible role(s) of PSENs and/or A3 in physiological or pathological events are warranted.

CONCLUSIONS

We have optimized an in vitro protocol to generate human BFCNs from iPSCs from presenilin 2 (PSEN2) mutation carriers and controls. As expected, PSEN2^{N141I} was associated with an increase in the A β 42/40 in iPSC-derived BFCNs, and this was reversed by CRISPR/Cas9-mediated gene editing. Unexpectedly, iPSC-derived BFCNs or cortical neurons from PSEN2^{N141I} carriers showed diminished basal excitability as quantified by a reduction of both spike frequency and spike amplitude. This electrophysiological phenotype was also abolished following CRISPR/Cas9 correction of the PSEN2^{N141I} mutation. The gene editing data confirm that there was a robust consistency of mutation-related changes that characterized all the expected findings and genotypes from all cells.

Abbreviations

AD: Alzheimer's disease;
 ApoE: Apolipoprotein E;
 APP: Amyloid protein precursor;
 AVG: Average; A3: Amyloid beta;
 BDNF: Brain derived neurotrophic factor;
 BF1: Brain factor 1;
 BFCNs: Basal forebrain cholinergic neurons;
 ChAT: Acetylcholine transferase;
 DAPT: (N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester);
 DIV: Days in vitro;
 DNA: Deoxyribonucleic acid;
 DPBS: Dulbecco's phosphate-buffered saline;
 DPBST: Dulbecco's phosphate-buffered saline+0.1% Triton X-100;
 EGTA: Ethylene-bis(oxyethylenitrilo)tetraacetic acid;
 EOFAD: Early onset familial Alzheimer's disease;
 ESC: Embryonic stem cells;
 FACS: Fluorescence-activated cell sorting;
 GAPDH: Glyceraldehyde-3-phosphate dehydrogenase;
 GFP: Green fluorescent protein;
 HDR: Homology directed repair;
 HFIP: 1,1,1,3,3,3-hexafluoro-2-propanol;
 HRP: horseradish peroxidase;
 iPSCs: Induced pluripotent stem cells;
 LDH: Lactate dehydrogenase;
 MAP2: Microtubule-associated protein 2;
 MGE: Medial ganglionic eminences;
 NEBs: Neuronal Embryoid Bodies;
 NGF: Nerve growth factor;
 NLRP2: NLR family pyrin domain containing 2;
 NPC: Neural progenitor cells;
 PFA: Paraformaldehyde;
 PSEN: Presenilin;
 RNA: Ribonucleic acid;
 Rock: Rho-associated, coiled-coil containing protein kinase;
 RT: Reverse Transcriptase;
 RT-qPCR: Real-time quantitative polymerase chain reaction;
 SAG: Smoothened agonist;
 SDS-PAGE: Sodium dodecyl sulfate polyacrylamide gel electrophoresis;
 SEM: Standard error of the mean;

sgRNA: Single guide RNA;
 Shh: Sonic hedgehog;
 SNP: Single nucleotide polymorphism;
 ssODN: Single stranded oligonucleotides;
 5 TBST: Tris-buffered saline+0.1% Tween;
 VACht: Vesicular acetylcholine transporter;
 WT: Wild type

REFERENCES (EACH ARE INCORPORATED HEREIN BY REFERENCE)

1. Arendt T, Bigl V, Arendt A, Tennstedt A (1983) Loss of neurons in the nucleus basalis of Meynert in Alzheimer's disease, paralysis agitans and Korsakoff's disease. *Acta Neuropathol* 61:101-108
2. Armijo E, Gonzalez C, Shah Nawaz M, Flores A, Davis B, Soto C (2017) Increased susceptibility to A3 toxicity in neuronal cultures derived from familial Alzheimer's disease (PSEN1^{A246E}) induced pluripotent stem cells. *Neurosci Lett* 639:74-81. doi:10.1016/j.neulet.2016.12.060
3. Bardy C, van den Hurk M, Eames T, Marchand C, Hernandez R V, Kellogg M, Gorris M, Galet B, Palomares V, Brown J, Bang A G, Mertens J, Bohnke L, Boyer L, Simon S, Gage F H (2015) Neuronal medium that supports basic synaptic functions and activity of human neurons in vitro. *Proc Natl Acad Sci USA* 112:E2725-E2734. doi:10.1073/pnas.1504393112
4. Bissonnette C J, Lyass L, Bhattacharyya B J, Belmadani A, Miller R J, Kessler J A (2011) The controlled generation of functional basal forebrain cholinergic neurons from human embryonic stem cells. *Stem Cells* 29:802-811. doi:10.1002/stem.626
5. Borchelt D R, Ratovitski T, van Lare J, Lee M K, Gonzales V, Jenkins N A, Copeland N G, Price D L, Sisodia S S (1997) Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. *Neuron* 19:939-945. doi:10.1016/S0896-6273(00)80974-5
6. Bowen D M, Smith C B, White P, Davison A N (1976) Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. *Brain* 99:459-496
7. Bragina O, Sergejeva S, Serg M, Zarkovsky T, Maloverjan A, Kogerman P, Zarkovsky A (2010) Smoothened agonist augments proliferation and survival of neural cells. *Neurosci Lett* 482:81-85. doi:10.1016/j.neulet.2010.06.068
8. Briggs C A, Schneider C, Richardson J C, Stutzmann G E (2013) Beta amyloid peptide plaques fail to alter evoked neuronal calcium signals in APP/PS1 Alzheimer's disease mice. *Neurobiol Aging* 34:1632-1643. doi:10.1016/j.neurobiolaging.2012.12.013
9. Brown J T, Chin J, Leiser S C, Pangalos M N, Randall A D (2011) Alleged intrinsic neuronal excitability and reduced Na⁺ currents in a mouse model of Alzheimer's disease. *Neurobiol Aging* 32:2109.e1-2109.e14. doi:10.1016/j.neurobiolaging.2011.05.025
10. Brueggen K, Dyrba M, Barkhof F, Hausner L, Filippi M, Nestor P J, Hauenstein K, Klöppel S, Grothe M J, Kasper E, Teipel S J (2015) Basal forebrain and hippocampus as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment—a multicenter DTI and Volumetry study. *J Alzheimers Dis* 48:197-204. doi:10.3233/JAD-150063
11. Bruey J M, Bruey-Sedano N, Newman R, Chandler S, Stehlik C, Reed J C (2004) PAN1/NALP2/PYPAP2, an inducible inflammatory mediator that regulates NF-kap-

- paB and caspase-1 activation in macrophages. *J Biol Chem* 279: 51897-51907. doi:10.1074/jbc.M406741200
12. Chambers S M, Fasano C A, Papapetrou E P, Tomishima M, Sadelain M, Studer L (2009) Highly efficient neural conversion of human E S and iPS cells by dual inhibition of SMAD signaling. *Nat Biotechnol* 27:275-280. doi: 10.1038/nbt.1529
 13. Chu V T, Weber T, Wefers B, Wurst W, Sander S, Rajewsky K, Kuhn R (2015) Increasing the efficiency of homology-directed repair for CRISPR-Cas9-induced precise gene editing in mammalian cells. *Nat Biotechnol* 33:543-548. doi:10.1038/nbt.3198
 14. Codolo G, Plotegher N, Pozzobon T, Brucale M, Tessari I, Bubacco L, de Bernard M (2013) Triggering of inflammasome by aggregated α -synuclein, an inflammatory response in synucleinopathies. *PLoS One* 8:e55375. doi: 10.1371/journal.pone.0055375
 15. Cong L, Ran F A, Cox D, Lin S, Barretto R, Habib N, Hsu P D, Wu X, Jiang W, Marraffini L A, Zhang F (2013) Multiplex genome engineering using CRISPR/Cas systems. *Science* 339:819-823. doi:10.1126/science.1231143
 16. Corder E H, Saunders A M, Strittmatter W J, Schmechel D E, Gaskell P C, Small G W, Roses A D, Haines J L, Pericak-Vance M A (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. *Science* 261:921-923
 17. Crompton L A, Byrne M L, Taylor H, Kerrigan T L, Bru-Mercier G, Badger J L, Barbuti P A, Jo J, Tyler S J, Allen S J, Kunath T, Cho K, Caldwell M A (2013) Stepwise, non-adherent differentiation of human pluripotent stem cells to generate basal forebrain cholinergic neurons via hedgehog signaling. *Stem Cell Res* 11:1206-1221. doi:10.1016/j.scr.2013.08.002
 18. Cummings D M, Liu W, Portelius E, Bayram S, Yasvoina M, Ho S-H, Smits H, Ali S S, Steinberg R, Pegasiou C-M, James O T, Matarin M, Richardson J C, Zetterberg H, Blennow K, Hardy J A, Salih D A, Edwards F A (2015) First effects of rising amyloid- β in transgenic mouse brain: synaptic transmission and gene expression. *Brain* 138:1992-2004. doi:10.1093/brain/awv127
 19. Danjo T, Eiraku M, Muguruma K, Watanabe K, Kawada M, Yanagawa Y, Rubenstein J L R, Sasai Y (2011) Subregional specification of embryonic stem cell-derived ventral Telencephalic tissues by timed and combinatory treatment with extrinsic signals. *J Neurosci* 31:1919-1933. doi:10.1523/JNEUROSCI.5128-10.2011
 20. Davies P, Maloney A J (1976) Selective loss of central cholinergic neurons in Alzheimer's disease. *Lancet* (London, England). 2:1403
 21. Davis K L, Mohs R C, Davis B M, Horvath T B, Greenwald B S, Rosen W G, Levy M I, Johns C A (1983) Oral physostigmine in Alzheimer's disease. *Psychopharmacol Bull* 19:451-453
 22. De Strooper B After Solanezumab: Where Should Alzheimer's Research Go? | ALZFORUM. 2017
 23. Echeverria V, Berman D E, Arancio O (2007) Oligomers of beta-amyloid peptide inhibit BDNF-induced arc expression in cultured cortical neurons. *Curr Alzheimer Res* 4:518-521
 24. Epelbaum S, Genthon R, Cavedo E, Habert M O, Lamari F, Gagliardi G, Lista S, Teichmann M, Bakardjian H, Hampel H, Dubois B (2017) Preclinical Alzheimer's disease: a systematic review of the cohorts underlying the concept. *Alzheimers Dement.* doi:10.1016/j.jalz.2016.12.003

25. Etcheberrigaray R, Ito E, Kim C S, Alkon D L (1994) Soluble beta-amyloid induction of Alzheimer's phenotype for human fibroblast K⁺ channels. *Science* 264:276-279
26. Flandin P, Zhao Y, Vogt D, Jeong J, Long J, Potter G, Westphal H, Rubenstein J L R (2011) Lhx6 and Lhx8 coordinately induce neuronal expression of Shh that controls the generation of interneuron progenitors. *Neuron* 70:939-950. doi:10.1016/j.neuron.2011.04.020
27. Francis P T, Palmer A M, Snape M, Wilcock G K (1999) The cholinergic hypothesis of Alzheimer's disease: a review of progress. *J Neurol Neurosurg Psychiatry* 66:137-147. doi:10.1136/JNNP.66.2.137
28. Gamzu E R, Thal L J, Davis K L (1990) Therapeutic trials using tacrine and other cholinesterase inhibitors. *Adv Neurol* 51:241-245
29. Gandy S, Doeven M K, Poolman B (2006) Alzheimer disease: presenilin springs a leak. *Nat Med* 12:1121-1123. doi:10.1038/nm1006-1121
30. Goulburn A L, Alden D, Davis R P, Micallef S J, Ng E S, Yu Q C, Lim S M, Soh C-L, Elliott D A, Hatzistavrou T, Bourke J, Watmuff B, Lang R J, Haynes J M, Pouton C W, Giudice A, Trounson A O, Anderson S A, Stanley E G, Elefanty A G (2011a) A targeted NKX2.1 human embryonic stem cell reporter line enables identification of human basal forebrain derivatives. *Stem Cells* 29:462-473. doi:10.1002/stem.587
31. Guo Q, Fu W, Holtsberg F W, Steiner S M, Mattson M P (1999) Superoxide mediates the cell-death-enhancing action of presenilin-1 mutations. *J Neurosci Res* 56:457-470. doi:10.1002/(SICI)1097-4547(19990601)56:5<457::AID-JNR2>3.0.CO;2-P
32. Gustot A, Gallea J I, Sarroukh R, Celej M S, Ruyschaert J-M, Raussens V (2015) Amyloid fibrils are the molecular trigger of inflammation in Parkinson's disease. *Biochem J* 471:323-333. doi:10.1042/BJ20150617
33. Hager K, Baseman A S, Nye J S, Brashear H R, Han J, Sano M, Davis B, Richards H M (2014) Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer's disease. *Neuropsychiatr Dis Treat* 10:391-401. doi:10.2147/NDT.S57909
34. Halle A, Hornung V, Petzold G C, Stewart C R, Monks B G, Reinheckel T, Fitzgerald K A, Latz E, Moore K J, Golenbock D T (2008) The NALP3 inflammasome is involved in the innate immune response to amyloid-Nat Immunol 9:857-865. doi:10.1038/ni.1636
35. Heine V M, Griveau A, Chapin C, Ballard P L, Chen J K, Rowitch D H (2011) A small-molecule smoothed agonist prevents Glucocorticoid-induced neonatal Cerebellar injury. *Sci Transl Med* 3:105ra104. doi:10.1126/scitranslmed.3002731
36. Hixson J E, Vernier D T (1990) Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. *J Lipid Res* 31:545-548. doi:10.0000/PMID2341813
37. Hoxha E, Boda E, Montarolo F, Parolisi R, Tempia F (2012) Excitability and synaptic alterations in the cerebellum of APP/PS1 mice. *PLoS One* 7:e34726. doi:10.1371/journal.pone.0034726
38. Hu Y, Qu Z, Cao S, Li Q, Ma L, Krencik R, Xu M, Liu Y (2016) Directed differentiation of basal forebrain cholinergic neurons from human pluripotent stem cells. *J Neurosci Methods* 266:42-49. doi:10.1016/j.jneumeth.2016.03.017
39. Hunsberger J G, Rao M, Kurtzberg J, Bulte J W M, Atala A, LaFerla F M, Greely H T, Sawa A, Gandy S, Schneider L S, Doraiswamy P M (2016) Accelerating stem cell trials

- for Alzheimer's disease. *Lancet Neurol* 15:219-230. doi: 10.1016/51474-4422(15)00332-4
40. Jack C R, Wiste H J, Weigand S D, Knopman D S, Lowe V, Vemuri P, Mielke M M, Jones D T, Senjem M L, Gunter J L, Gregg B E, Pankratz V S, Petersen R C (2013) Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity. *Neurology* 81:1732-1740. doi:10.1212/01.wnl.0000435556.21319.e4
41. Kinoshita T, Wang Y, Hasegawa M, Imamura R, Suda T (2005) PYPAF3, a PYRIN-containing APAF-1-like protein, is a feedback regulator of caspase-1-dependent interleukin-1 β secretion. *J Biol Chem* 280:21720-21725. doi:10.1074/jbc.M410057200
42. Kruglikov I, Rudy B (2008) Perisomatic GABA release and thalamocortical integration onto neocortical excitatory cells are regulated by neuromodulators. *Neuron* 58:911-924. doi:10.1016/j.neuron.2008.04.024
43. Levy-Lahad E, Wasco W, Poorkaj P, Romano D, Oshima J, Pettingell W, Yu C, Jondro P, Schmidt S, Wang K et al (1995) Candidate gene for the chromosome 1 familial Alzheimer's disease locus. *Science* 269:973-977. doi: 10.1126/science.7638622
44. Liu D, Pitta M, Lee J-H, Ray B, Lahiri D K, Furukawa K, Mughal M, Jiang H, Villarreal J, Cutler R G, Greig N H, Mattson M P (2010) The KATP channel activator diazoxide ameliorates amyloid- and tau pathologies and improves memory in the 3xTgAD mouse model of Alzheimer's disease. *J Alzheimers Dis* 22:443-457. doi: 10.3233/JAD-2010-101017
45. Liu L, Chan C (2014) The role of inflammasome in Alzheimer's disease. *Ageing Res Rev* 15:6-15. doi: 10.1016/j.arr.2013.12.007
46. Liu Y, Weick J P, Liu H, Krencik R, Zhang X, Ma L, Zhou G, Ayala M, Zhang S-C (2013) Medial ganglionic eminence-like cells derived from human embryonic stem cells correct learning and memory deficits. *Nat Biotechnol* 31:440-447. doi:10.1038/nbt.256
47. Mahairaki V, Ryu J, Peters A, Chang Q, Li T, Park T S, BurrIDGE P W, Talbot C C, Asnaghi L, Martin L J, Zambidis E T, Koliatsos V E, Koliatsos V E (2014) Induced pluripotent stem cells from familial Alzheimer's disease patients differentiate into mature neurons with amyloidogenic properties. *Stem Cells Dev* 23:2996-3010. doi:10.1089/scd.2013.0511
48. Marcantoni A, Raymond E F, Carbone E, Marie H (2014) Firing properties of entorhinal cortex neurons and early alterations in an Alzheimer's disease transgenic model. *Pflugers Arch* 466:1437-1450. doi:10.1007/s00424-013-1368-z
49. Marchani E E, Bird T D, Steinbart E J, Rosenthal B, Yu C-B, Schelleibeig G D, Wijsman E M (2010) Evidence for three loci modifying age-at-onset of Alzheimer's disease in early-onset PSEN2 families. *Am J Med Genet B Neuropsychiatr Genet* 153B:1031-1041. doi:10.1002/ajmg.b.31072
50. Maroof A M, Keros S, Tyson J A, Ying S-W, Ganat Y M, Merkle F T, Liu B, Goulburn A, Stanley E G, Elefanty A G, Widmer H R, Eggan K, Goldstein P A, Anderson S A, Studer L (2013) Directed differentiation and functional maturation of cortical interneurons from human embryonic stem cells. *Cell Stem Cell* 12:559-572. doi:10.1016/j.stem.2013.04.008
51. Minkiewicz J, de Rivero Vaccari J P, Keane R W (2013) Human astrocytes express a novel NLRP2 inflammasome. *Glia* 61:1113-1121. doi:10.1002/glia.22499

52. Mucke L, Selkoe D J (2012) Neurotoxicity of amyloid-protein: synaptic and network dysfunction. *Cold Spring Harb Perspect Med* 2:a006338. doi:10.1101/cshperspect.a006338
53. Müller U, Winter P, Graeber M B (2011) Alois Alzheimer's case, Auguste D., did not carry the N141I mutation in *PSEN2*; characteristic of Alzheimer disease in Volga Germans. *Arch Neurol* 68:1210. doi:10.1001/archneurol.2011.218
54. Nava-Mesa M O, Jiménez-Díaz L, Yajeya J, Navarro-Lopez J D (2013) Amyloid-induces synaptic dysfunction through G protein-gated inwardly rectifying potassium channels in the fimbria-CA3 hippocampal synapse. *Front Cell Neurosci* 7:117. doi:10.3389/fncel.2013.00117
55. Nelson O, Supnet C, Tolia A, Horre K, De Strooper B, Bezprozvanny I (2011) Mutagenesis mapping of the Presenilin 1 calcium leak conductance pore. *J Biol Chem* 286:22339-22347. doi:10.1074/jbc.M111.243063
56. Nieweg K, Andreyeva A, van Stegen B, Tanriover G, Gottmann K (2015) Alzheimer's disease-related amyloid-induces synaptotoxicity in human iPSC cell-derived neurons. *Cell Death Dis* 6:e1709. doi:10.1038/cddis.2015.72
57. Oddo S, Caccamo A, Shepherd J D, Murphy M P, Golde T E, Kaye R, Metherate R, Mattson M P, Akbari Y, LaFerla F M (2003) Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular A β and synaptic dysfunction. *Neuron* 39:409-421
58. Onos K D, Sukoff Rizzo S J, Howell G R, Sasner M (2016) Toward more predictive genetic mouse models of Alzheimer's disease. *Brain Res Bull* 122:1-11. doi: 10.1016/j.brainresbull.2015.12.003
59. Oyama F, Sawamura N, Kobayashi K, Morishima-Kawashima M, Kuramochi T, Ito M, Tomita T, Maruyama R, Saido T C, Iwatsubo T, Capell A, Walter J, Grünberg J, Ueyama Y, Haass C, Ihara Y (1998) Mutant presenilin 2 transgenic mouse: effect on an age-dependent increase of amyloid beta-protein 42 in the brain. *J Neurochem* 71:313-322
60. Paull D, Sevilla A, Zhou H, Hahn A K, Kim H, Napolitano C, Tsankov A, Shang L, Krumholz K, Jagadeesan P, Woodard C M, Sun B, Vilboux T, Zimmer M, Forero E, Moroziewicz D N, Martinez H, Malicdan M C V, Weiss K A, Vensand L B, Dusenberry C R, Polus H, Sy K T L, Kahler D J, Gahl W A, Solomon S L, Chang S, Meissner A, Eggan K, Noggle S A (2015) Automated, high-throughput derivation, characterization and differentiation of induced pluripotent stem cells. *Nat Methods* 12:885-892. doi:10.1038/nmeth.3507
61. Perry E K, Gibson P H, Blessed G, Perry R H, Tomlinson B E (1977) Neurotransmitter enzyme abnormalities in senile dementia. Choline acetyltransferase and glutamic acid decarboxylase activities in necropsy brain tissue. *J Neurol Sci* 34:247-265
62. Pini L, Pievani M, Bocchetta M, Altomare D, Bosco P, Cavado E, Galluzzi S, Marizzoni M, Frisoni G B (2016) Brain atrophy in Alzheimer's disease and aging. *Ageing Res Rev* 30:25-48. doi:10.1016/j.arr.2016.01.002
63. Price D L, Tanzi R E, Borchelt D R, Sisodia S S (1998) Alzheimer's disease: genetic studies and transgenic models. *Annu Rev Genet* 32:461-493. doi:10.1146/annurev-genet.32.1.461
64. Proulx É, Fraser P, McLaurin J, Lambe E K (2015) Impaired cholinergic excitation of prefrontal attention circuitry in the TgCRND8 model of Alzheimer's disease. *J Neurosci* 35:12779-12791. doi:10.1523/JNEUROSCI.4501-14.2015

65. Pruzak J, Sonntag K C, Aung M H, Sanchez-Pernaute R, Isacson O (2007) Markers and methods for cell sorting of human embryonic stem cell-derived neural cell populations. *Stem Cells* 25(9):2257-2268 Epub 2007 Jun. 21. PubMed PMID: 17588935; PubMed Central PMCID: PMC2238728
66. Ran F A, Hsu P D, Wright J, Agarwala V, Scott D A, Zhang F (2013) Genome engineering using the CRISPR-Cas9 system. *Nat Protoc* 8:2281-2308. doi:10.1038/nprot.2013.143
67. Ren S-C, Shao H, Ji W-G, Jiang H-H, Xu F, Chen P-Z, Mi Z, Wen B, Zhu G-X, Zhu Z-R (2015) Riluzole prevents soluble a_{1-42} oligomers-induced perturbation of spontaneous discharge in the hippocampal CA1 region of rats. *Amyloid* 22:36-44. doi:10.3109/13506129.2014.0.990558
68. Richardson C D, Ray G J, DeWitt M A, Curie G L, Corn J E (2016) Enhancing homology-directed genome editing by catalytically active and inactive CRISPR-Cas9 using asymmetric donor DNA. *Nat Biotechnol* 34:339-344. doi:10.1038/nbt.3481
69. Ripoli C, Cocco S, Li Puma D D, Piacentini R, Mastrodonato A, Scala F, Puzzo D, D'Ascenzo M, Grassi C (2014) Intracellular accumulation of Amyloid-(a) protein plays a major role in a-induced alterations of Glutamatergic synaptic transmission and plasticity. *J Neurosci* 34:12893-12903. doi:10.1523/JNEUROSCI.1201-14.2014
70. Roder S, Danober L, Pozza M, Lingenhoebl K, Wiederhold K-H, Olpe H-R (2003) Electrophysiological studies on the hippocampus and prefrontal cortex assessing the effects of amyloidosis in amyloid precursor protein 23 transgenic mice. *Neuroscience* 120:705-720. doi:10.1016/S0306-4522(03)00381-6
71. Rylett R J, Ball M J, Colhoun E H (1983) Evidence for high affinity choline transport in synaptosomes prepared from hippocampus and neocortex of patients with Alzheimer's disease. *Brain Res* 289:169-175
72. Sachse C C, Kim Y H, Agsten M, Huth T, Alzheimer C, Kovacs D M, Kim D Y (2013) BACE1 and presenilin/secretase regulate proteolytic processing of KCNE1 and 2, auxiliary subunits of voltage-gated potassium channels. *FASEB J* 27:2458-2467. doi:10.1096/fj.12-214056
73. Sawamura N, Morishima-Kawashima M, Waki H, Kobayashi K, Kuramochi T, Frosch M P, Ding K, Ito M, Kim T W, Tanzi R E, Oyama F, Tabira T, Ando S, Ihara Y (2000) Mutant-presenilin 2-transgenic mice: a large increase in the levels of a beta 42 is presumably associated with the low-density membrane domain that contains decreased levels of glycerophospholipids and sphingomyelin. *J Biol Chem* 275:27901-27908. doi:10.1074/jbc.M004308200
74. Sepulveda-Falla D, Barrera-Ocampo A, Hagel C, Korwitz A, Vinuesa-Veloz M F, Zhou K, Schonewille M, Zhou H, Velazquez-Perez L, Rodriguez-Labrada R, Villegas A, Ferrer I, Lopera F, Langer T, De Zeeuw C I, Glatzel M (2014) Familial Alzheimer's disease-associated presenilin-1 alters cerebellar activity and calcium homeostasis. *J Clin Invest* 124:1552-1567. doi:10.1172/JCI66407
75. Šišková. Z, Justus D, Kaneko H, Friedrichs D, Henneberg N, Beutel T, Pitsch J, Schoch S, Becker A, von der Kammer H, Remy S (2014) Dendritic structural degeneration is functionally linked to cellular Hyperexcitability in a mouse model of Alzheimer's disease. *Neuron* 84:1023-1033. doi:10.1016/j.neuron. 2014.10.024

76. Smilansky A, Dangoor L, Nakdimon I, Ben-Hail D, Mizrachi D, Shoshan-Barmatz V (2015) The voltage-dependent Anion Channel 1 mediates Amyloidtoxicity and represents a potential target for Alzheimer disease therapy. *J Biol Chem* 290:30670-30683. doi:10.1074/jbc.M115.69149
77. Sproul A A, Jacob S, Pre D, Kim S H, Nestor M W, Navarro-Sobrinho M, Santa-Maria I, Zimmer M, Aubry S, Steele J W, Kahler D J, Dranovsky A, Arancio O, Crary J F, Gandy S, Nogle S A (2014) Characterization and molecular profiling of PSEN1 familial Alzheimer's disease iPSC-derived neural progenitors. *PLoS One* 9:e84547. doi:10.1371/journal.pone.0084547
78. Stine W B, Dahlgren K N, Krafft G A, LaDu M J (2003) In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis. *J Biol Chem* 278:11612-11622. doi:10.1074/jbc.M210207200
79. Stutzmann G E, Caccamo A, LaFerla F M, Parker I (2004) Dysregulated IP3 signaling in cortical neurons of knock-in mice expressing an Alzheimer's-linked mutation in Presenilin1 results in exaggerated Ca²⁺ signals and altered membrane excitability. *J Neurosci* 24:508-513. doi:10.1523/JNEUROSCI.4386-03.2004
80. Supnet C, Bezprozvanny I (2011) Presenilins function in ER calcium leak and Alzheimer's disease pathogenesis. *Cell Calcium* 50:303-309. doi:10.1016/j.ceca.2011.05.013
81. Takahashi K, Yamanaka S (2006) Induction of Pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell* 126(4):663-676. doi:10.1016/j.cell.2006.07.024
82. Thal L J, Fuld P A, Masur D M, Sharpless N S (1983) Oral physostigmine and lecithin improve memory in Alzheimer disease. *Ann Neurol* 13:491-496. doi:10.1002/ana.410130504
83. Tomita T, Maruyama K, Saido T C, Kume H, Shinozaki K, Tokuhira S, Capell A, Walter J, Grünberg J, Haass C, Iwatsubo T, Obata K (1997) The presenilin 2 mutation (N141I) linked to familial Alzheimer disease (Volga German families) increases the secretion of amyloid beta protein ending at the 42nd (or 43rd) residue. *Proc Natl Acad Sci USA* 94:2025-2030
84. Tu H, Nelson O, Bezprozvanny A, Wang Z, Lee S-F, Hao Y-H, Serneels L, De Strooper B, Yu G, Bezprozvanny I (2006) Presenilins form ER Ca²⁺ leak channels, a function disrupted by familial Alzheimer's disease-linked mutations. *Cell* 126:981-993. doi:10.1016/j.cell.2006.06.059
85. Tucker E S, Segall S, Gopalakrishna D, Wu Y, Vernon M, Pollcux F, Lamantia A-S (2008) Molecular specification and patterning of progenitor cells in the lateral and medial ganglionic eminences. *J Neurosci* 28:9504-9518. doi:10.1523/JNEUROSCI.2341-08.2008
86. Varga E, Juhász G, Bozsó Z, Penke B, Fülöp L, Szegedi V (2014) Abeta(1-42) enhances neuronal excitability in the CA1 via NR2B subunit-containing NMDA receptors. *Neural Plast* 2014:1-12. doi:10.1155/2014/584314
87. Verdile G, Gandy S E, Martins R N (2007) The role of presenilin and its interacting proteins in the biogenesis of Alzheimer's beta amyloid. *Neurochem Res* 32:609-623. doi:10.1007/s11064-006-9131-x
88. Wang X, Zhang X-G, Zhou T-T, Li N, Jang C-Y, Xiao Z-C, Ma Q-H, Li S (2016) Elevated neuronal excitability due to modulation of the voltage-gated Sodium Channel Nav1.6 by A 1-42. *Front Neurosci* 10:94. doi:10.3389/fnins.2016.00094

89. Wicklund L, Leão R N, Strömberg A-M, Mousavi M, Hovatta O, Nordberg A, Marutle A (2010) B-amyloid 1-42 oligomers impair function of human embryonic stem cell-derived forebrain cholinergic neurons. *PLoS One* 5: e15600. doi:10.1371/journal.pone.0015600
90. Wolfe M S, Selkoe D J, Xia W, Ostaszewski B L, Diehl T S, Kimberly W T (1999) Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and [gamma]-secretase activity. *Nature* 398:513-517. doi:10.1038/19077
91. Xu H, Sakiyama-Elbert S E (2015) Directed differentiation of V3 Interneurons from mouse embryonic stem cells. *Stem Cells Dev* 24: 2723-2732. doi:10.1089/scd.2015.0122
92. Xu W, Fitzgerald S, Nixon R A, Levy E, Wilson D A (2015) Early hyperactivity in lateral entorhinal cortex is associated with elevated levels of A PP metabolites in the

- Tg2576 mouse model of Alzheimer's disease. *Exp Neurol* 264:82-91. doi:10.1016/j.expneurol.2014.12.008
93. Yagi T, Ito D, Okada Y, Akamatsu W, Nihei Y, Yoshizaki T, Yamanaka S, Okano H, Suzuki N (2011) Modeling familial Alzheimer's disease with induced pluripotent stem cells. *Hum Mol Genet* 20:4530-4539. doi:10.1093/hmg/ddr394
94. Yue W, Li Y, Zhang T, Jiang M, Qian Y, Zhang M, Sheng N, Feng S, Tang K, Yu X, Shu Y, Yue C, Jing N (2015) ESC-derived basal forebrain cholinergic neurons ameliorate the cognitive symptoms associated with Alzheimer's disease in mouse models. *Stem Cell Rep* 5:776-790. doi:10.1016/j.stemcr.2015.09.01
- Although the invention has been described with reference to the examples herein, it will be understood that modifications and variations are encompassed within the spirit and scope of the invention. Accordingly, the invention is limited only by the following claims.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 31

<210> SEQ ID NO 1

<211> LENGTH: 33258

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<220> FEATURE:

<221> NAME/KEY: misc_feature

<223> OTHER INFORMATION: chromosome 1, GRCh38.p12 Primary Assembly

<400> SEQUENCE: 1

```

ggggcctggg cggcgccgg gtccggccgg gcgctcagcc agctgcgtaa actccgctgg      60
agcgcggcgg cagagcaggt gagcggggcg tgccgggggg tgcccaggcc agggccctgt     120
cgctgcggc gctgagggc cggggtgggg ctgcgccctg agggccctgc cctgccctcc     180
gcacgcctct ggccaaggc ccttccccgg ctgtgggtct ggggcccctg cgtgcgcagc     240
gctcctggcc tctgcggcca gcgcgggggc ggagagagga gaggccccgg caggcggcgg     300
ctgggcggc cgggaactgg gtcggtggaag gatcgcgggg agcggccctc aggccttcgg     360
cctcactgcg tccccacttc cctgcgcccc cctgccgcgg agccccggct gggggtgggc     420
gcggcgcgag cggttaaagg gccgggtgcat ttaaaggagc ggtgcacgtg ggtctctgag     480
gcgtgtagca ggcggggggc ttttgttctt cttctctctc gccggagacc tccggtgccc     540
cgagtccatt cggcctctag caccgggtcc tgggcatgct tccccggga aggagcgcg     600
cgggggctct gcccgcacgt gaggggcagg gccgcaggct caagcctaga gccggtttct     660
gtagcagcg gtgtttggt gttttatcag gcatttccag cagtgaggag acagccagaa     720
gcaagctttt ggagctgaag gaacctgaga cagaagctag tccccctct gaattttact     780
gatgaagaaa ctgaggccac agagctaaag tgacttttcc caaggtcgcc caggtagcat     840
atagcagagc caggcttcga cccagtgtc ctggcttcta gatctgctgt ccatccctcc     900
gagcagacct caccctggt tattgcctta ataagtattc ctttgaaag gtatgaacgg     960
tgttgagtga agtaactgca tccctattta caaatggaga acctgagagc attccataga    1020
gacgattgta gactaactta actcagaagc gacagcctgg ggttgccaag gctgtctacg    1080
aagtaacttg attaggaccg accccagctt ccagtaagga agcctctgat gcctctgtag    1140
ccaattctgc agacacctga gcctccaagg ccttcagcca agacctttgg cggtaattgg    1200
agtctcggga taagctgctt cagggtgtgt agcctcagg tcttctctcc tgaatgtggt    1260
tgtgggcagc cggtgactgg cgcaggtgca gaaggggcct ggttcttggc cccacctcag    1320

```


-continued

agctgcgtcc	tcacgacgcc	cacggtgagc	cttgggttcc	agggcagaga	ctggagtgag	1380
ggcttggggg	catggtgctt	tgaagtggga	tggatgtatc	aggtttttgg	ggaaaactct	1440
gtaccctttg	gtgttgaagt	gcccattgtc	caagtcttga	gtccagcatg	ttcacatgtg	1500
gggagtgagt	ggcttggtcc	tgtctatttg	aaagagcagc	aaggaggagg	aggagcaagg	1560
gctaggggct	gctgctgggg	tgectggagc	tgtggtgcat	aatgtcacac	ctgtctcccc	1620
tccgtagctg	ctcacctgcc	ccccaggggg	ggtttgcctc	ttgcctactt	tgccctttct	1680
ctgttatcga	tgtaataaat	gacatatatc	tcgcttatga	gttggtcata	ataaaaagct	1740
atcttgtaga	gaatattaga	atttaagatc	ttaagaatth	caatgacact	gaaatagttt	1800
attattacct	ttttacagaa	gaggaaacaa	gttcagggag	ttaagcagct	agtccagtta	1860
tgtggcttca	gtgctttaag	caccaggatt	tgaacatagc	tggctacact	gtctttatct	1920
cttgagtttt	tgcgcaggag	gttctgtgat	tcaactccta	cccgtgtctc	tccactactg	1980
ctgggaaagt	tttgtggagt	ccccatgagc	aacttctga	caaacaacaa	aaattttttt	2040
aaagaaacca	aagcagtgtg	tgtaggtcac	atgcagtgtg	tctaatgaaa	acatctctgg	2100
cgggttttca	gctggtgctt	tgactttcgg	acactgttta	gttggggact	gataagacag	2160
caaatatttc	tgcaagtatt	cccacctggt	ctattcccag	ctgccacagc	tgccgaaagg	2220
cgggggtgag	gctgagaggc	cccagagagga	acattttcca	ctgggctcca	atcctggaga	2280
tgggatgacc	atcatgttaa	tgtctggaga	aaagaatgat	ttcaggctgg	gtgctgtggc	2340
tcatgtctgt	aatcccagca	ctttgggagg	ccgaggtggg	tggatcacct	gaggtcggaa	2400
gtttgagacc	agcctgacca	acatggagaa	acccatctt	tactaaaaat	acaaaattag	2460
ccgggctggt	tggcacatgc	ctgtaatccc	agctactcag	gaggctgagg	caggagaatc	2520
gcttgaacct	aggaggcggg	ggttgcagtg	agccgagatc	gggcatggc	actccagcct	2580
gggcaacaag	agcaaaactc	catctcaaaa	aaaaaaaaat	ggtttcacat	cagtctcag	2640
gaaagatcag	atgtcagtga	gggagatcat	ttcttgagag	cctcttcact	gagtgggaga	2700
atgggctgct	tgttcactct	tgtgaaaatt	ctagaacggg	aagaacaatt	caaaggtgt	2760
ccaccattct	gctgtacctt	aaccagaaac	ttactggact	cttttataaa	taaaagtaat	2820
tcatgtttat	tctagaaaat	tagggaaaaa	aaattttttt	tgagatggag	tttactctt	2880
gttgcccagg	ctggagtgcg	atggtatgat	ctcagctaac	tgcaacctct	gcttgccggg	2940
ttctagcgac	tctcctgcct	cagcctcctg	ggtagctggg	attacaggtg	cctgccacca	3000
ctcccagcta	atttttgtat	ttttattaga	ggcggggttt	caccatgttg	gccaggctgg	3060
tctcaaaactc	ctgacctcag	gtgatccgcc	aaccttgccc	tcccaaatg	ctggtattac	3120
aagcataagc	cattgcgctg	ggctgagata	accactotta	acatgcattt	ccttccacac	3180
tgttcacata	tgcatattta	tctattaaaa	caatagaggg	aggaaccgt	aggtgaagtt	3240
tgtgtatcct	gtttttctg	ttatgccttc	agaatthtcc	ttttattgag	tactcatgga	3300
aaagcagatt	tgatggctgt	gtagagcatt	tgaattatth	atcctaccag	tcccacagca	3360
ggacactttc	ccacctccc	ttttgcccc	gagaagcagt	gccctctgtc	ctcccctgc	3420
ccatattgtg	gcactcccc	ccatggagcc	aaacctacct	gggcaagtag	cagagggaga	3480
gcagagtgag	ccctgggggc	aggagagaga	cttgagagtt	ttgaggtgac	agatgagctg	3540
gtgagtgagt	gattagggag	catttcttga	cacatacctg	cccgtggtga	aggcatgtgt	3600
cttgtgagtg	tgctcccaga	aagcctgtgt	agtgtgtggt	gggctgcct	gtgtgaccaa	3660

-continued

accctggcca	ctgggtacgt	gaccctcaca	agtgctgact	gggctgagaa	gagctccttg	3720
atgggcagtt	tggagacttg	agttgtaact	gtggcttttg	gccatgggac	attaactgat	3780
tacttttgcc	cctctaggct	tcagttgtcc	ttaattataa	tacagggagc	tgactaggtg	3840
gcgttgatgg	cctttacggt	ccttgccagc	tctgacattg	tcctatggat	atgtcctttc	3900
atgtgataat	atgtttacgt	ggccatagtg	cctggggctg	ggccgggaat	ggaaacttga	3960
tctctggggc	ctggcctttg	aagccagttc	atgtgtctgg	tggttcagca	gatccgtaac	4020
tttccaagag	gcacatccat	aggetaccgt	gtcctttctc	actgtgtccc	tcctccattt	4080
catcttcttt	ataactacga	cttattgaac	atctactgtg	tgctggacac	tttacaggtt	4140
atctctaggt	tttacgataa	tcttgcaagg	tatgcctggt	ctgcttttta	cagcagagga	4200
aatgagctgt	gtcagattag	actgtctgag	gcctcttggc	cagggagtat	gtggttcaaa	4260
tcacataggc	aggcgatctg	aaccctgtca	gtctccaaag	cctctgcttt	tgaccgctga	4320
cttgctgctg	cttgtttaaa	aataaatgtg	tttctggagc	ctactccaga	ggggcgtgct	4380
aggggctccc	tctcccactt	ccccacaaac	cacccttttc	cctggctgct	tcaggaaatg	4440
agagaactct	gcctgggccc	caggcacttc	tgagtgggac	agggctgtta	gaggttaagtc	4500
tagagcctgg	cccaaaattc	aggaggcccc	atcagagggc	ccctggggcc	tgtgggtccgg	4560
gagggtggtg	gggcagtacc	tcacttccct	ttgagactca	ggccccagct	ctggcttagg	4620
ccagggagaa	ccatccccaa	gtggtatgtg	ttactatatg	agctgagatg	gatggtcagc	4680
tggaccaa	acatagtcgg	gtaccaggg	ccagggggag	gaaggtgagc	agggaagctg	4740
tgggcaattg	tctgggtatc	acctgacctt	agcaaactct	tccttgtttt	aagcgaggac	4800
gtgggacttc	tcagacgtca	ggagagtgat	gtgagggagc	tgtgtgacca	tagaaagtga	4860
cgtgttaaaa	accagcgtg	ccctctttga	aagccagggg	gcatcattca	tttagcctgc	4920
tgagaagaag	aaaccaagtg	tccgggattc	agacctctct	gcggccccaa	gtgttcgtgg	4980
taagtgcagt	gactcccaac	ctgcttttga	accctctttt	tccattagga	ttttctccgt	5040
ggaggcagat	ttccatggga	gtttgctgtg	gcattttgaa	atctgtttct	tacctagtcc	5100
cattggcctt	aaatgtaag	gccaaagcct	ttacatttct	ctgtaatgaa	aagaaggtcg	5160
aggaaattgg	gtcattgggt	ttccataatg	attgcaggaa	ctgctgacac	aagcacggct	5220
ggggagattc	tctaggtcag	actcccttgg	tttggtaat	tcagcagttt	gatccattc	5280
agctgattaa	tgggaatgtg	cagtggcttc	tttgatgtt	tgattttgca	tcctaatacca	5340
aagcagctat	cagcctcagc	acttccctgt	tgggaaggctt	tccagaacgt	agtctatgtt	5400
ggacacttcc	ttctgcctct	ctgcattttc	ctgccacttc	tctagagaat	ggggtgcagg	5460
gggtgggaga	cggggaaagc	tggtcgctga	gtggctgatg	ggacttgaca	tcaccagcc	5520
ccacccccac	ctgcccgta	gtcagcctcc	ggggagagtt	catcgctca	ccggcactct	5580
aatgtggaca	gacacctagc	agtgttgttt	atctgcacac	gtttgggtgg	tgatttttcc	5640
ctccaaggat	ttcagagcac	cagcaggctt	cagagcagac	ttaggtggct	tgcaaagcag	5700
gccctcagga	attcagaggg	tagcagaagt	ccatcccaga	tgctctgttt	tccttcagga	5760
gctaggtaaa	tcagaggggc	tgaggggaaa	atgaaaaaag	ttacagcctt	tgagtcccat	5820
ctgctcctcc	tggccaatga	gaggggatct	gggaggggca	gatgtagagg	aaaatctgtc	5880
taaatgttga	tgctegtatt	tttctttaa	agaattaata	gcctaaaata	aacctacag	5940
atacagtctg	tgtttattat	ggcgacttag	agaaatgcag	aaaaatatca	agaaaataaa	6000
aaccactctt	ggttctacca	tgcaaagata	atcatcttta	atgttttgta	atatttccga	6060

-continued

tcttttatat	acatacattt	tataaggaca	ttcagatgat	caggttcgt	aagttttatg	6120
ttcggttaaa	tttaacagcg	tgtcattggt	caggttatta	aatgtttgaa	ataagatttt	6180
tggtggctct	gtcacagtct	ccatgaagta	gcatttcagg	atcgaaaggt	atgctgtggt	6240
taaagtgttg	attcttactc	ctttcagtta	aggccagtgc	agtttgtcca	ggtagtgact	6300
gagaccagct	ttttccacac	tctcctccgc	agtgggcatt	gttttgggcc	tttttcagcc	6360
caagagctct	cttctcccca	tgcgctctg	ctggctctgag	atttttccac	tcctcctcct	6420
ccctagttgc	tctctgacca	gactctaggt	attcaggaga	aagtgttcat	tgtctcactc	6480
tctcatgtgg	caatcaagta	gtgccaagca	gtgagaggg	gaaggtgggt	gggtgaggg	6540
cactcacctt	gctgagaaa	ggccccagcc	tggtcgggtg	attataaagc	agagacagtg	6600
ccaggaaaag	tctgacactg	gctgagaatc	accgggggac	caacctccc	gaatgcggat	6660
ccctgacact	gggtgaggat	ggagcttgg	gatctgcatt	gttaataagc	agcctagcag	6720
agtgggaag	agtccagaca	cactacctag	gtccaaggg	aaccttgagc	taattacttt	6780
ttgagcctct	gtttcctcat	cagtacctag	gggaagaata	gtagcacctt	gctccaggat	6840
gtttagtgc	ggctaagggc	tcagcaggtg	ctggctccatc	tccaccagcc	cccagtggcc	6900
tgggccacct	ttgagaaaca	gtgatcctaa	gggattcagc	atttccctaa	ttgggtgcctc	6960
ccacctgtca	ccccacccc	accaggctag	gagggttgg	attagagggt	gccttgctg	7020
tgacagctga	gactagctct	tccctgatta	ttccttaatg	acagctctct	ccttccctgc	7080
tttcttgaag	tcttggctct	cgttgttgg	ggcacagctt	caggggaggc	cttgaggaa	7140
tttttgaaag	tggaatgagg	gaagcagcct	gctcaaggga	acacttgttt	tctggtgagg	7200
aggccgcag	tatgaatgac	gtttgtgggt	tagaaaagcat	gttttgtagt	ttttccttgt	7260
ttcttctga	agacatgtca	ggtcttgatg	agaccgggac	tgggcacagc	gcaggcagtc	7320
agcgagtgtg	gatgatgacg	acagtgggtca	ccaggctcact	gtctagacca	ggtcactgtc	7380
tagcgcagtg	tcacatggaa	agggtatggt	cctttaacc	taccctccc	agcacaacta	7440
tcacagatgt	cagggaaact	ctgctcacag	aactgcttcc	cagggattgt	cttttttttc	7500
tttttctttt	tctttctttt	ttttttgaga	cagagtctca	ctctgtcgcc	caggctgaag	7560
tgcagtgggtg	cgatctcagc	tcaactgcagc	ctccgcctcc	tgggttcaag	tgattatctt	7620
gctacagcct	tctgagtagc	tgggattaca	ggtgcctgcc	accatgtcca	gctaattttt	7680
gtatttttat	tagagacggg	gtttcccat	gttgctagg	ctggctctga	actcctgacc	7740
tcaggtgatc	tgccacctc	agacaggcat	gagcaccgca	cccagcccca	gggagcgtct	7800
tattagtgg	tggcaactga	atggagacgt	gggaattgta	aggaactgat	tctacttgat	7860
cctgggtccc	ctgcttctcc	atcttccccc	accatcagc	tccctttctc	ctttaaacag	7920
gcacctttgc	tctctgctta	tccatttttg	ttgtgcattg	ctatttggga	gcctaagaaa	7980
cacaacatcc	tctgaatgct	ccagctgttg	tgggtctgaa	gggtgagcct	gccctctgtc	8040
attggaggct	gcagcctgtg	gcttttttagg	tacagggact	cccagaactg	ctcctccagt	8100
catagcagag	ataaatcaca	ggagcttaag	aggcatggga	agaacagagg	gaggagatcg	8160
tagcttccct	gttcattcac	acccaaaaca	aaactgtcat	actagaaaag	gaggtattaa	8220
aagagccacc	tgtacagcct	cgtatctcat	ccagcacact	gctgcagatg	gaatattatg	8280
atthagcttg	agaaaatgca	gcaactcttt	gttgtgggtg	ccctctttga	gtaagagtga	8340
attccccatt	gccagagtgg	atagtgaggg	aaaccctggg	tccaggcagg	agtctgttta	8400

-continued

ggatztatct	agtgaggctg	agccagagga	ggaccttaca	gttttttctc	ttcaatttct	8460
tttatttatt	tatttatttt	tgtagagatg	gggttttgcc	atgttaccce	ggctggctct	8520
gaactcctgg	gctcaagcga	tctgtctgcc	tcagcctccc	aaactgttgg	gattacaggc	8580
gtgagccgag	ccaccatacc	cggcccttct	cctgcatttc	cacctgataa	tttctctcat	8640
ttccatagat	gatgaaggaa	ctaaagccaa	gaactttcca	aggctctgca	gctctttggg	8700
ggatgtgaag	ctgtgctcta	tttgtatgga	ttttgctggt	tcccagaact	tcctgtggc	8760
cctggggcct	agtctgaggg	tactctgagt	gaagagggag	gagggccacc	acctcttctg	8820
caaaggctgc	ttttgtaaag	ttcacttcag	ttcacatctt	cctcctggtc	agaaagcttc	8880
gggggctctc	ctctgctgca	ttaagctctt	actcctccat	caggcaccaa	actcctccct	8940
ggcatggccc	atcctaccag	gtccccacac	ttgagccaca	tccaattgct	cgatattatc	9000
aggataggtt	atgttatgtt	cccaactcat	atgtttactt	aagtggttac	ctctttccag	9060
aatgagcccc	ctcctccaaa	ctctgcctgg	tgaaatattc	ctaactttg	cagcttcaca	9120
tcctcttac	ttcttgtagc	ctgaggcatc	tactcctgac	aactgataga	ctgtgtcccc	9180
tcctgtcggg	tgcattgtcc	ttgtcactac	cctcctggct	tttagctggc	tttgcttccc	9240
gctgttgta	ctcctgtact	tgtctcatct	atcctaaaca	gaagggtgctg	caggctgggg	9300
agtttgttca	tgttgaaatc	cctgtgatgg	agggtgagcag	aggcagtctc	tgctgtgcc	9360
tcttatttgg	ggatgaagtt	aaagtccctg	taggaataat	ccaggccata	gccgggggtt	9420
ctgtcttcag	aaagaagggc	agccacaggt	cttgtaagg	ggattgaaat	tggtgactt	9480
ggtggaagga	acctgcctgc	tttgtttaaa	aaccacatat	agctgagtgt	agtggttcac	9540
actctgtaat	accagtgtt	tgggaggtg	aggcaggagg	atcacttgag	gccaggagtt	9600
tgagactagc	ttgggcaaca	acgtgagacc	ctcatttcta	caaaatattt	taaaaattag	9660
cctagtatgg	tggcgtgcat	ctgcagccct	agctactgag	gaggctgaag	tgggagaatt	9720
gcttgaacct	aggagttaa	ggctgcagtg	agctatgatt	gcaccactgt	actccaacgt	9780
aagtgaccag	tgagaccctg	tctctagaaa	taaaaataaa	aaaaatcaca	tatattgtgg	9840
ggtgacttac	ttggagacga	actttcagca	gagcgcacac	ctgctatccc	tgcccagggt	9900
gtgaagctca	gccctgaggg	tctctggaca	gcatcactc	agcctctgga	cagcgatcac	9960
tcagcctctg	gacagacagc	gatcactcag	cctctggaca	gcatcactc	agcctctgga	10020
cagcgatcac	tcagcctctg	gacagcgata	actcagcctc	tgtccccgtc	tgagatgttg	10080
gcagggactg	tcagatttgc	caggcattgt	ttgaagttct	tcccagccca	gaaacctgca	10140
tgtgtagatt	ttggtacact	gggtccccca	cttggtaacta	ctgtgtgaaa	ccccacttgg	10200
cactgtttta	gggggcaggc	ttccctcctg	tccccttggc	cttggccttc	ccctgggtcc	10260
cgccctcagt	ggcacttccc	cacctcacac	gtctgctctc	atggcttagg	tctccacttc	10320
taacctcagg	agacctggtc	ctcagacacc	tcccagacag	cttccccatt	ttatcccata	10380
gacctcaaaa	gggtgaaatt	catggctctt	cccagactc	tcttctccgg	tcttcctgt	10440
cttagtcccc	acctggctgc	cattctagac	tgtgttttct	ctcctgcgtc	aggctctgcc	10500
cttgacctct	tgacccttc	tggactctgc	cctcacttgc	atccatcctg	ctgctgtcct	10560
cagctctcct	cacctgccac	agttgtctct	gggggtcact	ttccctctct	ggctcagtggc	10620
cagactgact	tttataaacc	tggttcagat	cttgtctgtc	aagattgtcc	tcagggtgat	10680
gtgtgtctcc	ttaacatggt	gctgagacc	ctgatcatct	ccactgcccg	ccccacagtg	10740
tgaggccctc	actggaacat	tgtgccttct	gccttcctc	cctcctggga	aaaccagtct	10800

-continued

ccatcagata ggctcttctc tagaaaacat tcgtgatctc tgagatttgg ttccactttt 10860
gtgcttctgc acctaccatc aaacacccgg attgtatcat ttgtcacatt agatgatttt 10920
tgttttgttt taagacaagg gtgtttctta ctcatctttt tatccccaga gccagcatg 10980
atctttgggtg cataatagat gcaccacaga tgtttgctga ttgaatgaat gagcacactg 11040
acagtttggga gctgccctga ctttcgtggc tatgcgtttt gccccctggg atgtgagtca 11100
cctcaggcca gccccaggca aggccgctgc tgccctccatg gtaactctca aggccctctg 11160
ttttatggca gtcgtttgat tgacaggcat ctcttgggaag cttttggggc aggacttgtg 11220
tccaagtctc caggtcgcct ccagccaccc cctgagtccct ccactgcctt tgtctcacag 11280
gaaagtggaa caaggtcctt gtgctccttt ttccagggtc ttccagaggc agggctatgc 11340
tcacattcat ggccctctgac agcgaggaag aagtgtgtga tgagcggacg tccctaatgt 11400
cggctgagag ccccacgccg cgctcctgcc aggaggggcag gcagggccca gaggatggag 11460
agaacactgc ccagtgggta ggtcccacca gcagctgggg gccttcaaac aggtccctgc 11520
ggctactgta ccttacagat gaaaaccaga cattcattcc ctgatgcggg agggagaagg 11580
gaagtaatga tgaggattgg ccgaaaagggt ggggtggctgg ccatgatgga ccttccatct 11640
gcagggtttc ataggactgc gcattcacag ccagagatgg acttggcagt gggctgaagg 11700
acgctgtcca ctctgccacc ttgggttttac ctctctcatg caggtcactg tttccactgt 11760
aataggagag tttgtttgga tgccctgggtg ctaggacagg taacacagaa gcttaggatg 11820
gtagcagggg aagcattttt tggcagatgg ccagacatgg taagtgtgag aggagtctgc 11880
ctgatacacg attgactttt gagctgggga tatttgggct tcaactgtgat cattcagccc 11940
ccaggggagg agattgtaac gttagaaaga gtaggatatc gttgggagag ccacttagtt 12000
gtgtcctttc tctccgatc agggcagaac atctgaattt gcctgaacc tgttctctgt 12060
tttgcccatt atagaattaa aaaatgtctc tgtgtggact gttttcttgc agccagtctt 12120
aatcctgctt gctgaaattt gagctcactt ctccatgttc tccttgagaa cggaaccatc 12180
gtccctaagc cctgagtgaa atcacaccag cttaaaggcca ctgctctgcc actcctcagc 12240
cttttcttgt ttgttatctc cgggaagttt tgtacacttt ggttgtttca gtttctgttc 12300
atgagtagtc ttctttcttg gctgaacgtc tagattggga ctctctctgc agagaaccgg 12360
tactgaagca actgtcattt tcagtttttg tttcatttgg ctttttcttt agctgttcac 12420
ctcattagca aggcagccca tgacctgac ttgccacagt tccaaaacac aaattcttac 12480
agatcggttt gtgctagtgt ctggcaggtg tcctgccctc cctcgttacc tcctcatttg 12540
tgccctgcca ccttcccaga gcctgcgtct tctcagatgc ttaacacctg tttagcctct 12600
ctagttcaga gctacaaatt tacatgcttg attctgtggg gcagaaagt caaagtaatt 12660
tcttctctg caaattcca gtatcttagt cacacgcaa gagagtgtcc ctgtgcactg 12720
actcctctag ctagtattt gtcagccaaa aatgtttatt tatctcctgg cctgtttcct 12780
cccatacag tatggccaca tgaacagaat tgagtgaact cctgagtccc tgtattagga 12840
aggggaaaga tcttttgatt cattaacat taagttgatt cattaacat taagtcttg 12900
gcctgcagac catagcaacc ttccttctt catttatggt gcttcatcca gctccaaatc 12960
ttctctactt tgctctaca aacttttcat atgccttagt agctcataga ctgctcctta 13020
tatctggaaa gcaacattca aacttctcat ttctggttcc aaaaatccgt gcattacatg 13080
gataggctgc cgtgggggac attctgcggc cctcacgatg tggtttcca cagagaagcc 13140

-continued

aggagaacga	ggaggacggt	gaggaggacc	ctgaccgcta	tgtctgtagt	ggggttcccc	13200
ggcggccgcc	aggcctggag	gaagagctga	ccctcaaata	cggagcgaag	cacgtgatca	13260
tgctgtttgt	gcctgtcact	ctgtgcatga	tcgtgggtgt	agccaccatc	aagtctgtgc	13320
gcttctacac	agagaagaat	ggacagctgt	gagttggggg	gctgggggga	gcaggggtgg	13380
gtgagggctg	agttgccagg	gggtgggggg	cgcagcagcc	tgtgttggtc	actgtacctg	13440
cagctccaca	ccagcagcgg	taaagagcag	ggatgaagaa	ccgcccaggt	tcatggcctg	13500
gctcactgcc	tcctggattg	tgacctactt	gggcatgctt	ttaacatccc	tatgcctcag	13560
cttccttgtt	cgtataatgg	gttgataacg	cagttactgg	gagaattaag	tgagttaata	13620
tgagtgaagg	gcttagaaga	gtgtctactg	cacgtgagtg	ctcaggcaag	ctggatcctg	13680
ctgcagaaag	caagctcttg	atcctgggca	tggctgtgcc	actgatccct	gtgtgactgc	13740
aaacaaatca	cttcctctct	gagtcctctg	ttccctgaat	gtgaaacaag	gtggttggac	13800
cagatatttc	tcagctcact	tcagccttg	tgaggaagac	ttataaagcc	tttcgtttat	13860
tttagtaaaa	tacatgcaga	ggcagcagcg	tagaaaaatg	agaagcttcc	tccacttctt	13920
ccccctcccc	tttctgtggt	cctcactgct	aagcaccttc	tgtaaacttt	tttttttttt	13980
tttaaagtta	gggatttttg	tttcatttcg	tgtgtgttgg	ttttttttgt	tggtgttgtt	14040
tcttttaaag	aaaggaataa	ggccaggtgt	ggtgtctcat	gcctgtaatc	ccagcacttt	14100
gggagactga	ggtgagagga	ttatttgagc	ccaggagttt	gagaccagcc	tgggaaatgt	14160
ggcgagaccc	tgtctgtaca	aaaaatgcaa	aaattagcca	ggtgtggtgg	tacatgcctg	14220
tagtctcagc	tacttgggag	actgaggtgg	aagaacacct	gagcccagaa	gtcgaggctg	14280
cagtgagcca	tgattgcgcc	actgcactgc	agcctcagca	acagagtgag	accctgtctc	14340
aaaatttttt	taaaaaatta	aaaaagaagt	agagtcccat	cctcagaaag	cttatagtgt	14400
gtgggggatt	cagcgcagaa	caggtgaaag	catggagaga	atgcagccag	cggtttgttt	14460
gcagcagtcc	aggctgggaa	gagtgaggtt	tgagtgaatt	gcttcctgtg	tctgcttctt	14520
gagcttatga	gctgcaagga	cagcagttgc	ttcagcggat	gggggtcggg	tagtagcagg	14580
tggaggagtg	ctgggctggg	tggagctggt	ggagaggtgt	gggtgggtgg	gggaatgaga	14640
actggatggg	tgagagaagt	gcctagggag	cctttaatcc	ctgtgggggt	ggggaaagca	14700
gcagggaggt	catctagccc	tcgtcctcac	tgetgcaactg	ggcccagttg	gcaggctgag	14760
agccacaggt	ctgtggtcag	ggtgccagga	aatgagctgg	aggacagga	ctgctcatgg	14820
ggatggtgcc	cgcactccat	cagggcagca	tgtgggcagc	atgggcatcc	caggcacctc	14880
ccctagcagg	tccagaatca	ctcaaggtgg	ggagcctcga	ggagcagtca	gggcccggag	14940
catcagccct	ttgccttctc	cctcagcatc	tacacgccat	tactgagga	cacaccctcg	15000
gtgggcccagc	gcctcctcaa	ctccgtgctg	aacaccctca	tcatgatcag	cgatcatcgtg	15060
gttatgacca	tcttcttggg	ggtgctctac	aagtaccgct	gctacaaggt	gaggccctgg	15120
ccctgccctc	cagccacgct	tctctccgtc	tgccccacac	catggcggca	gggcccgtga	15180
aacagccgcc	tttagaaaaa	cacaaattag	aggaaaatag	accagattt	tttgtactcc	15240
tccccacccc	atcctgtctc	ccaccgtgga	tgacctata	ctgttctctt	ttatttttat	15300
ttattttctt	tttcttga	catggtctca	ctccattgcc	caggctggag	tgcagtgggtg	15360
cgatcatgac	tactgcagc	ctcaacctcc	tgggctcaag	ttctcccacc	cagcccctca	15420
agtagctagg	actacaggtt	tgcaccacca	tacctggcta	attaaaaaat	ttttttttgt	15480
gcaggctaga	tctcacagtg	ttgccaggc	tggctctcaa	ctcctggact	caagtgatct	15540

-continued

```

cccaccttgg cctcccaaag ttctgggatt acatgtgtga gccattgcat ccagcctggt 15600
gtcttttaaa tttacacatt atcccacttg agttcctcat tgcagtgttc caagcatcat 15660
ttctcatatt tcaaagttaa ttttgttttg cttctctttc tgaagttcta ttttaggctc 15720
ccctcacccc gataacttccc ctgaagattt attttttagtt ttccttttcc ttttcgggca 15780
aggatgtgca gaggccatgc tgaggtcttg cagccctggg agacttttgg gttgtagctg 15840
cctatagctg ccgagtagcc ccagggagta gtggaagggc agatcccatc tggccagaat 15900
catgggcaact gcctgtcccc aaagatgcca taagctttta gacagcggct tcaggctttt 15960
ctcccaggta aggggttgaa cccctaacga tggaaaggaa attaagctgg gcattaccta 16020
ttttaaaact gtttacacac aggtgcctca cagcattttt tgttcaggcc gctgccatcc 16080
atggagcagg tagatagaag tgcagagtgc ccaggctaga gggatgggac agggacagtg 16140
cagggagggg gctgagcccc cttccagcgg gggcagcaga ggggaaagcc atgggagggg 16200
ctgcaggatg tgcctgagc tgaagcttat caacaagtaa tgagtaccag ctgggcattg 16260
tggtgcacgc ctgtggtccc aactacttgg gagactgagg caggaggatc gcctgacccc 16320
aggagttaa gtctagcctg ggcaatgtaa gaccctgtct ctaaaaaat aataataaaa 16380
taagtaacaa ttacctgtgt aactgtgacg aggcagggtt tgaacattgc cgctgggagg 16440
ttggcagatg gtgggaagca ggggtggagg ctgctggttt ggagcagagg atacagattg 16500
catgggggtca agctagaaat tgcgtggcag atgtgaagag ctggccccac tgcgggcagt 16560
aggtgtctgg tggccagtcc cagaggctgt gaagaggggc tcagccatct gtctagtagg 16620
gcttccttgg aggttccacg atacaggcag atggtggtgg cccgggcagc cagggtggtg 16680
ctgggatgaa gagggttggc aggtcccaga ggcagccct tccccctttg gctgtgtgtg 16740
cagcagggcc gtggaggctg cttttagtcc aggtagacca gggccacgct gaggtcccag 16800
tgggctgagc tgggtactga tgagttggtc ctcaggggtg aggctggtgg gaagtgatgt 16860
cactgtcccg ccgatggcca gctaaggac tgggttagga tcagccccct cttgtccttc 16920
actctcccat ccttggccag gagaagagga acaggtcttt ctgaggacct gctttagtag 16980
ctttgggtag gaggggactt cccaggttct ctggtgaggc cactctatct aaaatagcac 17040
cccagtgagt ctctatcac tgtatcctaa cattattttc tccatggccc tcatcattac 17100
ctgctgatat actgtatgtt tgtctatatg tcatctaaca cccctcacac tggaacacaa 17160
tgcccgtggg cagagacttt gctagccttg gttccagagc ctagaacagt gcctggcaag 17220
taggagacac ccagcattac ctttctaagt gaaccagtag agatgggggg agaccgcaag 17280
gctatgccgg cagacctgag ggagtcctgt ctgcatgcgc tgcaggatga cctgagggga 17340
actccttggc cttctgtgcc ctctttatct gtaagggtgg cacctgatcc cttccagcgt 17400
aggcatgaag tagcctaag aagagcattc aggttgggt atcagtctca ggatcctggg 17460
ggccttagaa tttgtggcgc ttggggacac cttgtgatcg tgcaatttct gttgtctagt 17520
tcatccatgg ctggttgatc atgtcttcac tgatgctgct gttcctcttc acctatatct 17580
accttgggta agtgacagat aagcagcagg gtccctggga gccctctcc atgtggcaca 17640
agtggacatg ggcatgagga cctgggcggg gaaagatgac catcgagctc cagtcttccc 17700
cagtgccagc cgttttggga acccaggcct ccgtcgccct ctctcatggc cttgacacag 17760
gggagtggaa gtggggctgc atggtggacc acatgtttct gtctcgttcc tgatttaaaa 17820
tgaacccttc atggagaagg ctctctgtga accccagggg gatagaaacc ccccaaaatt 17880

```

-continued

tacattctga	tttttaggct	aggcctgggt	actttctggt	ttgtgggaaa	aattatctgt	17940
tctatcgccc	cttgatttgg	gatatcagcc	tgacccaggg	gcccagaagag	actgggagga	18000
caagagaaaa	cactttccca	aggacctttc	catgtgcaca	gggtcttcca	ggcatgccc	18060
atgcacattt	ctgtgatctg	ttccaagcat	ccccaccttg	ttttagaaaa	tgtctgcaat	18120
ggtaaattgt	aaggacagtg	aaggtcgggg	aaggaaatgt	tagtaaagag	ggccagggtg	18180
ggactgaatg	gtggtaaact	gctaggctgt	aatgcctcca	ctgagtccca	gtcacaggct	18240
ccaccttggg	cctgcaggga	agtgtcaag	acctacaatg	tggccatgga	ctaccccacc	18300
ctcttgctga	ctgtctgga	cttcggggca	gtgggcatgg	tgtgcatcca	ctggaagggc	18360
cctctgggtg	tgcagcaggc	ctacctcacc	atgatcagtg	cgctcatggc	cctagtgttc	18420
atcaagtacc	tcccagagtg	gtccgcgtgg	gtcatcctgg	gcgccatctc	tgtgtatggt	18480
aggtgggcag	caaggctggg	gggggcagtg	ggggcagatg	ccagggccaa	atcgtcccca	18540
gtgctgcaca	aggagggcag	gtgctgaagg	gcttgcaccc	ctttctgcag	aggcctgggt	18600
gggatccctc	ctgagagagt	cgcccttgta	aaacagaggg	gggtccacta	tttctggaac	18660
actcctgggtg	gtctagataa	aacgcagtag	tactgagct	cctcatttac	tttttttttt	18720
tttgagatgg	agtcttgctc	tgtcgcccag	gctggagtgt	agtggcgcca	tcttggtgga	18780
ctgcaacctc	cgccctcccg	gttcaagtga	ttctcctgcc	tcagcctcct	gagtagatag	18840
gattataggg	atgtgccacc	acgctgggct	aatttttgta	tttttagtag	agatgggggt	18900
tcaccatggt	ggccaggctg	atctcgaact	cctgaccttg	tgateggccc	gcctcagcct	18960
cccaaagtac	tgggattaca	ggcatgagcc	actacacca	gcctcatttt	ccattattac	19020
tgctatgctg	attgagcaag	tgcactgtta	agcactggac	acgctgtaag	tgatttggtc	19080
atcaagacag	tcctttgggt	accatgcata	tacataaccc	caaagttag	ctgctatttg	19140
atattagcat	gattatcatt	gccagtattg	ttacttccat	tttaaggtta	aagaattgga	19200
ggctcagaga	agtgggactc	cccagcctgg	ccaccgcgtc	tcgggtgcac	agctcctcca	19260
tgcttgacag	tgcctgcgag	gccctactct	ggctcacacc	agggcctgct	ctaagttgtg	19320
actggagaat	gagaatttgg	gatgccagcc	cagaggcaag	gcatgctctg	agagctccac	19380
ccggggctcc	tgtgctacag	ggcaggctct	tcttcagggg	gctgcccggg	gatagtttga	19440
caaggatgtc	tctgtcttcc	tagatctcgt	ggctgtgctg	tgtcccaaag	ggcctctgag	19500
aatgctggta	gaaactgcc	aggagagaaa	tgagccata	ttccctgcc	tgatatactc	19560
atgtgagtga	gccccctgtg	cctctgcttg	actcggggtc	agcaggcagc	ctgtgggggg	19620
acaggggctc	gcttctggc	cgtggctttc	agagttgact	gggcgatccc	aggagggtct	19680
ccactttcag	aagccaggga	gggcagtatc	ttgttattac	acagtaagaa	gcttagaaag	19740
ttaggacagg	aagcaggcat	ctgctgggat	gtgctgcagt	ccctgacttc	atcccgtcca	19800
tcctccagcg	gcatgctgcg	gtgcagggtg	cattcctgtg	atcccgcagc	cacccctcag	19860
ctctccaggc	tcttgagaag	ggactttgga	gagggattct	tcagggcagg	gggtcgggga	19920
gcaaggagct	tctgggcttc	cttgacagca	gcgtggctga	ttggcattaa	tcctaactga	19980
aggaaggca	cacgggatgg	cccctggcct	cggggtcaat	gtgtagagat	ttggacttac	20040
acatgcagtc	aacaaggca	catcaagtcc	ccattttgtg	acaggcactg	tgttaggcat	20100
tgggggacct	agcaggaaag	aagaccacag	ggcccaggc	ctcatggagc	tcacggccct	20160
gtgattgtga	tgcctcggg	ctggtgatgg	cggggcttaa	atagcctgaa	tttctggagc	20220
tctggcgtct	gcaaggtggc	ctgggaaaga	gttatggaa	cagctacaga	gttctaggta	20280

-continued

ccttcatgca gttgaggatt cgagcccgta gaggagaatc gcctgcagcg tggccccacg 20340
ggaaagcaca ttccaggcgc attccgagga tgagcggaga ccatgtatgg aaaggtagtg 20400
ccaggactgt catgagtgtc ccagggctcg ggggattcac ccgtgaactg tgaggtcttg 20460
gctctgatag acctggttct tatgctttag gaggggagac aaacagtaac agaatagaca 20520
aatgcaagag agagtgactc tggaccctc ccacaacggc ctctaaca tggagcatga 20580
gcagatacct gcaggatgga gggtcctgtg caggctttct gggacgcaga ctggccacct 20640
ccccaggcc ctgcaggcag ccaactgtag caccgcctga gatgtgaacc ttttctctc 20700
ccccagctgc catggtgtgg acggttggca tggcgaagct ggaccctcc tctcagggtg 20760
ccctccagct ccctacgac ccggagatgg gtgagtatct tggggagcta acagcctctc 20820
atcactgggg ggcagctccc taactgcacc cagctctgct cggcctggct tccctgagag 20880
gcatgagttc aggaggggca gagggaaagg tccgttgaaa accagccgga cacatgccc 20940
ttgaagattc agcaagtgtt ggaccctcgg tcctctgcca gcctctgttg catcgttctg 21000
ctgggcgtgg gtgggtggag tgggggaagc cctggtgtca ggtgctggtg ctcaggggga 21060
ccccttcttg gagctttgtt ccctggtaac actctgacca gctggtgttt ctctctcttg 21120
ttgtcccctc ctacagggtga tgacggacat cttctcttcc tggacacca gaagaagact 21180
cctatgacag ttttggggag ccttcatacc ccgaagtctt tgagcctccc ttgactggct 21240
accaggggga ggagctggag gaagaggagg aaagtaaggt gcccatgttc acacggcctg 21300
cttcagccta cggcgggagc ggagacagag ggtggaggct ccctgcagcc tgggtggagg 21360
agggcatgag gggaggggcc ccttttccca tcagaggcat ctctgtgaaa gtagaagatg 21420
cctgcagcgc tggggctctc tcagcaggcc ccatgtagtt gtccggcatg tattgagtat 21480
gggccacgtg cccgtgctgt gctgggtgag gccagccct ggtgggacc acaggctaag 21540
gagacacggg cagtaatcac atagactgag aagccaagga ctatgaagg ggccatgggg 21600
ttggggaggg gcggcaggag agcatgccac gggccttctt gacctggttg gcaggggtga 21660
gagaaagtca gctgaggaag taactgctga gctgagctct gaaggttgag tcacagcagt 21720
cactagagga gaggagcaca ggggtggggag catttctga cagacagact caggaatcag 21780
aggaagccgg ggcgggatgc agagagcaga agtggtggag agccttcaa acaggcctgg 21840
agacatgcca agataggagt tcatcctggc gtcagtacac ggtgcctgcc taacacccaa 21900
tgccagccca ctgctgcgtg ccaggcagca ccctggagca gggagatgct gcaactgctg 21960
aacagcccct gccttgagag gtgccttacg ggagcagcct ggtgacagtg gcttggcata 22020
caggactcca gtgacacggg aggggcaagc tagggaaaga tcaactctcg gtgggtctgg 22080
aaggaggagc aggtgcgcac cctccaggca ggcttggggg aggtatttat tccaaggcca 22140
actggtgtgc tgcagaccag gagttagcac agatcccacg gggcccag gactggcctc 22200
cctccagaca ccagccaaa gctctagagg gtctagatgc cacttgtgct tctgaccggc 22260
tgcaaattta gggctcccat gaccccctta ggttcaataa cttgctagaa tgactcacag 22320
aactcaggaa agcactacac ttaaaattgc agtttgtttt ttgttgcgt tttgttttg 22380
agacagggtc tcgctctgtt gccaggctg gactgcagta gcacgattgt ggctcactgc 22440
aaccttgact tcctgggctc aagtgatect cccaccttgg cctcctgagt agctgggatt 22500
acaggcacgt gctaccacac ctggctcatt tatattttta gtagagaaa ggttttgact 22560
tgttcccgg gctggttctg aactcctggg ctcaagtgat ccacctgcct tggccttcca 22620

-continued

aagtactggg	attataggtc	tgagccacag	cacccggcca	aaattagttt	tattataaga	22680
gatgcaactc	aggaccagcc	aatgaagag	acagtgaaga	agtaatgctg	atggatcaca	22740
cctggtgggg	gaaggaggac	agctggggcc	aggagcagga	gggacacctg	cagggctgga	22800
agggcagggg	aggtgggcct	ccatggtttg	tgtttattgc	ataaccattt	ttattgtcta	22860
cagtgagcaa	agttatccta	taaacaagtg	tcagggacca	ttgcactaaa	gaaaacaaac	22920
gagagcattt	tggaagctct	aatttcctga	tcagtaatgg	gtagactaat	tcccagttat	22980
atttacctgt	tgtaaggtga	aaggttcttc	agaggacctc	tgtcttgggtg	ttatatgggc	23040
ttttgaatgt	actgaaatta	aattccctaa	aaatctgtga	ttcagacttc	atactaaatt	23100
gtacagcagt	gcccagccca	aggccttgca	tttctatttg	ttgttttctt	tactctctaa	23160
gtgccaaca	ctggttttac	ctgagtttca	gaactgcccg	cttttctctg	cccaggttgt	23220
aagtcaccca	gtccacaggt	gtcccctgct	ttcccactgg	ccactgattt	ggggaggcag	23280
ctgtccatgt	ccccagtcca	catcttagct	tctagaggcc	aggtgggggtg	ggctgggctg	23340
ggcaagagca	gctgggcctt	ctgggccaga	gtttctcttc	tttttccatt	ctgtgcacgc	23400
ctcttcagta	cgggttactg	tctctcctca	cacagggggc	gtgaagcttg	gcctcgggga	23460
cttcatcttc	tacagtgtgc	tgggtggcaa	ggcggctgcc	acgggcagcg	gggactggaa	23520
taccacgctg	gcctgcttcg	tggccatcct	catgtgaggt	ggctggggat	gcgtccagct	23580
gcctcgtggg	gggggcccc	agggtcctca	ttgtggtggg	ggcaggtctc	aggatcccta	23640
gggatttttc	atttctctc	ttccctctga	gggacaagag	cagggagcgg	ggctggaagg	23700
gtcagcttga	gaccaaggct	cacaggaggt	gtgctcgccc	ctaggtgggc	tccagcctgt	23760
ggaggacagt	gcaggggagg	gtgaggagtg	taccggcccc	agcgtggctg	agcacacagc	23820
ctccaggccg	aggaccagc	tgacagcttt	gcgagtgat	gataccctcg	aggtggttgt	23880
gatgacatca	gatttgcaga	aaagaaaatt	gcttaagggc	cttgcccatg	ggcgcaaagc	23940
tagtgaggac	catgttttcc	ccctcctcca	tgccattggg	acaccacagg	gtctgaatct	24000
ggggcactag	gggtggcccc	gttactgtga	accacagcag	tgaaatgtgg	aggccctgta	24060
gtcagttaac	gtgaccagat	acacataatg	gggagacgtc	ctgccgtgac	ttcatctcag	24120
agatttogct	gtcacgttag	aggaggagga	gcgtctgagc	cgtgcgcttg	gcatctgccc	24180
cttagtgaaa	accctgggca	tggcatgatt	aaggttgatg	ctccagtgtc	cagaaggttt	24240
tctttttgcc	cacaagtata	tcagggatgg	gatggtggac	ccaggctcct	ccaccaccag	24300
actgccttac	ctgagccctg	ctggcccaaa	agatatagaa	ggcacccctg	ttccctgtgc	24360
tcacctggac	cactgcctgc	atcagctggg	tcaggggagg	atgggcagcc	cccacacctg	24420
cttcccaggg	gcaggttgcc	tggcggctct	gattcccttg	gtgccagctg	ctgagaacct	24480
tactgccatt	tcagttgagc	ccacctagct	ctcatataaa	tacatgttcc	ctgagggcat	24540
cttaccatcc	catgtgacca	ctccagccag	acaggggagg	cagcacggcc	tcggggcaca	24600
gcactgctcc	aggagtccag	aggcctgcct	tctggttca	tcactaacag	gtgaggtgat	24660
ctaatggggg	tgagaacttc	tgcccttaac	acctcaagag	ctggtgcagg	accaggggag	24720
ataatggggg	gtctagcgcc	gttatccgac	tggctctcga	acaagctcct	gtgcccaggg	24780
actagaccat	gactcacagc	toctgtccac	accagggatc	accacgctca	ccctcccctc	24840
catgtcctgc	agggcttgtg	tctgacctc	ctgctgcttg	ctgtgttcaa	gaaggcctg	24900
cccgcctcc	ccatctccat	cagttcggg	ctcatctttt	acttctccac	ggacaacctg	24960
gtgcggccgt	tcatggacac	cctggcctcc	catcagctct	acatctgagg	gacatggtgt	25020

-continued

gccacaggct gcaagctgca gggaaatcttc attggatgca gttgtatagt tttacactct 25080
 agtgccatat atttttaaga cttttctttc cttaaaaaat aaagtacgtg tttacttggg 25140
 gaggaggagg cagaaccagc tctttgggtc cagctgtttc atcaccagac tttggctccc 25200
 gctttgggga ggcctcgc tcaaggacag gaagcacagc aggtttatcc agatgaactg 25260
 agaaggtcag attagggcgg ggagaagagc atccggcatg agggctgaga tgcgcaaaga 25320
 gtgtgctcgg gagtggcccc tggcacctgg gtgctctggc tggagaggaa aagccagttc 25380
 cctacgagga gtgttcccaa tgctttgtcc atgatgtcct tgttatttta ttgcctttag 25440
 aaactgagtc ctgttcttgt tacggcagtc aactgctgg gaagtggctt aatagtaata 25500
 tcaataaata gatgagtcct gttagaatct tggagtttg tccgttgtaa atgttgacct 25560
 ctctccctgc atcttgggca cccctgggat aacttgctgt gtgagcccag gatggaggca 25620
 gtttgccctg tttgaaggaa cttttaatga tctgcctct ctgcacacat tttttaact 25680
 agaaagtctc ctaagcaaag gagttaggag agcaggggtg cctgacatct gccagccctg 25740
 agctgtaagg ctgtggatgc tgagcaggtc cctggactca gttgtgcacg gtggcacaga 25800
 cactgccagg tggttgcaa aacatccagt ggctcctca gcaagtgttc accctctgca 25860
 gaagcctgtg agggcctgag ctcagaaacc actctccttt ccttctctgg ctttggccct 25920
 gggcactgtg gtgggagagt ggacagtttg gctttgcctt ctctgtacat caatcatggg 25980
 ttgcaaagag aatctcagaa gtgcctcttc ctgagcacag tggctcacac ctgtaatccc 26040
 aatacttcgg gaggtcagat cggaaggatc acttgagccc aggagtttga gaccagccgg 26100
 ggcaacatag tgagactttg tacaaaaaaa aatttaaaaa ttagccaagc atggtggcat 26160
 gcatctgtag tctcagctac tctggaggct gaggtgggag gatcacttaa gccagggagg 26220
 ctgaggctgc aatgagccga gatcaagcag gtgttaggta tatcagacag ctgagaagac 26280
 gcaagtgtgc cctgggggtc aaactggtac ccctgtctcc ctgttccagg aataacatga 26340
 gtgccgggac aatgcatctt tattatgaga ggaatgagaa ttgtgtatct tgacatttga 26400
 caggagcttg ctttcccca ggctgtttga ggaaggcagc aggaaaatgt ggtgccctaa 26460
 gaaggaagga cagaggaggc cgaacactgg cgggtggaat cccactgatt agtagtgcag 26520
 gtcagagacc tgggatggg ggcattgccg tcatggaagc cacagcgggg agcgggtaaa 26580
 gcagacaggg atggtccctg atggtgacaa ctgcgaagag gtttaaggga aagaaaaact 26640
 gaaaagctta ttcaatttgg caattatggc agtgttatc ttcagaagag cagttttagg 26700
 gtgggggttc caaagatggg attggacata tattttgaat cattaagctt gaggtctttc 26760
 aaaggcctgg ccaagggttg ctgggtggag accacattca gaggtaaagg cagaaattgg 26820
 gggcccttaa gtagacagcg agggaggaag aatgaaggg gcctgggtgat ggtaggggtg 26880
 aagtgttaag actgagaaaa caaggacatg tgagaagacg agggaagagc attggagaga 26940
 acaaagacac tggaggagat gctacttggg ggtccccaga gagcaggag acaaatgaac 27000
 ccagaacaca aatggcaaag aagaaaaatg agagaatttg taaaagacag cattcgaaca 27060
 tgccgaacaa gagcagggtg ctggtgttca aacacctgta tctccccgt gtaaccctc 27120
 aactaatatc tttccatatt tgctccagat ttgtctttag aaataaaacc cacgttctga 27180
 agtctgttt gtatgtggc ccagtctgt tgctccgcc tcctgtcctg aagtcgattt 27240
 ctgcccttct catctatggg tagttttgtt ttgtatgtg gcatgttttc ttaactttac 27300
 agaaatggta tcatactgta catatttgat aatttttta aatattgcat tctggaggca 27360

-continued

tgtataaatg	tagctccagt	tcatttattt	tatttatttt	ttgagatgga	gttttgctct	27420
tgtcaccag	gctagagtgc	aatggcgtga	tgttggtca	ctgcaacctc	tgectcctgg	27480
gttcaagcaa	ttctcctgtc	tcaatttctt	gagtagctgg	gattacagtt	gcccggccacc	27540
atgcctggct	aattttgtat	tttagtagag	acggggtttc	accacgttag	ccaggctggg	27600
ctcaaaactcc	tgactgcagg	tgatccacgc	accttggcct	ccaaaagtgc	tgggattaca	27660
ggcgtgagcc	accgtgccc	gcccagttat	ttaactatt	gtatagtgtt	ccattgtatg	27720
agttctactg	tttatatgct	attgatcgac	ctgtaggggt	tttgcagtgt	ttctgtatta	27780
cagctgtgct	gcagtgagca	tcccatcaca	ttgtgtggat	ttgaggaagt	attggaattc	27840
ccccaattga	ctggacattc	ccaattacc	tccaagtatg	tgtctgttta	tccttccatc	27900
cgcaatctga	gagttcccca	actctataat	acttgggtgc	atcagacttt	tcatcttgtc	27960
tgattggatg	gggtgcattt	cctttagggt	ttataattat	cttttcatat	gtgtattggc	28020
tgtacaagg	tccttctctg	ttcattatta	ttaatttttt	tagacagagt	ctcgcgctgt	28080
cgcccaggct	ggagtgcagc	agcgtgatct	tggctcactg	caagctccgc	ctcccgggtt	28140
catgccattc	tcctgcctca	gctcctgag	tagctgggat	tacagggtgc	tgccatcacg	28200
cccggctagt	ttttttgtat	tttgagtaga	gatggggttt	caccgtgtta	gccaggaggg	28260
tctcgatctc	ctgacctcgt	gatccaccgc	cctcggcctc	ccaaagtgc	gggattacag	28320
gtgtgagtca	ctgcgccag	cccaagtttc	cttctctgtt	acttgttcat	atcctctgcc	28380
catttttca	ttggattttt	tgtcttacgg	atatttaagc	ctcttaaaat	atatattctg	28440
gagagatgct	aatctttgat	taattatatg	cattgcaaat	gtctggtaca	ttgtggcttg	28500
cctctcttcc	ctgccttag	gagtgttttg	ctggacccaa	gtaattttta	aatgttaatg	28560
ttattaaatc	tatcagtttt	ttgcttgtat	ggcttatgcc	attgaatctt	gttttaagag	28620
atccttccct	accctcaagg	ttttctaaat	ttttattttc	ataataagat	ttttagttca	28680
tctgaaatgt	atttttatga	ttgtatttag	tagggacct	attttgtttt	tctttgtaac	28740
cagggtgtccc	agcactgttt	actgaacagt	ctctcctttc	tcgctggtct	gtagaactct	28800
cctgacatat	accaagtttc	cataagtggg	tggatgggtt	cctgagctct	ctactgttaa	28860
tagaacttgc	tctctcgcag	gccaatgcct	caccagggtga	ttgaagcaga	gaaacttagg	28920
tggtgaaagg	agaagatggg	gctgtcctg	agagttctg	ttcctgagat	gctagaggca	28980
gagggtatgt	aatctgaag	ttacactgga	tctcctaaaa	cagtataaag	ctacagaagt	29040
ataatagtgt	ggaatgggtg	tgggagtcag	taagggttag	gtcactgcag	tggtttaaac	29100
aagatgggct	agaatccttt	cacaggcaca	ggcagcttgg	agagggtgca	atagtgcag	29160
gtatcagggg	tcagatgcct	ctttttcctt	tgagatcagt	aagtggcttt	cacctcatga	29220
cctaggctgg	ctgctgtgtg	ctagccgtca	agtcacactc	catccagcat	gaaaggaggt	29280
tagaaaagg	tgcatcttct	cttcttaaaa	acatgtctca	aagttgcaca	cagcactttt	29340
gcctatattc	aattggccat	tagtcccacg	gccatactg	tctgagactg	agagactggg	29400
aaatgtcttt	atctcaagtg	gccatatatc	cacctaaaca	agataaggga	tacgtggtta	29460
tggcgtgtct	tttggtttac	caatgcagat	aatgaagtta	ccaaaacaat	gagaaaatgg	29520
ggtcgtgagg	gatcatgtga	atcacaagct	gatgtcttca	aagacggtgg	aaatgggccc	29580
cgggaggcag	cagatgacag	cagtggggat	taaggtagac	ctccatcctg	gggttaaaat	29640
gaggggaagg	tgatggagct	ggaccagcag	tcagaatggt	cagtgggttag	gagaccctct	29700
gccccccacc	gctgccacca	ttggctctct	acagaatgcc	tgcgagtggc	ttagagtgac	29760

-continued

caaggatgag	gtgcagatcc	atgtgcaccc	cctgcccc	tctgtggaca	atthcatgc	29820
ctgacagcac	agtctatgtg	gattgcaagc	cgatgaaact	atgcaaagta	gaagcatgcc	29880
tgcagtttgt	gattcgggtga	tgtgttttat	gcttatgtga	gtcgaatggg	gcggcaggg	29940
cctgtggtea	cccgtgaga	aggaagggtc	ctgtaaccac	tgcctttctt	tcagctactt	30000
gagaaaggtg	ttgtgagga	cogtggattt	tgggacagct	ttgaatggtg	gtagggagga	30060
agggctccgg	ctgagtgaat	ggccagaaa	ctgtggggaa	gcttttagga	cattggccaa	30120
gagctccctg	aaggcagcca	gggagatact	tgtcagtaca	tgtgactaat	ggccaactga	30180
atataagcag	aagtgctgtg	ttgctgtgtg	caacactgga	caccttagga	aggacctcga	30240
gacagtgggt	gtggactctg	tagagagtaa	cagtgcagct	agcaaaccct	taccagctgc	30300
caacctgtg	ctaggctcgc	actaaatgag	ttaccttca	attctcgtaa	caataggagg	30360
taactactat	tctaatttcc	atthtataga	tgaggaaact	aaggcacaga	gatcactgac	30420
ttgccccaaa	tcaagcagg	agtagttagt	atataagccc	acggtatgtg	gtttgtagaa	30480
taggtgctct	tgactagcag	aaataggctc	tcctgcagct	gtgtaattga	taacaagcat	30540
gggctgccat	cttctgtcgc	aggccactca	aaacacccaa	caggctacgc	acggtggctc	30600
acacctgtaa	tcccagcact	gtgggagggc	gaggtggggc	ggcacctga	ggtcaggagt	30660
tcgagaccag	cctggccgac	atggtgaaac	tcctctcta	ctaacagtac	aaaattagc	30720
tggcggtgg	ggcgggcacc	tgtaatccca	gctactcagg	aggctgagac	agaagaatca	30780
cttgaaccag	ggaggcagag	gttgcagtga	gacaagatca	cgccattgca	ctccagcctg	30840
tgtgacaaaa	gcgaaactgt	ctcaaaaaaa	aaaaaaaaaa	aagtatgatt	ttataatccc	30900
agcaccttgg	gaggctgagt	cgtgagaatc	acttgagccc	aggagtthaa	gaccaatcta	30960
ggcaacatgg	caagacccca	tctctgccc	aaataaaaaa	tagtctaatt	ttagctattc	31020
atgtgtgtgt	gaagtgggtg	ctcttcgtgg	ctttgatctg	catttcctta	atgctgacta	31080
atgacgttgg	gcacctgttc	atgtgcttac	tggtcagata	tctttctttt	gttacattht	31140
attaagthtt	aaaatttaaa	gtcaaagatt	tcctatgag	aatgacttht	aaaatgacca	31200
aaaaggggaa	gataacatta	attcttgaag	agaaggcctc	tgagaaaaat	acagttgtag	31260
caagctgcta	ctttgcaaat	gacctatgca	thtaattht	cccctaagga	aggccaagga	31320
agagtcttat	cacctcagg	caggagatgt	aggacttgg	gtcatttaat	aagagtggta	31380
ggthtgaaaa	ctcaaacc	gaagactcct	tagagthtct	cccaggaggt	agggaaggg	31440
ccgcacccat	ggagagagga	ggatgtgact	tagagcagtg	gtccccaatc	thtagggacc	31500
agggactgg	gtcatgtag	acagthtttc	cacagatagg	ggttgggggg	atgatttgg	31560
gctgaaactg	ctccacctca	ggcatcagg	cattagattc	tcatgtggag	tgtgccactt	31620
agatccttgg	cgtgcacagt	tcacaatggg	gttcgaggtc	ctatgagaat	ccgatgccac	31680
tgatttgaca	ggaggcggag	ctcaggtgg	aatgctcacc	tccaccgctt	accacctgct	31740
gtgcagcctg	gttcctaata	ggctatagac	tggtagctgt	ccatggcctg	ggggttgggg	31800
accctgatt	tagaggaagt	aagggcatgg	cttaccgtgg	gccctgggg	gttctgggaa	31860
tggggaggat	ggagagaaga	gaggaggtag	ggaagacctc	cccttgcctc	ccatttggga	31920
thtggggaga	aagtcaggtc	tcaggctcaa	cagtacctga	tctgtacca	tcttccaaag	31980
ggaagtcagt	ggggttggaa	ggtaggcagg	ggttatcttc	tctgagccac	ggcacaagac	32040
agaagthtcc	caccattcct	gagggggcag	gtgtaggtc	cccaagcaga	gagccagcag	32100

-continued

```

tccctctctg aggctgcaa tggaatgggg tggggtgtcc actgagccaa gggctctgtca 32160
gtgagagctg gggaggctgg gctggcttgc aagcacctgt tataacccaaa ccaggaaatc 32220
aggttccgag tcttgccagc aagggcctac agctgccagc agagatggac agccaggaga 32280
ccccaattgg ccaccagag ccaccctcct ctgcctaccc caccctccag tactccagag 32340
cctactcgga ggggaacaga aacctgagag gctgaacaca cacacatgga gaaacaaacg 32400
tagtaaaata tttggggaat caggaagaat tatttgtact attcctgcaa cttttctata 32460
ggcttgaaat tatcaaaata aatttttaaa aattgtaata acatttcat actaaaacac 32520
tgagtttttt tctttcattt tttgattttt tctttttgac tccagcatga cttactctaa 32580
caatgggtgg tctcgatttt gaaatacttt cttctccaag cttttcatga caccctgtct 32640
ctgttggttc tgaaaatgtt ggattttgtc tcagcccttg cttctgaaa cagccaaggt 32700
taagaaaacc ccccatgctt tgtgttctag cagacagctt cctgcaaaga gccatcttcc 32760
cagagcactt aggcctctta gatgtctccc ttgtttaatt atgacaagag cacacacaca 32820
gaccctccaa attcccattc ttagtcttct aatgatttag ctgagctgct tttcccact 32880
gattaatcgg aataaaatgc tcattaacca aacttccctc ctttccccag gtcocctaac 32940
tttctgagt cggcagacat cccctctgga gaagaggttg gcccagagt cgaacatcct 33000
ctgatctacc tgatcctgct gcccttccat tccacttccc cacatctggt ctttctggtc 33060
gtgtttactc ccctattaa aaaacaaaac cagaaaacgt gtttgcttag atcttgagac 33120
tctggaagat cttaacagtc agaggttccc cctatttgca atgatctcct ttctgcccc 33180
ttcctatcct tgcaataatc cttttgaata aagtctctcc ttactaaatc cagttcctaa 33240
aaattaattt ttttagag 33258

```

```

<210> SEQ ID NO 2
<211> LENGTH: 448
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: presenilin-2 isoform 1

```

```

<400> SEQUENCE: 2

```

```

Met Leu Thr Phe Met Ala Ser Asp Ser Glu Glu Glu Val Cys Asp Glu
1           5           10           15
Arg Thr Ser Leu Met Ser Ala Glu Ser Pro Thr Pro Arg Ser Cys Gln
20           25           30
Glu Gly Arg Gln Gly Pro Glu Asp Gly Glu Asn Thr Ala Gln Trp Arg
35           40           45
Ser Gln Glu Asn Glu Glu Asp Gly Glu Glu Asp Pro Asp Arg Tyr Val
50           55           60
Cys Ser Gly Val Pro Gly Arg Pro Pro Gly Leu Glu Glu Glu Leu Thr
65           70           75           80
Leu Lys Tyr Gly Ala Lys His Val Ile Met Leu Phe Val Pro Val Thr
85           90           95
Leu Cys Met Ile Val Val Val Ala Thr Ile Lys Ser Val Arg Phe Tyr
100          105          110
Thr Glu Lys Asn Gly Gln Leu Ile Tyr Thr Pro Phe Thr Glu Asp Thr
115          120          125
Pro Ser Val Gly Gln Arg Leu Leu Asn Ser Val Leu Asn Thr Leu Ile
130          135          140
Met Ile Ser Val Ile Val Val Met Thr Ile Phe Leu Val Val Leu Tyr

```

-continued

145	150	155	160
Lys Tyr Arg Cys Tyr Lys Phe Ile His Gly Trp Leu Ile Met Ser Ser	165	170	175
Leu Met Leu Leu Phe Leu Phe Thr Tyr Ile Tyr Leu Gly Glu Val Leu	180	185	190
Lys Thr Tyr Asn Val Ala Met Asp Tyr Pro Thr Leu Leu Leu Thr Val	195	200	205
Trp Asn Phe Gly Ala Val Gly Met Val Cys Ile His Trp Lys Gly Pro	210	215	220
Leu Val Leu Gln Gln Ala Tyr Leu Ile Met Ile Ser Ala Leu Met Ala	225	230	235
Leu Val Phe Ile Lys Tyr Leu Pro Glu Trp Ser Ala Trp Val Ile Leu	245	250	255
Gly Ala Ile Ser Val Tyr Asp Leu Val Ala Val Leu Cys Pro Lys Gly	260	265	270
Pro Leu Arg Met Leu Val Glu Thr Ala Gln Glu Arg Asn Glu Pro Ile	275	280	285
Phe Pro Ala Leu Ile Tyr Ser Ser Ala Met Val Trp Thr Val Gly Met	290	295	300
Ala Lys Leu Asp Pro Ser Ser Gln Gly Ala Leu Gln Leu Pro Tyr Asp	305	310	315
Pro Glu Met Glu Glu Asp Ser Tyr Asp Ser Phe Gly Glu Pro Ser Tyr	325	330	335
Pro Glu Val Phe Glu Pro Pro Leu Thr Gly Tyr Pro Gly Glu Glu Leu	340	345	350
Glu Glu Glu Glu Glu Arg Gly Val Lys Leu Gly Leu Gly Asp Phe Ile	355	360	365
Phe Tyr Ser Val Leu Val Gly Lys Ala Ala Ala Thr Gly Ser Gly Asp	370	375	380
Trp Asn Thr Thr Leu Ala Cys Phe Val Ala Ile Leu Ile Gly Leu Cys	385	390	395
Leu Thr Leu Leu Leu Leu Ala Val Phe Lys Lys Ala Leu Pro Ala Leu	405	410	415
Pro Ile Ser Ile Thr Phe Gly Leu Ile Phe Tyr Phe Ser Thr Asp Asn	420	425	430
Leu Val Arg Pro Phe Met Asp Thr Leu Ala Ser His Gln Leu Tyr Ile	435	440	445

<210> SEQ ID NO 3
 <211> LENGTH: 19
 <212> TYPE: DNA
 <213> ORGANISM: Homo sapiens
 <220> FEATURE:
 <221> NAME/KEY: misc_feature
 <223> OTHER INFORMATION: Forward 5'-3' Primer

<400> SEQUENCE: 3

catcagccct ttgccttct

19

<210> SEQ ID NO 4
 <211> LENGTH: 20
 <212> TYPE: DNA
 <213> ORGANISM: Homo sapiens
 <220> FEATURE:
 <221> NAME/KEY: misc_feature
 <223> OTHER INFORMATION: Reverse 3'-5' Primer

<400> SEQUENCE: 4

-continued

ctcaccttgt agcagcggta 20

<210> SEQ ID NO 5
 <211> LENGTH: 26
 <212> TYPE: DNA
 <213> ORGANISM: Homo sapiens
 <220> FEATURE:
 <221> NAME/KEY: misc_feature
 <223> OTHER INFORMATION: Forward 5'-3' Primer

<400> SEQUENCE: 5

acagaattcg ccccggcctg gtacac 26

<210> SEQ ID NO 6
 <211> LENGTH: 25
 <212> TYPE: DNA
 <213> ORGANISM: Homo sapiens
 <220> FEATURE:
 <221> NAME/KEY: misc_feature
 <223> OTHER INFORMATION: Reverse 3'-5' Primer

<400> SEQUENCE: 6

taagcttggc acggctgtcc aagga 25

<210> SEQ ID NO 7
 <211> LENGTH: 20
 <212> TYPE: DNA
 <213> ORGANISM: Homo sapiens
 <220> FEATURE:
 <221> NAME/KEY: misc_feature
 <223> OTHER INFORMATION: Forward 5'-3' Primer

<400> SEQUENCE: 7

tcagcatcta cagccattc 20

<210> SEQ ID NO 8
 <211> LENGTH: 20
 <212> TYPE: DNA
 <213> ORGANISM: Homo sapiens
 <220> FEATURE:
 <221> NAME/KEY: misc_feature
 <223> OTHER INFORMATION: Reverse 3'-5' Primer

<400> SEQUENCE: 8

agcaccacca agaagatggt 20

<210> SEQ ID NO 9
 <211> LENGTH: 26
 <212> TYPE: DNA
 <213> ORGANISM: Homo sapiens
 <220> FEATURE:
 <221> NAME/KEY: misc_feature
 <223> OTHER INFORMATION: Forward 5'-3' Primer

<400> SEQUENCE: 9

attcgccccg gcctgtaca ctgcca 26

<210> SEQ ID NO 10
 <211> LENGTH: 27
 <212> TYPE: DNA
 <213> ORGANISM: Homo sapiens
 <220> FEATURE:
 <221> NAME/KEY: misc_feature
 <223> OTHER INFORMATION: Reverse 3'-5' Primer

<400> SEQUENCE: 10

-continued

 ctgtccaagg agctgcaggc ggcgcag 27

<210> SEQ ID NO 11
 <211> LENGTH: 25
 <212> TYPE: DNA
 <213> ORGANISM: Homo sapiens
 <220> FEATURE:
 <221> NAME/KEY: misc_feature
 <223> OTHER INFORMATION: g1N141I guide RNA F

<400> SEQUENCE: 11

caccgatca tgatcagcgt catcg 25

<210> SEQ ID NO 12
 <211> LENGTH: 25
 <212> TYPE: DNA
 <213> ORGANISM: Homo sapiens
 <220> FEATURE:
 <221> NAME/KEY: misc_feature
 <223> OTHER INFORMATION: g1N141I guide RNA R

<400> SEQUENCE: 12

aaaccgatga cgctgatcat gatgc 25

<210> SEQ ID NO 13
 <211> LENGTH: 100
 <212> TYPE: DNA
 <213> ORGANISM: Homo sapiens
 <220> FEATURE:
 <221> NAME/KEY: misc_feature
 <223> OTHER INFORMATION: Donor ssODN#A N141I

<400> SEQUENCE: 13

gagagaagcg tggctggagg gcagggccag gccctcacct tgtagcagcg gtactttag 60

agcaccacca agaagatggt caggggtgttc agcacggagt 100

<210> SEQ ID NO 14
 <211> LENGTH: 21
 <212> TYPE: DNA
 <213> ORGANISM: Homo sapiens
 <220> FEATURE:
 <221> NAME/KEY: misc_feature
 <223> OTHER INFORMATION: Forward 5' Primer

<400> SEQUENCE: 14

taacggcggc agacaaaaag a 21

<210> SEQ ID NO 15
 <211> LENGTH: 22
 <212> TYPE: DNA
 <213> ORGANISM: Homo sapiens
 <220> FEATURE:
 <221> NAME/KEY: misc_feature
 <223> OTHER INFORMATION: Reverse 5'-3' Primer

<400> SEQUENCE: 15

gaagtattgc ttcagttggc ct 22

<210> SEQ ID NO 16
 <211> LENGTH: 21
 <212> TYPE: DNA
 <213> ORGANISM: Homo sapiens
 <220> FEATURE:
 <221> NAME/KEY: misc_feature
 <223> OTHER INFORMATION: Forward 5' Primer

<400> SEQUENCE: 16

-continued

agaagaacgg caagtacgag a 21

<210> SEQ ID NO 17
 <211> LENGTH: 21
 <212> TYPE: DNA
 <213> ORGANISM: Homo sapiens
 <220> FEATURE:
 <221> NAME/KEY: misc_feature
 <223> OTHER INFORMATION: Reverse 5'-3' Primer

<400> SEQUENCE: 17

tgttgagggga cagattgtgg c 21

<210> SEQ ID NO 18
 <211> LENGTH: 21
 <212> TYPE: DNA
 <213> ORGANISM: Homo sapiens
 <220> FEATURE:
 <221> NAME/KEY: misc_feature
 <223> OTHER INFORMATION: Forward 5' Primer

<400> SEQUENCE: 18

taacggcggc agacaaaaag a 21

<210> SEQ ID NO 19
 <211> LENGTH: 22
 <212> TYPE: DNA
 <213> ORGANISM: Homo sapiens
 <220> FEATURE:
 <221> NAME/KEY: misc_feature
 <223> OTHER INFORMATION: Reverse 5'-3' Primer

<400> SEQUENCE: 19

gaagtattgc ttcagttggc ct 22

<210> SEQ ID NO 20

<400> SEQUENCE: 20

000

<210> SEQ ID NO 21

<400> SEQUENCE: 21

000

<210> SEQ ID NO 22
 <211> LENGTH: 20
 <212> TYPE: DNA
 <213> ORGANISM: Homo sapiens
 <220> FEATURE:
 <221> NAME/KEY: misc_feature
 <223> OTHER INFORMATION: Forward 5' Primer

<400> SEQUENCE: 22

acgaatctcc gaccaccact 20

<210> SEQ ID NO 23
 <211> LENGTH: 20
 <212> TYPE: DNA
 <213> ORGANISM: Homo sapiens
 <220> FEATURE:
 <221> NAME/KEY: misc_feature
 <223> OTHER INFORMATION: Reverse 5'-3' Primer

<400> SEQUENCE: 23

-continued

ccatggccac aacaactgac 20

<210> SEQ ID NO 24
 <211> LENGTH: 22
 <212> TYPE: DNA
 <213> ORGANISM: Homo sapiens
 <220> FEATURE:
 <221> NAME/KEY: misc_feature
 <223> OTHER INFORMATION: Forward 5' Primer

<400> SEQUENCE: 24

gaagtgtccc aggacatgat aa 22

<210> SEQ ID NO 25
 <211> LENGTH: 22
 <212> TYPE: DNA
 <213> ORGANISM: Homo sapiens
 <220> FEATURE:
 <221> NAME/KEY: misc_feature
 <223> OTHER INFORMATION: Reverse 5'-3' Primer

<400> SEQUENCE: 25

ctcttgagta gctgggattg ag 22

<210> SEQ ID NO 26
 <211> LENGTH: 46
 <212> TYPE: DNA
 <213> ORGANISM: Homo sapiens
 <220> FEATURE:
 <221> NAME/KEY: misc_feature
 <223> OTHER INFORMATION: Forward 5'-3' Primer

<400> SEQUENCE: 26

ctccgtgctg atcacctca tcatgatcag cgtcacggg tatgac 46

<210> SEQ ID NO 27
 <211> LENGTH: 48
 <212> TYPE: DNA
 <213> ORGANISM: Homo sapiens
 <220> FEATURE:
 <221> NAME/KEY: misc_feature
 <223> OTHER INFORMATION: Reverse 3'-5' Primer

<400> SEQUENCE: 27

gaggcacgac tagtgggagt agtactagtc gcagtagcac caatactg 48

<210> SEQ ID NO 28
 <211> LENGTH: 20
 <212> TYPE: DNA
 <213> ORGANISM: Homo sapiens
 <220> FEATURE:
 <221> NAME/KEY: misc_feature
 <223> OTHER INFORMATION: Forward 5'-3' Primer

<400> SEQUENCE: 28

catcatgatc agcgtcatcg 20

<210> SEQ ID NO 29
 <211> LENGTH: 25
 <212> TYPE: DNA
 <213> ORGANISM: Homo sapiens
 <220> FEATURE:
 <221> NAME/KEY: misc_feature
 <223> OTHER INFORMATION: g1N2411 guide RNA F

<400> SEQUENCE: 29

-continued

caccgcatca tgatcagcgt catcg

25

<210> SEQ ID NO 30
 <211> LENGTH: 25
 <212> TYPE: DNA
 <213> ORGANISM: Homo sapiens
 <220> FEATURE:
 <221> NAME/KEY: misc_feature
 <223> OTHER INFORMATION: g1N2411 guide RNA R

<400> SEQUENCE: 30

aaaccgatga cgctgatcat gatgc

25

<210> SEQ ID NO 31
 <211> LENGTH: 118
 <212> TYPE: DNA
 <213> ORGANISM: Homo sapiens
 <220> FEATURE:
 <221> NAME/KEY: misc_feature
 <223> OTHER INFORMATION: Donor ssODN#A N141I

<400> SEQUENCE: 31

gagagaagcg tggctggagg gcagggccag ggcctcacct tgtagcagcg gtactttag 60

agcaccacca agaagatggt cataaccacg atgacgctga tcatgatgag ggtgttca 118

What is claimed is:

1. A method of generating basal forebrain cholinergic neurons (BFCNs) comprising:

culturing pluripotent stem cells (PSCs) in a basal media comprising an inhibitor of transforming growth factor beta (TGF- β) signaling and an activator of sonic hedgehog (Shh) signaling thereby inducing neuroectodermal differentiation, wherein the inhibitor of TGF- β signaling is SB431542 and LDN193189 and the activator of Shh signaling is smoothened agonist (SAG) and purmorphamine, and

wherein the basal media lacks basic fibroblast growth factor (bFGF), TGF- β , lithium chloride (Li-Cl), GABA and pipecolic acid, thereby generating BFCNs.

2. The method of claim 1, wherein culturing is performed for a duration of about 4 to 9 days.

3. The method of claim 1, wherein the inhibitor is present in the culture media from about day 2 to day 8.

4. The method of claim 1, further comprising selecting for isolating CD271+cells.

5. The method of claim 4, wherein isolating is performed after about 9 to 12 days of culturing.

6. The method of claim 5, further comprising culturing the CD271+cells to generate neuronal embryoid bodies (NEBs).

7. The method of claim 6, wherein the CD271+cells are cultured for about 7 days thereby generating NEBs.

8. The method of claim 7, further comprising:

a) harvesting the NEBs; and

b) dissociating cells of the NEBs and re-plating the dissociated cells as a monolayer.

9. The method of claim 8, wherein the re-plated cells are cultured for an additional duration in culture media having growth factors to maintain survival of the cells, and wherein the cells express Tuj1, MAP2, BF1, Nkx2.1 and p75.

10. The method of claim 8, where the cultured cells exhibit mature action potentials.

11. The method of claim 1, further comprising culturing the cells to confluence prior to contacting the cells with the activator or inhibitor.

12. The method of claim 1, wherein the PSCs are human cells.

13. The method of claim 1, wherein the PSCs are induced pluripotent stem cells (iPSCs).

14. The method of claim 13, wherein the iPSCs are derived from a subject diagnosed with, or at risk of having Alzheimer's disease (AD).

15. The method of claim 14, wherein the iPSCs are produced using a BFCN from the subject having a mutation in presenilin 2 (PSEN2).

16. The method of claim 15, wherein the mutation is PSEN2^{N141I}.

17. The method of claim 15, wherein the mutation is repaired after generation of the iPSCs.

18. The method of claim 17, wherein the mutation is repaired using a gene editing system selected from the group consisting of CRISPR/Cas system, Cre/Lox system, TALEN system and homologous recombination.

19. The method of claim 17, wherein the cultured cells exhibit a normalization of A β 42/40 ratio as compared to control.

20. The method of claim 17, wherein the cultured cells exhibit a reduction in electrophysiological deficit as compared to control.

21. The method of claim 20, wherein the reduction in electrophysiological deficit comprises restoration of maximal number of spikes and spike height in response to depolarizing current as compared to control.

22. The method of claim 1, wherein the cultured cells exhibit homogeneous expression of Nkx2.1 by day 8 of culturing.

23. The method of claim 1, wherein the cultured cells exhibit recordable action potentials by day 8 of culturing.

24. The method of claim 1, wherein the cultured cells exhibit mature action potentials by day 38 of culturing.

* * * * *